id	sid	tid	token	lemma	pos
dpc-2939	1	1	dermatology	dermatology	NOUN
dpc-2939	1	2	:	:	PUNCT
dpc-2939	1	3	practical	practical	ADJ
dpc-2939	1	4	and	and	CCONJ
dpc-2939	1	5	conceptual	conceptual	ADJ
dpc-2939	1	6	original	original	ADJ
dpc-2939	1	7	article	article	NOUN
dpc-2939	1	8	|	|	ADV
dpc-2939	1	9	dermatol	dermatol	ADJ
dpc-2939	1	10	pract	pract	NOUN
dpc-2939	1	11	concept	concept	NOUN
dpc-2939	1	12	.	.	PUNCT
dpc-2939	2	1	2023;13(2):e2023151	2023;13(2):e2023151	NUM
dpc-2939	2	2	1	1	NUM
dpc-2939	2	3	real	real	ADJ
dpc-2939	2	4	-	-	PUNCT
dpc-2939	2	5	world	world	NOUN
dpc-2939	2	6	experience	experience	NOUN
dpc-2939	2	7	with	with	ADP
dpc-2939	2	8	topical	topical	ADJ
dpc-2939	2	9	5	5	NUM
dpc-2939	2	10	-	-	PUNCT
dpc-2939	2	11	fluorouracil	fluorouracil	NOUN
dpc-2939	2	12	 	 	SPACE
dpc-2939	2	13	4	4	NUM
dpc-2939	2	14	%	%	NOUN
dpc-2939	2	15	(	(	PUNCT
dpc-2939	2	16	40	40	NUM
dpc-2939	2	17	mg	mg	PROPN
dpc-2939	2	18	/	/	SYM
dpc-2939	2	19	g	g	NOUN
dpc-2939	2	20	)	)	PUNCT
dpc-2939	2	21	cream	cream	NOUN
dpc-2939	2	22	for	for	ADP
dpc-2939	2	23	the	the	DET
dpc-2939	2	24	treatment	treatment	NOUN
dpc-2939	2	25	of	of	ADP
dpc-2939	2	26	actinic	actinic	ADJ
dpc-2939	2	27	keratosis	keratosis	NOUN
dpc-2939	2	28	giulia	giulia	NOUN
dpc-2939	2	29	briatico1	briatico1	VERB
dpc-2939	2	30	,	,	PUNCT
dpc-2939	2	31	gabriella	gabriella	PROPN
dpc-2939	2	32	brancaccio1	brancaccio1	PROPN
dpc-2939	2	33	,	,	PUNCT
dpc-2939	2	34	camila	camila	PROPN
dpc-2939	2	35	scharf1	scharf1	PROPN
dpc-2939	2	36	,	,	PUNCT
dpc-2939	2	37	eugenia	eugenia	PROPN
dpc-2939	2	38	veronica	veronica	PROPN
dpc-2939	2	39	di	di	PROPN
dpc-2939	2	40	brizzi1	brizzi1	PROPN
dpc-2939	2	41	,	,	PUNCT
dpc-2939	2	42	sebastiano	sebastiano	PROPN
dpc-2939	2	43	pellerone1	pellerone1	PROPN
dpc-2939	2	44	,	,	PUNCT
dpc-2939	2	45	stefano	stefano	PROPN
dpc-2939	2	46	caccavale1	caccavale1	PROPN
dpc-2939	2	47	,	,	PUNCT
dpc-2939	2	48	caterina	caterina	PROPN
dpc-2939	2	49	mariarosaria	mariarosaria	PROPN
dpc-2939	2	50	giorgio1	giorgio1	PROPN
dpc-2939	2	51	,	,	PUNCT
dpc-2939	2	52	enrico	enrico	PROPN
dpc-2939	2	53	maria	maria	PROPN
dpc-2939	2	54	procaccini1	procaccini1	PROPN
dpc-2939	2	55	,	,	PUNCT
dpc-2939	2	56	elvira	elvira	PROPN
dpc-2939	2	57	moscarella1	moscarella1	PROPN
dpc-2939	2	58	,	,	PUNCT
dpc-2939	2	59	giuseppe	giuseppe	PROPN
dpc-2939	2	60	argenziano1	argenziano1	NOUN
dpc-2939	2	61	1	1	NUM
dpc-2939	2	62	dermatology	dermatology	NOUN
dpc-2939	2	63	unit	unit	NOUN
dpc-2939	2	64	,	,	PUNCT
dpc-2939	2	65	university	university	PROPN
dpc-2939	2	66	of	of	ADP
dpc-2939	2	67	campania	campania	PROPN
dpc-2939	2	68	,	,	PUNCT
dpc-2939	2	69	naples	naples	PROPN
dpc-2939	2	70	,	,	PUNCT
dpc-2939	2	71	italy	italy	PROPN
dpc-2939	2	72	key	key	ADJ
dpc-2939	2	73	words	word	NOUN
dpc-2939	2	74	:	:	PUNCT
dpc-2939	2	75	actinic	actinic	ADJ
dpc-2939	2	76	keratosis	keratosis	NOUN
dpc-2939	2	77	,	,	PUNCT
dpc-2939	2	78	5	5	NUM
dpc-2939	2	79	-	-	PUNCT
dpc-2939	2	80	fluorouracil	fluorouracil	NOUN
dpc-2939	2	81	,	,	PUNCT
dpc-2939	2	82	treatment	treatment	NOUN
dpc-2939	2	83	,	,	PUNCT
dpc-2939	2	84	efficacy	efficacy	NOUN
dpc-2939	2	85	,	,	PUNCT
dpc-2939	2	86	safety	safety	NOUN
dpc-2939	2	87	citation	citation	NOUN
dpc-2939	2	88	:	:	PUNCT
dpc-2939	2	89	briatico	briatico	PROPN
dpc-2939	2	90	g	g	PROPN
dpc-2939	2	91	,	,	PUNCT
dpc-2939	2	92	brancaccio	brancaccio	NOUN
dpc-2939	2	93	g	g	NOUN
dpc-2939	2	94	,	,	PUNCT
dpc-2939	2	95	scharf	scharf	PROPN
dpc-2939	2	96	c	c	NOUN
dpc-2939	2	97	,	,	PUNCT
dpc-2939	2	98	et	et	PROPN
dpc-2939	2	99	al	al	PROPN
dpc-2939	2	100	.	.	PUNCT
dpc-2939	3	1	real	real	ADJ
dpc-2939	3	2	-	-	PUNCT
dpc-2939	3	3	world	world	NOUN
dpc-2939	3	4	experience	experience	NOUN
dpc-2939	3	5	with	with	ADP
dpc-2939	3	6	topical	topical	ADJ
dpc-2939	3	7	5	5	NUM
dpc-2939	3	8	-	-	PUNCT
dpc-2939	3	9	fluorouracil	fluorouracil	NOUN
dpc-2939	3	10	4	4	NUM
dpc-2939	3	11	%	%	NOUN
dpc-2939	3	12	(	(	PUNCT
dpc-2939	3	13	40	40	NUM
dpc-2939	3	14	mg	mg	PROPN
dpc-2939	3	15	/	/	SYM
dpc-2939	3	16	g	g	NOUN
dpc-2939	3	17	)	)	PUNCT
dpc-2939	3	18	cream	cream	NOUN
dpc-2939	3	19	for	for	ADP
dpc-2939	3	20	the	the	DET
dpc-2939	3	21	treatment	treatment	NOUN
dpc-2939	3	22	of	of	ADP
dpc-2939	3	23	actinic	actinic	ADJ
dpc-2939	3	24	keratosis	keratosis	NOUN
dpc-2939	3	25	.	.	PUNCT
dpc-2939	4	1	dermatol	dermatol	NOUN
dpc-2939	4	2	pract	pract	PROPN
dpc-2939	4	3	concept	concept	NOUN
dpc-2939	4	4	.	.	PUNCT
dpc-2939	5	1	2023;13(2):e2023151	2023;13(2):e2023151	X
dpc-2939	5	2	.	.	X
dpc-2939	5	3	doi	doi	PROPN
dpc-2939	5	4	:	:	PUNCT
dpc-2939	5	5	https://doi.org/10.5826/dpc.1302a151	https://doi.org/10.5826/dpc.1302a151	PROPN
dpc-2939	5	6	accepted	accept	VERB
dpc-2939	5	7	:	:	PUNCT
dpc-2939	5	8	november	november	PROPN
dpc-2939	5	9	30	30	NUM
dpc-2939	5	10	,	,	PUNCT
dpc-2939	5	11	2023	2023	NUM
dpc-2939	5	12	;	;	PUNCT
dpc-2939	5	13	published	publish	VERB
dpc-2939	5	14	:	:	PUNCT
dpc-2939	6	1	april	april	PROPN
dpc-2939	6	2	2023	2023	NUM
dpc-2939	6	3	copyright	copyright	NOUN
dpc-2939	6	4	:	:	PUNCT
dpc-2939	6	5	©	©	PROPN
dpc-2939	6	6	2023	2023	NUM
dpc-2939	6	7	briatico	briatico	NOUN
dpc-2939	6	8	et	et	PROPN
dpc-2939	6	9	al	al	PROPN
dpc-2939	6	10	.	.	PUNCT
dpc-2939	7	1	this	this	PRON
dpc-2939	7	2	is	be	AUX
dpc-2939	7	3	an	an	DET
dpc-2939	7	4	open	open	ADJ
dpc-2939	7	5	-	-	PUNCT
dpc-2939	7	6	access	access	NOUN
dpc-2939	7	7	article	article	NOUN
dpc-2939	7	8	distributed	distribute	VERB
dpc-2939	7	9	under	under	ADP
dpc-2939	7	10	the	the	DET
dpc-2939	7	11	terms	term	NOUN
dpc-2939	7	12	of	of	ADP
dpc-2939	7	13	the	the	DET
dpc-2939	7	14	creative	creative	ADJ
dpc-2939	7	15	commons	common	NOUN
dpc-2939	7	16	attributionnoncommercial	attributionnoncommercial	ADJ
dpc-2939	7	17	license	license	NOUN
dpc-2939	7	18	(	(	PUNCT
dpc-2939	7	19	by	by	ADP
dpc-2939	7	20	-	-	PUNCT
dpc-2939	7	21	nc-4.0	nc-4.0	NOUN
dpc-2939	7	22	)	)	PUNCT
dpc-2939	7	23	,	,	PUNCT
dpc-2939	7	24	https://creativecommons.org/licenses/by-nc/4.0/	https://creativecommons.org/licenses/by-nc/4.0/	PROPN
dpc-2939	7	25	,	,	PUNCT
dpc-2939	7	26	which	which	PRON
dpc-2939	7	27	permits	permit	VERB
dpc-2939	7	28	unrestricted	unrestricted	ADJ
dpc-2939	7	29	noncommercial	noncommercial	ADJ
dpc-2939	7	30	use	use	NOUN
dpc-2939	7	31	,	,	PUNCT
dpc-2939	7	32	distribution	distribution	NOUN
dpc-2939	7	33	,	,	PUNCT
dpc-2939	7	34	and	and	CCONJ
dpc-2939	7	35	reproduction	reproduction	NOUN
dpc-2939	7	36	in	in	ADP
dpc-2939	7	37	any	any	DET
dpc-2939	7	38	medium	medium	NOUN
dpc-2939	7	39	,	,	PUNCT
dpc-2939	7	40	provided	provide	VERB
dpc-2939	7	41	the	the	DET
dpc-2939	7	42	original	original	ADJ
dpc-2939	7	43	authors	author	NOUN
dpc-2939	7	44	and	and	CCONJ
dpc-2939	7	45	source	source	NOUN
dpc-2939	7	46	are	be	AUX
dpc-2939	7	47	credited	credit	VERB
dpc-2939	7	48	.	.	PUNCT
dpc-2939	8	1	funding	funding	NOUN
dpc-2939	8	2	:	:	PUNCT
dpc-2939	8	3	none	none	NOUN
dpc-2939	8	4	.	.	PUNCT
dpc-2939	9	1	competing	compete	VERB
dpc-2939	9	2	interests	interest	NOUN
dpc-2939	9	3	:	:	PUNCT
dpc-2939	9	4	none	none	NOUN
dpc-2939	9	5	.	.	PUNCT
dpc-2939	10	1	authorship	authorship	NOUN
dpc-2939	10	2	:	:	PUNCT
dpc-2939	10	3	all	all	DET
dpc-2939	10	4	authors	author	NOUN
dpc-2939	10	5	have	have	AUX
dpc-2939	10	6	contributed	contribute	VERB
dpc-2939	10	7	significantly	significantly	ADV
dpc-2939	10	8	to	to	ADP
dpc-2939	10	9	this	this	DET
dpc-2939	10	10	publication	publication	NOUN
dpc-2939	10	11	.	.	PUNCT
dpc-2939	11	1	corresponding	correspond	VERB
dpc-2939	11	2	author	author	NOUN
dpc-2939	11	3	:	:	PUNCT
dpc-2939	11	4	giulia	giulia	PROPN
dpc-2939	11	5	briatico	briatico	PROPN
dpc-2939	11	6	,	,	PUNCT
dpc-2939	11	7	dermatology	dermatology	NOUN
dpc-2939	11	8	unit	unit	NOUN
dpc-2939	11	9	,	,	PUNCT
dpc-2939	11	10	university	university	PROPN
dpc-2939	11	11	of	of	ADP
dpc-2939	11	12	campania	campania	PROPN
dpc-2939	11	13	,	,	PUNCT
dpc-2939	11	14	via	via	ADP
dpc-2939	11	15	pansini	pansini	PROPN
dpc-2939	11	16	,	,	PUNCT
dpc-2939	11	17	5	5	NUM
dpc-2939	11	18	,	,	PUNCT
dpc-2939	11	19	80131	80131	NUM
dpc-2939	11	20	,	,	PUNCT
dpc-2939	11	21	naples	naples	PROPN
dpc-2939	11	22	,	,	PUNCT
dpc-2939	11	23	italy	italy	PROPN
dpc-2939	11	24	,	,	PUNCT
dpc-2939	11	25	giuliabriatico@gmail.com	giuliabriatico@gmail.com	X
dpc-2939	12	1	introduction	introduction	NOUN
dpc-2939	12	2	:	:	PUNCT
dpc-2939	12	3	5	5	NUM
dpc-2939	12	4	-	-	PUNCT
dpc-2939	12	5	fluorouracil	fluorouracil	NOUN
dpc-2939	12	6	(	(	PUNCT
dpc-2939	12	7	5	5	NUM
dpc-2939	12	8	-	-	PUNCT
dpc-2939	12	9	fu	fu	NOUN
dpc-2939	12	10	)	)	PUNCT
dpc-2939	12	11	is	be	AUX
dpc-2939	12	12	one	one	NUM
dpc-2939	12	13	of	of	ADP
dpc-2939	12	14	the	the	DET
dpc-2939	12	15	most	most	ADV
dpc-2939	12	16	effective	effective	ADJ
dpc-2939	12	17	topical	topical	ADJ
dpc-2939	12	18	treatments	treatment	NOUN
dpc-2939	12	19	for	for	ADP
dpc-2939	12	20	actinic	actinic	ADJ
dpc-2939	12	21	keratosis	keratosis	NOUN
dpc-2939	12	22	(	(	PUNCT
dpc-2939	12	23	ak	ak	PROPN
dpc-2939	12	24	)	)	PUNCT
dpc-2939	12	25	.	.	PUNCT
dpc-2939	13	1	a	a	DET
dpc-2939	13	2	new	new	ADJ
dpc-2939	13	3	4	4	NUM
dpc-2939	13	4	%	%	NOUN
dpc-2939	13	5	formulation	formulation	NOUN
dpc-2939	13	6	of	of	ADP
dpc-2939	13	7	5	5	NUM
dpc-2939	13	8	-	-	PUNCT
dpc-2939	13	9	fu	fu	NOUN
dpc-2939	13	10	was	be	AUX
dpc-2939	13	11	recently	recently	ADV
dpc-2939	13	12	approved	approve	VERB
dpc-2939	13	13	in	in	ADP
dpc-2939	13	14	europe	europe	PROPN
dpc-2939	13	15	.	.	PUNCT
dpc-2939	14	1	objectives	objective	NOUN
dpc-2939	14	2	:	:	PUNCT
dpc-2939	14	3	this	this	DET
dpc-2939	14	4	study	study	NOUN
dpc-2939	14	5	aimed	aim	VERB
dpc-2939	14	6	at	at	ADP
dpc-2939	14	7	evaluating	evaluate	VERB
dpc-2939	14	8	4	4	NUM
dpc-2939	14	9	%	%	NOUN
dpc-2939	14	10	5	5	NUM
dpc-2939	14	11	-	-	PUNCT
dpc-2939	14	12	fu	fu	NOUN
dpc-2939	14	13	cream	cream	NOUN
dpc-2939	14	14	safety	safety	NOUN
dpc-2939	14	15	and	and	CCONJ
dpc-2939	14	16	effectiveness	effectiveness	NOUN
dpc-2939	14	17	in	in	ADP
dpc-2939	14	18	a	a	DET
dpc-2939	14	19	real	real	ADJ
dpc-2939	14	20	-	-	PUNCT
dpc-2939	14	21	world	world	NOUN
dpc-2939	14	22	setting	setting	NOUN
dpc-2939	14	23	.	.	PUNCT
dpc-2939	15	1	methods	method	NOUN
dpc-2939	15	2	:	:	PUNCT
dpc-2939	15	3	adult	adult	PROPN
dpc-2939	15	4	ak	ak	PROPN
dpc-2939	15	5	patients	patient	NOUN
dpc-2939	15	6	were	be	AUX
dpc-2939	15	7	retrospectively	retrospectively	ADV
dpc-2939	15	8	selected	select	VERB
dpc-2939	15	9	from	from	ADP
dpc-2939	15	10	the	the	DET
dpc-2939	15	11	university	university	PROPN
dpc-2939	15	12	of	of	ADP
dpc-2939	15	13	campania	campania	PROPN
dpc-2939	15	14	dermatology	dermatology	PROPN
dpc-2939	15	15	unit	unit	NOUN
dpc-2939	15	16	database	database	NOUN
dpc-2939	15	17	.	.	PUNCT
dpc-2939	16	1	selection	selection	NOUN
dpc-2939	16	2	criteria	criterion	NOUN
dpc-2939	16	3	included	include	VERB
dpc-2939	16	4	a	a	DET
dpc-2939	16	5	diagnosis	diagnosis	NOUN
dpc-2939	16	6	of	of	ADP
dpc-2939	16	7	non	non	ADJ
dpc-2939	16	8	-	-	ADJ
dpc-2939	16	9	hyperkeratotic	hyperkeratotic	ADJ
dpc-2939	16	10	,	,	PUNCT
dpc-2939	16	11	non	non	ADJ
dpc-2939	16	12	-	-	ADJ
dpc-2939	16	13	hypertrophic	hypertrophic	ADJ
dpc-2939	16	14	ak	ak	PROPN
dpc-2939	16	15	(	(	PUNCT
dpc-2939	16	16	olsen	olsen	NOUN
dpc-2939	16	17	grade	grade	NOUN
dpc-2939	16	18	i	i	PROPN
dpc-2939	16	19	and	and	CCONJ
dpc-2939	16	20	ii	ii	NOUN
dpc-2939	16	21	)	)	PUNCT
dpc-2939	16	22	of	of	ADP
dpc-2939	16	23	the	the	DET
dpc-2939	16	24	face	face	NOUN
dpc-2939	16	25	,	,	PUNCT
dpc-2939	16	26	ears	ear	NOUN
dpc-2939	16	27	,	,	PUNCT
dpc-2939	16	28	and/or	and/or	CCONJ
dpc-2939	16	29	scalp	scalp	NOUN
dpc-2939	16	30	,	,	PUNCT
dpc-2939	16	31	treatment	treatment	NOUN
dpc-2939	16	32	with	with	ADP
dpc-2939	16	33	4	4	NUM
dpc-2939	16	34	%	%	NOUN
dpc-2939	16	35	5	5	NUM
dpc-2939	16	36	-	-	PUNCT
dpc-2939	16	37	fu	fu	NOUN
dpc-2939	16	38	once	once	ADV
dpc-2939	16	39	daily	daily	ADV
dpc-2939	16	40	for	for	ADP
dpc-2939	16	41	4	4	NUM
dpc-2939	16	42	weeks	week	NOUN
dpc-2939	16	43	,	,	PUNCT
dpc-2939	16	44	and	and	CCONJ
dpc-2939	16	45	at	at	ADV
dpc-2939	16	46	least	least	ADJ
dpc-2939	16	47	3	3	NUM
dpc-2939	16	48	follow	follow	VERB
dpc-2939	16	49	-	-	PUNCT
dpc-2939	16	50	up	up	NOUN
dpc-2939	16	51	visits	visit	NOUN
dpc-2939	16	52	(	(	PUNCT
dpc-2939	16	53	4	4	NUM
dpc-2939	16	54	and	and	CCONJ
dpc-2939	16	55	8	8	NUM
dpc-2939	16	56	weeks	week	NOUN
dpc-2939	16	57	after	after	ADP
dpc-2939	16	58	treatment	treatment	NOUN
dpc-2939	16	59	initiation	initiation	NOUN
dpc-2939	16	60	,	,	PUNCT
dpc-2939	16	61	and	and	CCONJ
dpc-2939	16	62	6	6	NUM
dpc-2939	16	63	months	month	NOUN
dpc-2939	16	64	after	after	ADP
dpc-2939	16	65	treatment	treatment	NOUN
dpc-2939	16	66	end	end	NOUN
dpc-2939	16	67	)	)	PUNCT
dpc-2939	16	68	.	.	PUNCT
dpc-2939	17	1	the	the	DET
dpc-2939	17	2	primary	primary	ADJ
dpc-2939	17	3	objectives	objective	NOUN
dpc-2939	17	4	were	be	AUX
dpc-2939	17	5	to	to	PART
dpc-2939	17	6	evaluate	evaluate	VERB
dpc-2939	17	7	ak	ak	PROPN
dpc-2939	17	8	lesions	lesion	NOUN
dpc-2939	17	9	improvement	improvement	NOUN
dpc-2939	17	10	at	at	ADP
dpc-2939	17	11	8	8	NUM
dpc-2939	17	12	weeks	week	NOUN
dpc-2939	17	13	and	and	CCONJ
dpc-2939	17	14	relapse	relapse	NOUN
dpc-2939	17	15	rate	rate	NOUN
dpc-2939	17	16	at	at	ADP
dpc-2939	17	17	6	6	NUM
dpc-2939	17	18	months	month	NOUN
dpc-2939	17	19	.	.	PUNCT
dpc-2939	18	1	patient	patient	NOUN
dpc-2939	18	2	-	-	PUNCT
dpc-2939	18	3	reported	report	VERB
dpc-2939	18	4	erythema	erythema	NOUN
dpc-2939	18	5	and	and	CCONJ
dpc-2939	18	6	burning	burn	VERB
dpc-2939	18	7	sensation	sensation	NOUN
dpc-2939	18	8	intensity	intensity	NOUN
dpc-2939	18	9	were	be	AUX
dpc-2939	18	10	also	also	ADV
dpc-2939	18	11	assessed	assess	VERB
dpc-2939	18	12	at	at	ADP
dpc-2939	18	13	4	4	NUM
dpc-2939	18	14	weeks	week	NOUN
dpc-2939	18	15	.	.	PUNCT
dpc-2939	19	1	results	result	NOUN
dpc-2939	19	2	:	:	PUNCT
dpc-2939	19	3	ninety	ninety	NUM
dpc-2939	19	4	-	-	PUNCT
dpc-2939	19	5	eight	eight	NUM
dpc-2939	19	6	patients	patient	NOUN
dpc-2939	19	7	were	be	AUX
dpc-2939	19	8	included	include	VERB
dpc-2939	19	9	in	in	ADP
dpc-2939	19	10	this	this	DET
dpc-2939	19	11	analysis	analysis	NOUN
dpc-2939	19	12	(	(	PUNCT
dpc-2939	19	13	male	male	NOUN
dpc-2939	19	14	/	/	SYM
dpc-2939	19	15	female	female	ADJ
dpc-2939	19	16	80/18	80/18	NUM
dpc-2939	19	17	,	,	PUNCT
dpc-2939	19	18	mean	mean	NOUN
dpc-2939	19	19	age	age	NOUN
dpc-2939	19	20	74.7	74.7	NUM
dpc-2939	19	21	years	year	NOUN
dpc-2939	19	22	)	)	PUNCT
dpc-2939	19	23	.	.	PUNCT
dpc-2939	20	1	ak	ak	PROPN
dpc-2939	20	2	lesions	lesion	NOUN
dpc-2939	20	3	improvement	improvement	NOUN
dpc-2939	20	4	at	at	ADP
dpc-2939	20	5	8	8	NUM
dpc-2939	20	6	weeks	week	NOUN
dpc-2939	20	7	resulted	result	VERB
dpc-2939	20	8	complete	complete	ADJ
dpc-2939	20	9	or	or	CCONJ
dpc-2939	20	10	significant	significant	ADJ
dpc-2939	20	11	in	in	ADP
dpc-2939	20	12	74.5	74.5	NUM
dpc-2939	20	13	%	%	NOUN
dpc-2939	20	14	and	and	CCONJ
dpc-2939	20	15	20.4	20.4	NUM
dpc-2939	20	16	%	%	NOUN
dpc-2939	20	17	of	of	ADP
dpc-2939	20	18	the	the	DET
dpc-2939	20	19	patients	patient	NOUN
dpc-2939	20	20	,	,	PUNCT
dpc-2939	20	21	respectively	respectively	ADV
dpc-2939	20	22	.	.	PUNCT
dpc-2939	21	1	at	at	ADP
dpc-2939	21	2	6	6	NUM
dpc-2939	21	3	months	month	NOUN
dpc-2939	21	4	,	,	PUNCT
dpc-2939	21	5	65.3	65.3	NUM
dpc-2939	21	6	%	%	NOUN
dpc-2939	21	7	of	of	ADP
dpc-2939	21	8	the	the	DET
dpc-2939	21	9	patients	patient	NOUN
dpc-2939	21	10	did	do	AUX
dpc-2939	21	11	not	not	PART
dpc-2939	21	12	show	show	VERB
dpc-2939	21	13	ak	ak	PROPN
dpc-2939	21	14	relapses	relapse	NOUN
dpc-2939	21	15	.	.	PUNCT
dpc-2939	22	1	burning	burn	VERB
dpc-2939	22	2	sensation	sensation	NOUN
dpc-2939	22	3	at	at	ADP
dpc-2939	22	4	4	4	NUM
dpc-2939	22	5	weeks	week	NOUN
dpc-2939	22	6	was	be	AUX
dpc-2939	22	7	reported	report	VERB
dpc-2939	22	8	as	as	ADP
dpc-2939	22	9	light	light	ADJ
dpc-2939	22	10	,	,	PUNCT
dpc-2939	22	11	moderate	moderate	ADJ
dpc-2939	22	12	,	,	PUNCT
dpc-2939	22	13	or	or	CCONJ
dpc-2939	22	14	absent	absent	ADJ
dpc-2939	22	15	by	by	ADP
dpc-2939	22	16	44.9	44.9	NUM
dpc-2939	22	17	%	%	NOUN
dpc-2939	22	18	,	,	PUNCT
dpc-2939	22	19	22.4	22.4	NUM
dpc-2939	22	20	%	%	NOUN
dpc-2939	22	21	,	,	PUNCT
dpc-2939	22	22	and	and	CCONJ
dpc-2939	22	23	31.6	31.6	NUM
dpc-2939	22	24	%	%	NOUN
dpc-2939	22	25	of	of	ADP
dpc-2939	22	26	the	the	DET
dpc-2939	22	27	patients	patient	NOUN
dpc-2939	22	28	,	,	PUNCT
dpc-2939	22	29	respectively	respectively	ADV
dpc-2939	22	30	.	.	PUNCT
dpc-2939	23	1	erythema	erythema	PROPN
dpc-2939	23	2	was	be	AUX
dpc-2939	23	3	reported	report	VERB
dpc-2939	23	4	as	as	ADP
dpc-2939	23	5	light	light	ADJ
dpc-2939	23	6	,	,	PUNCT
dpc-2939	23	7	moderate	moderate	ADJ
dpc-2939	23	8	,	,	PUNCT
dpc-2939	23	9	or	or	CCONJ
dpc-2939	23	10	absent	absent	ADJ
dpc-2939	23	11	by	by	ADP
dpc-2939	23	12	37.8	37.8	NUM
dpc-2939	23	13	%	%	NOUN
dpc-2939	23	14	,	,	PUNCT
dpc-2939	23	15	51	51	NUM
dpc-2939	23	16	%	%	NOUN
dpc-2939	23	17	,	,	PUNCT
dpc-2939	23	18	and	and	CCONJ
dpc-2939	23	19	10	10	NUM
dpc-2939	23	20	%	%	NOUN
dpc-2939	23	21	of	of	ADP
dpc-2939	23	22	the	the	DET
dpc-2939	23	23	patients	patient	NOUN
dpc-2939	23	24	,	,	PUNCT
dpc-2939	23	25	respectively	respectively	ADV
dpc-2939	23	26	.	.	PUNCT
dpc-2939	24	1	burning	burn	VERB
dpc-2939	24	2	sensation	sensation	NOUN
dpc-2939	24	3	and	and	CCONJ
dpc-2939	24	4	erythema	erythema	ADV
dpc-2939	24	5	disappeared	disappear	VERB
dpc-2939	24	6	gradually	gradually	ADV
dpc-2939	24	7	during	during	ADP
dpc-2939	24	8	follow	follow	NOUN
dpc-2939	24	9	-	-	PUNCT
dpc-2939	24	10	up	up	NOUN
dpc-2939	24	11	.	.	PUNCT
dpc-2939	25	1	no	no	DET
dpc-2939	25	2	other	other	ADJ
dpc-2939	25	3	side	side	NOUN
dpc-2939	25	4	effects	effect	NOUN
dpc-2939	25	5	were	be	AUX
dpc-2939	25	6	reported	report	VERB
dpc-2939	25	7	.	.	PUNCT
dpc-2939	26	1	conclusions	conclusion	NOUN
dpc-2939	26	2	:	:	PUNCT
dpc-2939	26	3	in	in	ADP
dpc-2939	26	4	this	this	DET
dpc-2939	26	5	real	real	ADJ
dpc-2939	26	6	-	-	PUNCT
dpc-2939	26	7	world	world	NOUN
dpc-2939	26	8	study	study	NOUN
dpc-2939	26	9	4	4	NUM
dpc-2939	26	10	%	%	NOUN
dpc-2939	26	11	5	5	NUM
dpc-2939	26	12	-	-	PUNCT
dpc-2939	26	13	fu	fu	NOUN
dpc-2939	26	14	proved	prove	VERB
dpc-2939	26	15	to	to	PART
dpc-2939	26	16	be	be	AUX
dpc-2939	26	17	highly	highly	ADV
dpc-2939	26	18	effective	effective	ADJ
dpc-2939	26	19	for	for	ADP
dpc-2939	26	20	ak	ak	PROPN
dpc-2939	26	21	lesions	lesion	NOUN
dpc-2939	26	22	clearance	clearance	NOUN
dpc-2939	26	23	with	with	ADP
dpc-2939	26	24	a	a	DET
dpc-2939	26	25	favorable	favorable	ADJ
dpc-2939	26	26	safety	safety	NOUN
dpc-2939	26	27	profile	profile	NOUN
dpc-2939	26	28	.	.	PUNCT
dpc-2939	27	1	abstract	abstract	ADJ
dpc-2939	27	2	2	2	NUM
dpc-2939	27	3	original	original	ADJ
dpc-2939	27	4	article	article	NOUN
dpc-2939	27	5	|	|	ADV
dpc-2939	27	6	dermatol	dermatol	ADJ
dpc-2939	27	7	pract	pract	NOUN
dpc-2939	27	8	concept	concept	NOUN
dpc-2939	27	9	.	.	PUNCT
dpc-2939	28	1	2023;13(2):e2023151	2023;13(2):e2023151	NUM
dpc-2939	28	2	introduction	introduction	NOUN
dpc-2939	28	3	actinic	actinic	ADJ
dpc-2939	28	4	keratosis	keratosis	NOUN
dpc-2939	28	5	(	(	PUNCT
dpc-2939	28	6	ak	ak	PROPN
dpc-2939	28	7	)	)	PUNCT
dpc-2939	28	8	is	be	AUX
dpc-2939	28	9	a	a	DET
dpc-2939	28	10	common	common	ADJ
dpc-2939	28	11	skin	skin	NOUN
dpc-2939	28	12	disease	disease	NOUN
dpc-2939	28	13	caused	cause	VERB
dpc-2939	28	14	by	by	ADP
dpc-2939	28	15	chronic	chronic	ADJ
dpc-2939	28	16	sun	sun	NOUN
dpc-2939	28	17	exposure	exposure	NOUN
dpc-2939	28	18	[	[	X
dpc-2939	28	19	1	1	NUM
dpc-2939	28	20	]	]	PUNCT
dpc-2939	28	21	.	.	PUNCT
dpc-2939	29	1	clinically	clinically	ADV
dpc-2939	29	2	,	,	PUNCT
dpc-2939	29	3	ak	ak	PROPN
dpc-2939	29	4	presents	present	NOUN
dpc-2939	29	5	with	with	ADP
dpc-2939	29	6	small	small	ADJ
dpc-2939	29	7	,	,	PUNCT
dpc-2939	29	8	dry	dry	ADJ
dpc-2939	29	9	,	,	PUNCT
dpc-2939	29	10	erythematous	erythematous	ADJ
dpc-2939	29	11	,	,	PUNCT
dpc-2939	29	12	scaly	scaly	NOUN
dpc-2939	29	13	and	and	CCONJ
dpc-2939	29	14	sometimes	sometimes	ADV
dpc-2939	29	15	pigmented	pigment	VERB
dpc-2939	29	16	papules	papule	NOUN
dpc-2939	29	17	 	 	SPACE
dpc-2939	30	1	[	[	X
dpc-2939	30	2	2	2	NUM
dpc-2939	30	3	]	]	PUNCT
dpc-2939	30	4	;	;	PUNCT
dpc-2939	30	5	these	these	DET
dpc-2939	30	6	lesions	lesion	NOUN
dpc-2939	30	7	result	result	VERB
dpc-2939	30	8	from	from	ADP
dpc-2939	30	9	abnormal	abnormal	ADJ
dpc-2939	30	10	proliferation	proliferation	NOUN
dpc-2939	30	11	of	of	ADP
dpc-2939	30	12	atypical	atypical	ADJ
dpc-2939	30	13	epidermal	epidermal	ADJ
dpc-2939	30	14	keratinocytes	keratinocyte	NOUN
dpc-2939	30	15	and	and	CCONJ
dpc-2939	30	16	are	be	AUX
dpc-2939	30	17	located	locate	VERB
dpc-2939	30	18	in	in	ADP
dpc-2939	30	19	chronically	chronically	ADV
dpc-2939	30	20	sun	sun	NOUN
dpc-2939	30	21	-	-	PUNCT
dpc-2939	30	22	exposed	expose	VERB
dpc-2939	30	23	body	body	NOUN
dpc-2939	30	24	areas	area	NOUN
dpc-2939	30	25	such	such	ADJ
dpc-2939	30	26	as	as	ADP
dpc-2939	30	27	the	the	DET
dpc-2939	30	28	face	face	NOUN
dpc-2939	30	29	,	,	PUNCT
dpc-2939	30	30	scalp	scalp	NOUN
dpc-2939	30	31	,	,	PUNCT
dpc-2939	30	32	neck	neck	NOUN
dpc-2939	30	33	,	,	PUNCT
dpc-2939	30	34	hands	hand	NOUN
dpc-2939	30	35	,	,	PUNCT
dpc-2939	30	36	and	and	CCONJ
dpc-2939	30	37	forearms	forearm	NOUN
dpc-2939	31	1	[	[	X
dpc-2939	31	2	1,2	1,2	NUM
dpc-2939	31	3	]	]	PUNCT
dpc-2939	31	4	.	.	PUNCT
dpc-2939	32	1	italy	italy	PROPN
dpc-2939	32	2	shows	show	VERB
dpc-2939	32	3	one	one	NUM
dpc-2939	32	4	of	of	ADP
dpc-2939	32	5	the	the	DET
dpc-2939	32	6	highest	high	ADJ
dpc-2939	32	7	prevalence	prevalence	NOUN
dpc-2939	32	8	of	of	ADP
dpc-2939	32	9	ak	ak	PROPN
dpc-2939	32	10	worldwide	worldwide	ADV
dpc-2939	32	11	[	[	X
dpc-2939	32	12	2,3	2,3	NUM
dpc-2939	32	13	]	]	PUNCT
dpc-2939	32	14	.	.	PUNCT
dpc-2939	33	1	in	in	ADP
dpc-2939	33	2	a	a	DET
dpc-2939	33	3	retrospective	retrospective	ADJ
dpc-2939	33	4	,	,	PUNCT
dpc-2939	33	5	observational	observational	ADJ
dpc-2939	33	6	study	study	NOUN
dpc-2939	33	7	published	publish	VERB
dpc-2939	33	8	in	in	ADP
dpc-2939	33	9	2017	2017	NUM
dpc-2939	33	10	,	,	PUNCT
dpc-2939	33	11	which	which	PRON
dpc-2939	33	12	enrolled	enrol	VERB
dpc-2939	33	13	7,284	7,284	NUM
dpc-2939	33	14	outpatients	outpatient	NOUN
dpc-2939	33	15	attending	attend	VERB
dpc-2939	33	16	italian	italian	ADJ
dpc-2939	33	17	general	general	ADJ
dpc-2939	33	18	dermatology	dermatology	NOUN
dpc-2939	33	19	clinics	clinic	NOUN
dpc-2939	33	20	,	,	PUNCT
dpc-2939	33	21	the	the	DET
dpc-2939	33	22	overall	overall	ADJ
dpc-2939	33	23	mean	mean	ADJ
dpc-2939	33	24	prevalence	prevalence	NOUN
dpc-2939	33	25	of	of	ADP
dpc-2939	33	26	ak	ak	PROPN
dpc-2939	33	27	was	be	AUX
dpc-2939	33	28	27.4	27.4	NUM
dpc-2939	33	29	%	%	NOUN
dpc-2939	33	30	,	,	PUNCT
dpc-2939	33	31	with	with	ADP
dpc-2939	33	32	a	a	DET
dpc-2939	33	33	significantly	significantly	ADV
dpc-2939	33	34	higher	high	ADJ
dpc-2939	33	35	rate	rate	NOUN
dpc-2939	33	36	in	in	ADP
dpc-2939	33	37	males	male	NOUN
dpc-2939	33	38	compared	compare	VERB
dpc-2939	33	39	with	with	ADP
dpc-2939	33	40	females	female	NOUN
dpc-2939	33	41	(	(	PUNCT
dpc-2939	33	42	34.3	34.3	NUM
dpc-2939	33	43	%	%	NOUN
dpc-2939	33	44	versus	versus	ADP
dpc-2939	33	45	20.0	20.0	NUM
dpc-2939	33	46	%	%	NOUN
dpc-2939	33	47	,	,	PUNCT
dpc-2939	33	48	respectively	respectively	ADV
dpc-2939	33	49	;	;	PUNCT
dpc-2939	33	50	p	p	X
dpc-2939	33	51	<	<	NOUN
dpc-2939	33	52	0.001	0.001	NUM
dpc-2939	33	53	)	)	PUNCT
dpc-2939	34	1	[	[	X
dpc-2939	34	2	2	2	NUM
dpc-2939	34	3	]	]	PUNCT
dpc-2939	34	4	.	.	PUNCT
dpc-2939	35	1	the	the	DET
dpc-2939	35	2	same	same	ADJ
dpc-2939	35	3	study	study	NOUN
dpc-2939	35	4	confirmed	confirm	VERB
dpc-2939	35	5	in	in	ADP
dpc-2939	35	6	the	the	DET
dpc-2939	35	7	italian	italian	ADJ
dpc-2939	35	8	population	population	NOUN
dpc-2939	35	9	the	the	DET
dpc-2939	35	10	well	well	ADV
dpc-2939	35	11	-	-	PUNCT
dpc-2939	35	12	known	know	VERB
dpc-2939	35	13	,	,	PUNCT
dpc-2939	35	14	independent	independent	ADJ
dpc-2939	35	15	risk	risk	NOUN
dpc-2939	35	16	factors	factor	NOUN
dpc-2939	35	17	of	of	ADP
dpc-2939	35	18	ak	ak	PROPN
dpc-2939	35	19	,	,	PUNCT
dpc-2939	35	20	i.e.	i.e.	X
dpc-2939	35	21	 	 	SPACE
dpc-2939	35	22	older	old	ADJ
dpc-2939	35	23	age	age	NOUN
dpc-2939	35	24	,	,	PUNCT
dpc-2939	35	25	male	male	ADJ
dpc-2939	35	26	gender	gender	NOUN
dpc-2939	35	27	,	,	PUNCT
dpc-2939	35	28	fair	fair	ADJ
dpc-2939	35	29	skin	skin	NOUN
dpc-2939	35	30	(	(	PUNCT
dpc-2939	35	31	fitzpatrick	fitzpatrick	PROPN
dpc-2939	35	32	phototypes	phototype	VERB
dpc-2939	35	33	i	i	PROPN
dpc-2939	35	34	-	-	PUNCT
dpc-2939	35	35	ii	ii	NOUN
dpc-2939	35	36	)	)	PUNCT
dpc-2939	35	37	,	,	PUNCT
dpc-2939	35	38	prolonged	prolong	VERB
dpc-2939	35	39	uv	uv	NOUN
dpc-2939	35	40	exposure	exposure	NOUN
dpc-2939	35	41	for	for	ADP
dpc-2939	35	42	professional	professional	ADJ
dpc-2939	35	43	or	or	CCONJ
dpc-2939	35	44	recreational	recreational	ADJ
dpc-2939	35	45	reasons	reason	NOUN
dpc-2939	35	46	,	,	PUNCT
dpc-2939	35	47	and	and	CCONJ
dpc-2939	35	48	alcohol	alcohol	NOUN
dpc-2939	35	49	consumption	consumption	NOUN
dpc-2939	35	50	[	[	X
dpc-2939	35	51	1,2	1,2	NUM
dpc-2939	35	52	]	]	PUNCT
dpc-2939	35	53	.	.	PUNCT
dpc-2939	36	1	ak	ak	PROPN
dpc-2939	36	2	is	be	AUX
dpc-2939	36	3	considered	consider	VERB
dpc-2939	36	4	a	a	DET
dpc-2939	36	5	precursor	precursor	NOUN
dpc-2939	36	6	of	of	ADP
dpc-2939	36	7	invasive	invasive	ADJ
dpc-2939	36	8	squamous	squamous	ADJ
dpc-2939	36	9	cell	cell	NOUN
dpc-2939	36	10	carcinoma	carcinoma	NOUN
dpc-2939	36	11	(	(	PUNCT
dpc-2939	36	12	scc	scc	NOUN
dpc-2939	36	13	)	)	PUNCT
dpc-2939	36	14	,	,	PUNCT
dpc-2939	36	15	a	a	DET
dpc-2939	36	16	malignancy	malignancy	NOUN
dpc-2939	36	17	which	which	PRON
dpc-2939	36	18	can	can	AUX
dpc-2939	36	19	produce	produce	VERB
dpc-2939	36	20	distant	distant	ADJ
dpc-2939	36	21	metastases	metastasis	NOUN
dpc-2939	36	22	[	[	X
dpc-2939	36	23	2,3	2,3	NUM
dpc-2939	36	24	]	]	PUNCT
dpc-2939	36	25	.	.	PUNCT
dpc-2939	37	1	the	the	DET
dpc-2939	37	2	ak	ak	PROPN
dpc-2939	37	3	progression	progression	NOUN
dpc-2939	37	4	rate	rate	NOUN
dpc-2939	37	5	is	be	AUX
dpc-2939	37	6	highly	highly	ADV
dpc-2939	37	7	variable	variable	ADJ
dpc-2939	37	8	(	(	PUNCT
dpc-2939	37	9	from	from	ADP
dpc-2939	37	10	0.025	0.025	NUM
dpc-2939	37	11	%	%	NOUN
dpc-2939	37	12	to	to	PART
dpc-2939	37	13	20	20	NUM
dpc-2939	37	14	%	%	NOUN
dpc-2939	37	15	)	)	PUNCT
dpc-2939	37	16	and	and	CCONJ
dpc-2939	37	17	increases	increase	NOUN
dpc-2939	37	18	with	with	ADP
dpc-2939	37	19	the	the	DET
dpc-2939	37	20	number	number	NOUN
dpc-2939	37	21	of	of	ADP
dpc-2939	37	22	lesions	lesion	NOUN
dpc-2939	37	23	,	,	PUNCT
dpc-2939	37	24	being	be	AUX
dpc-2939	37	25	11	11	NUM
dpc-2939	37	26	-	-	NOUN
dpc-2939	37	27	fold	fold	VERB
dpc-2939	37	28	higher	higher	ADV
dpc-2939	37	29	in	in	ADP
dpc-2939	37	30	patients	patient	NOUN
dpc-2939	37	31	with	with	ADP
dpc-2939	37	32	>	>	SYM
dpc-2939	37	33	20	20	NUM
dpc-2939	37	34	lesions	lesion	NOUN
dpc-2939	37	35	[	[	X
dpc-2939	37	36	1,4	1,4	NUM
dpc-2939	37	37	]	]	PUNCT
dpc-2939	37	38	.	.	PUNCT
dpc-2939	38	1	since	since	SCONJ
dpc-2939	38	2	it	it	PRON
dpc-2939	38	3	is	be	AUX
dpc-2939	38	4	impossible	impossible	ADJ
dpc-2939	38	5	to	to	PART
dpc-2939	38	6	predict	predict	VERB
dpc-2939	38	7	lesions	lesion	NOUN
dpc-2939	38	8	risk	risk	NOUN
dpc-2939	38	9	of	of	ADP
dpc-2939	38	10	transformation	transformation	NOUN
dpc-2939	38	11	based	base	VERB
dpc-2939	38	12	on	on	ADP
dpc-2939	38	13	their	their	PRON
dpc-2939	38	14	morphological	morphological	ADJ
dpc-2939	38	15	features	feature	NOUN
dpc-2939	38	16	,	,	PUNCT
dpc-2939	38	17	a	a	DET
dpc-2939	38	18	prompt	prompt	ADJ
dpc-2939	38	19	diagnosis	diagnosis	NOUN
dpc-2939	38	20	and	and	CCONJ
dpc-2939	38	21	treatment	treatment	NOUN
dpc-2939	38	22	of	of	ADP
dpc-2939	38	23	every	every	DET
dpc-2939	38	24	aks	ak	NOUN
dpc-2939	38	25	are	be	AUX
dpc-2939	38	26	essential	essential	ADJ
dpc-2939	38	27	to	to	PART
dpc-2939	38	28	reduce	reduce	VERB
dpc-2939	38	29	the	the	DET
dpc-2939	38	30	risk	risk	NOUN
dpc-2939	38	31	of	of	ADP
dpc-2939	38	32	scc	scc	NOUN
dpc-2939	39	1	[	[	X
dpc-2939	39	2	2,3,5	2,3,5	NUM
dpc-2939	39	3	]	]	X
dpc-2939	39	4	.	.	PUNCT
dpc-2939	40	1	importantly	importantly	ADV
dpc-2939	40	2	,	,	PUNCT
dpc-2939	40	3	according	accord	VERB
dpc-2939	40	4	to	to	ADP
dpc-2939	40	5	the	the	DET
dpc-2939	40	6	“	"	PUNCT
dpc-2939	40	7	field	field	NOUN
dpc-2939	40	8	cancerization	cancerization	NOUN
dpc-2939	40	9	”	"	PUNCT
dpc-2939	40	10	(	(	PUNCT
dpc-2939	40	11	fc	fc	INTJ
dpc-2939	40	12	)	)	PUNCT
dpc-2939	40	13	concept	concept	NOUN
dpc-2939	40	14	,	,	PUNCT
dpc-2939	40	15	treatment	treatment	NOUN
dpc-2939	40	16	should	should	AUX
dpc-2939	40	17	also	also	ADV
dpc-2939	40	18	target	target	VERB
dpc-2939	40	19	the	the	DET
dpc-2939	40	20	skin	skin	NOUN
dpc-2939	40	21	surrounding	surround	VERB
dpc-2939	40	22	ak	ak	PROPN
dpc-2939	40	23	lesions	lesion	NOUN
dpc-2939	40	24	,	,	PUNCT
dpc-2939	40	25	where	where	SCONJ
dpc-2939	40	26	subclinical	subclinical	ADJ
dpc-2939	40	27	lesions	lesion	NOUN
dpc-2939	40	28	with	with	ADP
dpc-2939	40	29	the	the	DET
dpc-2939	40	30	potential	potential	NOUN
dpc-2939	40	31	of	of	ADP
dpc-2939	40	32	malignant	malignant	ADJ
dpc-2939	40	33	transformation	transformation	NOUN
dpc-2939	40	34	could	could	AUX
dpc-2939	40	35	be	be	AUX
dpc-2939	40	36	present	present	ADJ
dpc-2939	40	37	[	[	X
dpc-2939	40	38	6	6	NUM
dpc-2939	40	39	]	]	PUNCT
dpc-2939	40	40	.	.	PUNCT
dpc-2939	41	1	the	the	DET
dpc-2939	41	2	cutaneous	cutaneous	ADJ
dpc-2939	41	3	fc	fc	PROPN
dpc-2939	41	4	is	be	AUX
dpc-2939	41	5	due	due	ADJ
dpc-2939	41	6	to	to	ADP
dpc-2939	41	7	chronic	chronic	ADJ
dpc-2939	41	8	ultraviolet	ultraviolet	ADJ
dpc-2939	41	9	radiation	radiation	NOUN
dpc-2939	41	10	exposure	exposure	NOUN
dpc-2939	41	11	,	,	PUNCT
dpc-2939	41	12	which	which	PRON
dpc-2939	41	13	results	result	VERB
dpc-2939	41	14	in	in	ADP
dpc-2939	41	15	clonal	clonal	ADJ
dpc-2939	41	16	proliferation	proliferation	NOUN
dpc-2939	41	17	of	of	ADP
dpc-2939	41	18	p53mutated	p53mutate	VERB
dpc-2939	41	19	fields	field	NOUN
dpc-2939	41	20	,	,	PUNCT
dpc-2939	41	21	high	high	ADJ
dpc-2939	41	22	burden	burden	NOUN
dpc-2939	41	23	of	of	ADP
dpc-2939	41	24	both	both	CCONJ
dpc-2939	41	25	clinical	clinical	ADJ
dpc-2939	41	26	and	and	CCONJ
dpc-2939	41	27	subclinical	subclinical	ADJ
dpc-2939	41	28	actinic	actinic	ADJ
dpc-2939	41	29	damage	damage	NOUN
dpc-2939	41	30	,	,	PUNCT
dpc-2939	41	31	and	and	CCONJ
dpc-2939	41	32	high	high	ADJ
dpc-2939	41	33	risk	risk	NOUN
dpc-2939	41	34	of	of	ADP
dpc-2939	41	35	developing	develop	VERB
dpc-2939	41	36	multiple	multiple	ADJ
dpc-2939	41	37	sccs	sccs	NOUN
dpc-2939	41	38	;	;	PUNCT
dpc-2939	41	39	these	these	PRON
dpc-2939	41	40	,	,	PUNCT
dpc-2939	41	41	in	in	ADP
dpc-2939	41	42	turn	turn	NOUN
dpc-2939	41	43	,	,	PUNCT
dpc-2939	41	44	are	be	AUX
dpc-2939	41	45	associated	associate	VERB
dpc-2939	41	46	with	with	ADP
dpc-2939	41	47	relevant	relevant	ADJ
dpc-2939	41	48	mortality	mortality	NOUN
dpc-2939	41	49	,	,	PUNCT
dpc-2939	41	50	morbidity	morbidity	NOUN
dpc-2939	41	51	and	and	CCONJ
dpc-2939	41	52	high	high	ADJ
dpc-2939	41	53	costs	cost	NOUN
dpc-2939	41	54	for	for	ADP
dpc-2939	41	55	national	national	ADJ
dpc-2939	41	56	healthcare	healthcare	PROPN
dpc-2939	41	57	systems	system	NOUN
dpc-2939	41	58	[	[	X
dpc-2939	41	59	6	6	NUM
dpc-2939	41	60	]	]	PUNCT
dpc-2939	41	61	.	.	PUNCT
dpc-2939	42	1	given	give	VERB
dpc-2939	42	2	the	the	DET
dpc-2939	42	3	need	need	NOUN
dpc-2939	42	4	for	for	ADP
dpc-2939	42	5	an	an	DET
dpc-2939	42	6	effective	effective	ADJ
dpc-2939	42	7	ak	ak	PROPN
dpc-2939	42	8	treatment	treatment	NOUN
dpc-2939	42	9	,	,	PUNCT
dpc-2939	42	10	several	several	ADJ
dpc-2939	42	11	therapeutic	therapeutic	ADJ
dpc-2939	42	12	options	option	NOUN
dpc-2939	42	13	have	have	AUX
dpc-2939	42	14	been	be	AUX
dpc-2939	42	15	developed	develop	VERB
dpc-2939	42	16	.	.	PUNCT
dpc-2939	43	1	they	they	PRON
dpc-2939	43	2	include	include	VERB
dpc-2939	43	3	lesion	lesion	NOUN
dpc-2939	43	4	-	-	PUNCT
dpc-2939	43	5	directed	direct	VERB
dpc-2939	43	6	treatments	treatment	NOUN
dpc-2939	43	7	,	,	PUNCT
dpc-2939	43	8	such	such	ADJ
dpc-2939	43	9	as	as	ADP
dpc-2939	43	10	cryosurgery	cryosurgery	NOUN
dpc-2939	43	11	,	,	PUNCT
dpc-2939	43	12	curettage	curettage	NOUN
dpc-2939	43	13	,	,	PUNCT
dpc-2939	43	14	and	and	CCONJ
dpc-2939	43	15	excision	excision	NOUN
dpc-2939	43	16	surgery	surgery	NOUN
dpc-2939	43	17	,	,	PUNCT
dpc-2939	43	18	which	which	PRON
dpc-2939	43	19	remove	remove	VERB
dpc-2939	43	20	atypical	atypical	ADJ
dpc-2939	43	21	keratinocytes	keratinocyte	NOUN
dpc-2939	43	22	of	of	ADP
dpc-2939	43	23	every	every	DET
dpc-2939	43	24	single	single	ADJ
dpc-2939	43	25	lesion	lesion	NOUN
dpc-2939	43	26	,	,	PUNCT
dpc-2939	43	27	and	and	CCONJ
dpc-2939	43	28	field	field	NOUN
dpc-2939	43	29	-	-	PUNCT
dpc-2939	43	30	directed	direct	VERB
dpc-2939	43	31	treatment	treatment	NOUN
dpc-2939	43	32	,	,	PUNCT
dpc-2939	43	33	such	such	ADJ
dpc-2939	43	34	as	as	ADP
dpc-2939	43	35	photodynamic	photodynamic	ADJ
dpc-2939	43	36	therapy	therapy	NOUN
dpc-2939	43	37	(	(	PUNCT
dpc-2939	43	38	pdt	pdt	PROPN
dpc-2939	43	39	)	)	PUNCT
dpc-2939	43	40	and	and	CCONJ
dpc-2939	43	41	topical	topical	ADJ
dpc-2939	43	42	treatments	treatment	NOUN
dpc-2939	43	43	,	,	PUNCT
dpc-2939	43	44	whose	whose	DET
dpc-2939	43	45	therapeutic	therapeutic	ADJ
dpc-2939	43	46	action	action	NOUN
dpc-2939	43	47	is	be	AUX
dpc-2939	43	48	extended	extend	VERB
dpc-2939	43	49	to	to	ADP
dpc-2939	43	50	the	the	DET
dpc-2939	43	51	whole	whole	ADJ
dpc-2939	43	52	fc	fc	PROPN
dpc-2939	44	1	[	[	X
dpc-2939	44	2	1	1	NUM
dpc-2939	44	3	]	]	PUNCT
dpc-2939	44	4	.	.	PUNCT
dpc-2939	45	1	5	5	NUM
dpc-2939	45	2	-	-	PUNCT
dpc-2939	45	3	fluorouracil	fluorouracil	NOUN
dpc-2939	45	4	(	(	PUNCT
dpc-2939	45	5	5	5	NUM
dpc-2939	45	6	-	-	PUNCT
dpc-2939	45	7	fu	fu	NOUN
dpc-2939	45	8	)	)	PUNCT
dpc-2939	45	9	is	be	AUX
dpc-2939	45	10	an	an	DET
dpc-2939	45	11	antineoplastic	antineoplastic	ADJ
dpc-2939	45	12	drug	drug	NOUN
dpc-2939	45	13	commonly	commonly	ADV
dpc-2939	45	14	used	use	VERB
dpc-2939	45	15	as	as	ADP
dpc-2939	45	16	a	a	DET
dpc-2939	45	17	topical	topical	ADJ
dpc-2939	45	18	,	,	PUNCT
dpc-2939	45	19	field	field	NOUN
dpc-2939	45	20	-	-	PUNCT
dpc-2939	45	21	directed	direct	VERB
dpc-2939	45	22	treatment	treatment	NOUN
dpc-2939	45	23	for	for	ADP
dpc-2939	45	24	ak	ak	PROPN
dpc-2939	45	25	[	[	X
dpc-2939	45	26	7	7	NUM
dpc-2939	45	27	]	]	PUNCT
dpc-2939	45	28	.	.	PUNCT
dpc-2939	46	1	5	5	NUM
dpc-2939	46	2	-	-	PUNCT
dpc-2939	46	3	fu	fu	NOUN
dpc-2939	46	4	is	be	AUX
dpc-2939	46	5	a	a	DET
dpc-2939	46	6	pyrimidine	pyrimidine	NOUN
dpc-2939	46	7	analogue	analogue	NOUN
dpc-2939	46	8	,	,	PUNCT
dpc-2939	46	9	which	which	PRON
dpc-2939	46	10	irreversibly	irreversibly	ADV
dpc-2939	46	11	inactivates	inactivate	VERB
dpc-2939	46	12	thymidylate	thymidylate	NOUN
dpc-2939	46	13	synthase	synthase	NOUN
dpc-2939	46	14	,	,	PUNCT
dpc-2939	46	15	interfering	interfere	VERB
dpc-2939	46	16	with	with	ADP
dpc-2939	46	17	dna	dna	NOUN
dpc-2939	46	18	synthesis	synthesis	NOUN
dpc-2939	46	19	and	and	CCONJ
dpc-2939	46	20	causing	cause	VERB
dpc-2939	46	21	apoptosis	apoptosis	NOUN
dpc-2939	46	22	of	of	ADP
dpc-2939	46	23	the	the	DET
dpc-2939	46	24	high	high	ADJ
dpc-2939	46	25	proliferative	proliferative	ADJ
dpc-2939	46	26	ak	ak	PROPN
dpc-2939	46	27	keratinocytes	keratinocytes	PROPN
dpc-2939	46	28	  	  	SPACE
dpc-2939	47	1	[	[	X
dpc-2939	47	2	1,8	1,8	NUM
dpc-2939	47	3	]	]	X
dpc-2939	47	4	.	.	PUNCT
dpc-2939	48	1	it	it	PRON
dpc-2939	48	2	was	be	AUX
dpc-2939	48	3	the	the	DET
dpc-2939	48	4	first	first	ADJ
dpc-2939	48	5	drug	drug	NOUN
dpc-2939	48	6	for	for	ADP
dpc-2939	48	7	ak	ak	PROPN
dpc-2939	48	8	field	field	NOUN
dpc-2939	48	9	-	-	PUNCT
dpc-2939	48	10	directed	direct	VERB
dpc-2939	48	11	treatment	treatment	NOUN
dpc-2939	48	12	and	and	CCONJ
dpc-2939	48	13	its	its	PRON
dpc-2939	48	14	approval	approval	NOUN
dpc-2939	48	15	dates	date	VERB
dpc-2939	48	16	back	back	ADV
dpc-2939	48	17	to	to	ADP
dpc-2939	48	18	1962	1962	NUM
dpc-2939	48	19	[	[	X
dpc-2939	48	20	3	3	NUM
dpc-2939	48	21	]	]	PUNCT
dpc-2939	48	22	.	.	PUNCT
dpc-2939	49	1	5	5	NUM
dpc-2939	49	2	-	-	PUNCT
dpc-2939	49	3	fu	fu	NOUN
dpc-2939	49	4	is	be	AUX
dpc-2939	49	5	available	available	ADJ
dpc-2939	49	6	for	for	ADP
dpc-2939	49	7	ak	ak	PROPN
dpc-2939	49	8	treatment	treatment	NOUN
dpc-2939	49	9	in	in	ADP
dpc-2939	49	10	various	various	ADJ
dpc-2939	49	11	formulations	formulation	NOUN
dpc-2939	49	12	,	,	PUNCT
dpc-2939	49	13	with	with	ADP
dpc-2939	49	14	concentrations	concentration	NOUN
dpc-2939	49	15	ranging	range	VERB
dpc-2939	49	16	from	from	ADP
dpc-2939	49	17	0.5	0.5	NUM
dpc-2939	49	18	to	to	PART
dpc-2939	49	19	5	5	NUM
dpc-2939	49	20	%	%	NOUN
dpc-2939	49	21	[	[	X
dpc-2939	49	22	8	8	NUM
dpc-2939	49	23	]	]	PUNCT
dpc-2939	49	24	.	.	PUNCT
dpc-2939	50	1	the	the	DET
dpc-2939	50	2	5	5	NUM
dpc-2939	50	3	%	%	NOUN
dpc-2939	50	4	5	5	NUM
dpc-2939	50	5	-	-	PUNCT
dpc-2939	50	6	fu	fu	NOUN
dpc-2939	50	7	cream	cream	NOUN
dpc-2939	50	8	efficacy	efficacy	NOUN
dpc-2939	50	9	is	be	AUX
dpc-2939	50	10	supported	support	VERB
dpc-2939	50	11	by	by	ADP
dpc-2939	50	12	a	a	DET
dpc-2939	50	13	substantial	substantial	ADJ
dpc-2939	50	14	number	number	NOUN
dpc-2939	50	15	of	of	ADP
dpc-2939	50	16	studies	study	NOUN
dpc-2939	50	17	.	.	PUNCT
dpc-2939	51	1	in	in	ADP
dpc-2939	51	2	a	a	DET
dpc-2939	51	3	network	network	NOUN
dpc-2939	51	4	meta	meta	ADJ
dpc-2939	51	5	-	-	PUNCT
dpc-2939	51	6	analysis	analysis	NOUN
dpc-2939	51	7	published	publish	VERB
dpc-2939	51	8	in	in	ADP
dpc-2939	51	9	2019	2019	NUM
dpc-2939	51	10	by	by	ADP
dpc-2939	51	11	wu	wu	PROPN
dpc-2939	51	12	et	et	PROPN
dpc-2939	51	13	al	al	PROPN
dpc-2939	51	14	,	,	PUNCT
dpc-2939	51	15	including	include	VERB
dpc-2939	51	16	11	11	NUM
dpc-2939	51	17	studies	study	NOUN
dpc-2939	51	18	and	and	CCONJ
dpc-2939	51	19	more	more	ADJ
dpc-2939	51	20	than	than	ADP
dpc-2939	51	21	2200	2200	NUM
dpc-2939	51	22	patients	patient	NOUN
dpc-2939	51	23	,	,	PUNCT
dpc-2939	51	24	5	5	NUM
dpc-2939	51	25	%	%	NOUN
dpc-2939	51	26	5	5	NUM
dpc-2939	51	27	-	-	PUNCT
dpc-2939	51	28	fu	fu	NOUN
dpc-2939	51	29	was	be	AUX
dpc-2939	51	30	more	more	ADV
dpc-2939	51	31	likely	likely	ADJ
dpc-2939	51	32	to	to	PART
dpc-2939	51	33	be	be	AUX
dpc-2939	51	34	effective	effective	ADJ
dpc-2939	51	35	in	in	ADP
dpc-2939	51	36	ak	ak	PROPN
dpc-2939	51	37	lesions	lesion	NOUN
dpc-2939	51	38	total	total	NOUN
dpc-2939	51	39	clearance	clearance	NOUN
dpc-2939	51	40	compared	compare	VERB
dpc-2939	51	41	with	with	ADP
dpc-2939	51	42	the	the	DET
dpc-2939	51	43	association	association	NOUN
dpc-2939	51	44	of	of	ADP
dpc-2939	51	45	5	5	NUM
dpc-2939	51	46	-	-	PUNCT
dpc-2939	51	47	fu	fu	NOUN
dpc-2939	51	48	with	with	ADP
dpc-2939	51	49	salicylic	salicylic	ADJ
dpc-2939	51	50	acid	acid	NOUN
dpc-2939	51	51	,	,	PUNCT
dpc-2939	51	52	3	3	NUM
dpc-2939	51	53	%	%	NOUN
dpc-2939	51	54	diclofenac	diclofenac	NOUN
dpc-2939	51	55	sodium	sodium	NOUN
dpc-2939	51	56	,	,	PUNCT
dpc-2939	51	57	and	and	CCONJ
dpc-2939	51	58	cryosurgery	cryosurgery	NOUN
dpc-2939	51	59	(	(	PUNCT
dpc-2939	51	60	56.8	56.8	NUM
dpc-2939	51	61	%	%	NOUN
dpc-2939	51	62	vs	vs	ADP
dpc-2939	51	63	37.5	37.5	NUM
dpc-2939	51	64	%	%	NOUN
dpc-2939	51	65	,	,	PUNCT
dpc-2939	51	66	6.6	6.6	NUM
dpc-2939	51	67	%	%	NOUN
dpc-2939	51	68	,	,	PUNCT
dpc-2939	51	69	and	and	CCONJ
dpc-2939	51	70	0.9	0.9	NUM
dpc-2939	51	71	%	%	NOUN
dpc-2939	51	72	,	,	PUNCT
dpc-2939	51	73	respectively	respectively	ADV
dpc-2939	51	74	)	)	PUNCT
dpc-2939	52	1	[	[	X
dpc-2939	52	2	7	7	NUM
dpc-2939	52	3	]	]	PUNCT
dpc-2939	52	4	.	.	PUNCT
dpc-2939	53	1	5	5	NUM
dpc-2939	53	2	%	%	NOUN
dpc-2939	53	3	5	5	NUM
dpc-2939	53	4	-	-	PUNCT
dpc-2939	53	5	fu	fu	NOUN
dpc-2939	53	6	resulted	result	VERB
dpc-2939	53	7	also	also	ADV
dpc-2939	53	8	more	more	ADV
dpc-2939	53	9	likely	likely	ADJ
dpc-2939	53	10	to	to	PART
dpc-2939	53	11	be	be	AUX
dpc-2939	53	12	the	the	DET
dpc-2939	53	13	most	most	ADV
dpc-2939	53	14	effective	effective	ADJ
dpc-2939	53	15	treatment	treatment	NOUN
dpc-2939	53	16	among	among	ADP
dpc-2939	53	17	patients	patient	NOUN
dpc-2939	53	18	with	with	ADP
dpc-2939	53	19	lesions	lesion	NOUN
dpc-2939	53	20	reduction	reduction	NOUN
dpc-2939	53	21	from	from	ADP
dpc-2939	53	22	baseline	baseline	PROPN
dpc-2939	53	23	(	(	PUNCT
dpc-2939	53	24	98.6	98.6	NUM
dpc-2939	53	25	%	%	NOUN
dpc-2939	53	26	)	)	PUNCT
dpc-2939	53	27	.	.	PUNCT
dpc-2939	54	1	in	in	ADP
dpc-2939	54	2	a	a	DET
dpc-2939	54	3	multicentre	multicentre	NOUN
dpc-2939	54	4	,	,	PUNCT
dpc-2939	54	5	single	single	ADJ
dpc-2939	54	6	-	-	PUNCT
dpc-2939	54	7	blind	blind	ADJ
dpc-2939	54	8	,	,	PUNCT
dpc-2939	54	9	randomized	randomize	VERB
dpc-2939	54	10	trial	trial	NOUN
dpc-2939	54	11	published	publish	VERB
dpc-2939	54	12	by	by	ADP
dpc-2939	54	13	jansen	jansen	PROPN
dpc-2939	54	14	et	et	PROPN
dpc-2939	54	15	al	al	PROPN
dpc-2939	54	16	in	in	ADP
dpc-2939	54	17	2019	2019	NUM
dpc-2939	54	18	,	,	PUNCT
dpc-2939	54	19	patients	patient	NOUN
dpc-2939	54	20	treated	treat	VERB
dpc-2939	54	21	with	with	ADP
dpc-2939	54	22	5	5	NUM
dpc-2939	54	23	%	%	NOUN
dpc-2939	54	24	5	5	NUM
dpc-2939	54	25	-	-	PUNCT
dpc-2939	54	26	fu	fu	NOUN
dpc-2939	54	27	showed	show	VERB
dpc-2939	54	28	a	a	DET
dpc-2939	54	29	significantly	significantly	ADV
dpc-2939	54	30	higher	high	ADJ
dpc-2939	54	31	cumulative	cumulative	ADJ
dpc-2939	54	32	probability	probability	NOUN
dpc-2939	54	33	of	of	ADP
dpc-2939	54	34	remaining	remain	VERB
dpc-2939	54	35	free	free	ADJ
dpc-2939	54	36	from	from	ADP
dpc-2939	54	37	treatment	treatment	NOUN
dpc-2939	54	38	failure	failure	NOUN
dpc-2939	54	39	at	at	ADP
dpc-2939	54	40	12	12	NUM
dpc-2939	54	41	months	month	NOUN
dpc-2939	54	42	compared	compare	VERB
dpc-2939	54	43	with	with	ADP
dpc-2939	54	44	patients	patient	NOUN
dpc-2939	54	45	who	who	PRON
dpc-2939	54	46	received	receive	VERB
dpc-2939	54	47	5	5	NUM
dpc-2939	54	48	%	%	NOUN
dpc-2939	54	49	imiquimod	imiquimod	ADJ
dpc-2939	54	50	,	,	PUNCT
dpc-2939	54	51	methyl	methyl	NOUN
dpc-2939	54	52	aminolevulinate	aminolevulinate	NOUN
dpc-2939	54	53	pdt	pdt	PROPN
dpc-2939	54	54	,	,	PUNCT
dpc-2939	54	55	or	or	CCONJ
dpc-2939	54	56	0.015	0.015	NUM
dpc-2939	54	57	%	%	NOUN
dpc-2939	54	58	ingenol	ingenol	PROPN
dpc-2939	54	59	mebutate	mebutate	NOUN
dpc-2939	54	60	(	(	PUNCT
dpc-2939	54	61	74.7	74.7	NUM
dpc-2939	54	62	%	%	NOUN
dpc-2939	54	63	vs	vs	ADP
dpc-2939	54	64	53.9	53.9	NUM
dpc-2939	54	65	%	%	NOUN
dpc-2939	54	66	,	,	PUNCT
dpc-2939	54	67	37.7	37.7	NUM
dpc-2939	54	68	%	%	NOUN
dpc-2939	54	69	,	,	PUNCT
dpc-2939	54	70	and	and	CCONJ
dpc-2939	54	71	28.6	28.6	NUM
dpc-2939	54	72	%	%	NOUN
dpc-2939	54	73	,	,	PUNCT
dpc-2939	54	74	respectively	respectively	ADV
dpc-2939	54	75	;	;	PUNCT
dpc-2939	55	1	p	p	NOUN
dpc-2939	55	2	≤0.001	≤0.001	NOUN
dpc-2939	55	3	)	)	PUNCT
dpc-2939	56	1	[	[	X
dpc-2939	56	2	9	9	NUM
dpc-2939	56	3	]	]	PUNCT
dpc-2939	56	4	.	.	PUNCT
dpc-2939	57	1	finally	finally	ADV
dpc-2939	57	2	,	,	PUNCT
dpc-2939	57	3	according	accord	VERB
dpc-2939	57	4	to	to	ADP
dpc-2939	57	5	a	a	DET
dpc-2939	57	6	recent	recent	ADJ
dpc-2939	57	7	secondary	secondary	ADJ
dpc-2939	57	8	analysis	analysis	NOUN
dpc-2939	57	9	of	of	ADP
dpc-2939	57	10	a	a	DET
dpc-2939	57	11	randomized	randomized	ADJ
dpc-2939	57	12	clinical	clinical	ADJ
dpc-2939	57	13	trial	trial	NOUN
dpc-2939	57	14	,	,	PUNCT
dpc-2939	57	15	5	5	NUM
dpc-2939	57	16	%	%	NOUN
dpc-2939	57	17	5	5	NUM
dpc-2939	57	18	-	-	PUNCT
dpc-2939	57	19	fu	fu	NOUN
dpc-2939	57	20	seems	seem	VERB
dpc-2939	57	21	to	to	PART
dpc-2939	57	22	reduce	reduce	VERB
dpc-2939	57	23	longterm	longterm	ADJ
dpc-2939	57	24	scc	scc	ADJ
dpc-2939	57	25	risk	risk	NOUN
dpc-2939	57	26	compared	compare	VERB
dpc-2939	57	27	with	with	ADP
dpc-2939	57	28	other	other	ADJ
dpc-2939	57	29	field	field	NOUN
dpc-2939	57	30	-	-	PUNCT
dpc-2939	57	31	directed	direct	VERB
dpc-2939	57	32	ak	ak	PROPN
dpc-2939	57	33	treatments	treatment	NOUN
dpc-2939	57	34	 	 	SPACE
dpc-2939	58	1	[	[	X
dpc-2939	58	2	10	10	NUM
dpc-2939	58	3	]	]	PUNCT
dpc-2939	58	4	.	.	PUNCT
dpc-2939	59	1	in	in	ADP
dpc-2939	59	2	this	this	DET
dpc-2939	59	3	analysis	analysis	NOUN
dpc-2939	59	4	,	,	PUNCT
dpc-2939	59	5	conducted	conduct	VERB
dpc-2939	59	6	on	on	ADP
dpc-2939	59	7	624	624	NUM
dpc-2939	59	8	patients	patient	NOUN
dpc-2939	59	9	with	with	ADP
dpc-2939	59	10	ak	ak	PROPN
dpc-2939	59	11	,	,	PUNCT
dpc-2939	59	12	the	the	DET
dpc-2939	59	13	4	4	NUM
dpc-2939	59	14	-	-	PUNCT
dpc-2939	59	15	year	year	NOUN
dpc-2939	59	16	risk	risk	NOUN
dpc-2939	59	17	of	of	ADP
dpc-2939	59	18	cutaneous	cutaneous	ADJ
dpc-2939	59	19	scc	scc	NOUN
dpc-2939	59	20	in	in	ADP
dpc-2939	59	21	the	the	DET
dpc-2939	59	22	treated	treat	VERB
dpc-2939	59	23	area	area	NOUN
dpc-2939	59	24	resulted	result	VERB
dpc-2939	59	25	lower	lower	ADV
dpc-2939	59	26	in	in	ADP
dpc-2939	59	27	subjects	subject	NOUN
dpc-2939	59	28	who	who	PRON
dpc-2939	59	29	initially	initially	ADV
dpc-2939	59	30	received	receive	VERB
dpc-2939	59	31	5	5	NUM
dpc-2939	59	32	%	%	NOUN
dpc-2939	59	33	5	5	NUM
dpc-2939	59	34	-	-	PUNCT
dpc-2939	59	35	fu	fu	NOUN
dpc-2939	59	36	(	(	PUNCT
dpc-2939	59	37	2.2	2.2	NUM
dpc-2939	59	38	%	%	NOUN
dpc-2939	59	39	)	)	PUNCT
dpc-2939	59	40	compared	compare	VERB
dpc-2939	59	41	with	with	ADP
dpc-2939	59	42	imiquimod	imiquimod	PROPN
dpc-2939	59	43	(	(	PUNCT
dpc-2939	59	44	5.8	5.8	NUM
dpc-2939	59	45	%	%	NOUN
dpc-2939	59	46	)	)	PUNCT
dpc-2939	59	47	,	,	PUNCT
dpc-2939	59	48	methyl	methyl	NOUN
dpc-2939	59	49	aminolevulinate	aminolevulinate	NOUN
dpc-2939	59	50	pdt	pdt	PROPN
dpc-2939	59	51	(	(	PUNCT
dpc-2939	59	52	3.6	3.6	NUM
dpc-2939	59	53	%	%	NOUN
dpc-2939	59	54	)	)	PUNCT
dpc-2939	59	55	,	,	PUNCT
dpc-2939	59	56	or	or	CCONJ
dpc-2939	59	57	ingenol	ingenol	PROPN
dpc-2939	59	58	mebutate	mebutate	NOUN
dpc-2939	59	59	(	(	PUNCT
dpc-2939	59	60	3.0	3.0	NUM
dpc-2939	59	61	%	%	NOUN
dpc-2939	59	62	)	)	PUNCT
dpc-2939	60	1	[	[	X
dpc-2939	60	2	10	10	NUM
dpc-2939	60	3	]	]	PUNCT
dpc-2939	60	4	.	.	PUNCT
dpc-2939	61	1	in	in	ADP
dpc-2939	61	2	2020	2020	NUM
dpc-2939	61	3	,	,	PUNCT
dpc-2939	61	4	the	the	DET
dpc-2939	61	5	european	european	PROPN
dpc-2939	61	6	medicines	medicine	NOUN
dpc-2939	61	7	agency	agency	NOUN
dpc-2939	61	8	approved	approve	VERB
dpc-2939	61	9	a	a	DET
dpc-2939	61	10	novel	novel	NOUN
dpc-2939	61	11	4	4	NUM
dpc-2939	61	12	%	%	NOUN
dpc-2939	61	13	5	5	NUM
dpc-2939	61	14	-	-	PUNCT
dpc-2939	61	15	fu	fu	NOUN
dpc-2939	61	16	formulation	formulation	NOUN
dpc-2939	61	17	for	for	ADP
dpc-2939	61	18	the	the	DET
dpc-2939	61	19	treatment	treatment	NOUN
dpc-2939	61	20	of	of	ADP
dpc-2939	61	21	olsen	olsen	NOUN
dpc-2939	61	22	grade	grade	NOUN
dpc-2939	61	23	i	i	PROPN
dpc-2939	61	24	or	or	CCONJ
dpc-2939	61	25	ii	ii	PROPN
dpc-2939	61	26	ak	ak	PROPN
dpc-2939	62	1	[	[	X
dpc-2939	62	2	11,12	11,12	NOUN
dpc-2939	62	3	]	]	PUNCT
dpc-2939	62	4	.	.	PUNCT
dpc-2939	63	1	the	the	DET
dpc-2939	63	2	4	4	NUM
dpc-2939	63	3	%	%	NOUN
dpc-2939	63	4	formulation	formulation	NOUN
dpc-2939	63	5	has	have	VERB
dpc-2939	63	6	a	a	DET
dpc-2939	63	7	more	more	ADV
dpc-2939	63	8	convenient	convenient	ADJ
dpc-2939	63	9	dosage	dosage	NOUN
dpc-2939	63	10	compared	compare	VERB
dpc-2939	63	11	with	with	ADP
dpc-2939	63	12	twice	twice	ADV
dpc-2939	63	13	daily	daily	ADJ
dpc-2939	63	14	5	5	NUM
dpc-2939	63	15	%	%	NOUN
dpc-2939	63	16	5	5	NUM
dpc-2939	63	17	-	-	PUNCT
dpc-2939	63	18	fu	fu	NOUN
dpc-2939	63	19	:	:	PUNCT
dpc-2939	63	20	it	it	PRON
dpc-2939	63	21	should	should	AUX
dpc-2939	63	22	be	be	AUX
dpc-2939	63	23	applied	apply	VERB
dpc-2939	63	24	once	once	ADV
dpc-2939	63	25	daily	daily	ADV
dpc-2939	63	26	for	for	ADP
dpc-2939	63	27	a	a	DET
dpc-2939	63	28	maximum	maximum	NOUN
dpc-2939	63	29	of	of	ADP
dpc-2939	63	30	4	4	NUM
dpc-2939	63	31	weeks	week	NOUN
dpc-2939	63	32	,	,	PUNCT
dpc-2939	63	33	potentially	potentially	ADV
dpc-2939	63	34	improving	improve	VERB
dpc-2939	63	35	treatment	treatment	NOUN
dpc-2939	63	36	compliance	compliance	NOUN
dpc-2939	63	37	[	[	X
dpc-2939	63	38	12,13	12,13	NUM
dpc-2939	63	39	]	]	PUNCT
dpc-2939	63	40	.	.	PUNCT
dpc-2939	64	1	in	in	ADP
dpc-2939	64	2	a	a	DET
dpc-2939	64	3	multicenter	multicenter	NOUN
dpc-2939	64	4	,	,	PUNCT
dpc-2939	64	5	randomized	randomize	VERB
dpc-2939	64	6	,	,	PUNCT
dpc-2939	64	7	double	double	ADJ
dpc-2939	64	8	-	-	PUNCT
dpc-2939	64	9	blind	blind	ADJ
dpc-2939	64	10	,	,	PUNCT
dpc-2939	64	11	parallel	parallel	ADJ
dpc-2939	64	12	group	group	NOUN
dpc-2939	64	13	,	,	PUNCT
dpc-2939	64	14	phase	phase	NOUN
dpc-2939	64	15	iii	iii	NUM
dpc-2939	64	16	study	study	NOUN
dpc-2939	64	17	conducted	conduct	VERB
dpc-2939	64	18	in	in	ADP
dpc-2939	64	19	841	841	NUM
dpc-2939	64	20	subjects	subject	NOUN
dpc-2939	64	21	with	with	ADP
dpc-2939	64	22	ak	ak	PROPN
dpc-2939	64	23	,	,	PUNCT
dpc-2939	64	24	4	4	NUM
dpc-2939	64	25	%	%	NOUN
dpc-2939	64	26	5	5	NUM
dpc-2939	64	27	-	-	PUNCT
dpc-2939	64	28	fu	fu	NOUN
dpc-2939	64	29	efficacy	efficacy	NOUN
dpc-2939	64	30	was	be	AUX
dpc-2939	64	31	similar	similar	ADJ
dpc-2939	64	32	to	to	ADP
dpc-2939	64	33	5	5	NUM
dpc-2939	64	34	%	%	NOUN
dpc-2939	64	35	5	5	NUM
dpc-2939	64	36	-	-	PUNCT
dpc-2939	64	37	fu	fu	NOUN
dpc-2939	64	38	in	in	ADP
dpc-2939	64	39	terms	term	NOUN
dpc-2939	64	40	of	of	ADP
dpc-2939	64	41	100	100	NUM
dpc-2939	64	42	%	%	NOUN
dpc-2939	64	43	lesions	lesion	NOUN
dpc-2939	64	44	clearance	clearance	NOUN
dpc-2939	64	45	at	at	ADP
dpc-2939	64	46	4	4	NUM
dpc-2939	64	47	weeks	week	NOUN
dpc-2939	64	48	(	(	PUNCT
dpc-2939	64	49	54.4	54.4	NUM
dpc-2939	64	50	%	%	NOUN
dpc-2939	64	51	versus	versus	ADP
dpc-2939	64	52	57.9	57.9	NUM
dpc-2939	64	53	%	%	NOUN
dpc-2939	64	54	,	,	PUNCT
dpc-2939	64	55	respectively	respectively	ADV
dpc-2939	64	56	)	)	PUNCT
dpc-2939	64	57	,	,	PUNCT
dpc-2939	64	58	≥75	≥75	NOUN
dpc-2939	64	59	%	%	NOUN
dpc-2939	64	60	lesions	lesion	NOUN
dpc-2939	64	61	clearance	clearance	NOUN
dpc-2939	64	62	at	at	ADP
dpc-2939	64	63	4	4	NUM
dpc-2939	64	64	weeks	week	NOUN
dpc-2939	64	65	(	(	PUNCT
dpc-2939	64	66	80.5	80.5	NUM
dpc-2939	64	67	%	%	NOUN
dpc-2939	64	68	versus	versus	ADP
dpc-2939	64	69	80.2	80.2	NUM
dpc-2939	64	70	%	%	NOUN
dpc-2939	64	71	,	,	PUNCT
dpc-2939	64	72	respectively	respectively	ADV
dpc-2939	64	73	)	)	PUNCT
dpc-2939	64	74	,	,	PUNCT
dpc-2939	64	75	and	and	CCONJ
dpc-2939	64	76	percentage	percentage	NOUN
dpc-2939	64	77	change	change	NOUN
dpc-2939	64	78	from	from	ADP
dpc-2939	64	79	baseline	baseline	NOUN
dpc-2939	64	80	in	in	ADP
dpc-2939	64	81	ak	ak	PROPN
dpc-2939	64	82	lesions	lesion	NOUN
dpc-2939	64	83	count	count	NOUN
dpc-2939	64	84	(	(	PUNCT
dpc-2939	64	85	80.1	80.1	NUM
dpc-2939	64	86	%	%	NOUN
dpc-2939	64	87	versus	versus	ADP
dpc-2939	64	88	79	79	NUM
dpc-2939	64	89	%	%	NOUN
dpc-2939	64	90	)	)	PUNCT
dpc-2939	65	1	[	[	X
dpc-2939	65	2	11,13	11,13	NUM
dpc-2939	65	3	]	]	PUNCT
dpc-2939	65	4	.	.	PUNCT
dpc-2939	66	1	notably	notably	ADV
dpc-2939	66	2	,	,	PUNCT
dpc-2939	66	3	4	4	NUM
dpc-2939	66	4	%	%	NOUN
dpc-2939	66	5	5	5	NUM
dpc-2939	66	6	-	-	PUNCT
dpc-2939	66	7	fu	fu	NOUN
dpc-2939	66	8	showed	show	VERB
dpc-2939	66	9	an	an	DET
dpc-2939	66	10	improved	improved	ADJ
dpc-2939	66	11	safety	safety	NOUN
dpc-2939	66	12	profile	profile	NOUN
dpc-2939	66	13	compared	compare	VERB
dpc-2939	66	14	with	with	ADP
dpc-2939	66	15	5	5	NUM
dpc-2939	66	16	%	%	NOUN
dpc-2939	66	17	5	5	NUM
dpc-2939	66	18	-	-	PUNCT
dpc-2939	66	19	fu	fu	NOUN
dpc-2939	66	20	,	,	PUNCT
dpc-2939	66	21	with	with	ADP
dpc-2939	66	22	a	a	DET
dpc-2939	66	23	lower	low	ADJ
dpc-2939	66	24	rate	rate	NOUN
dpc-2939	66	25	of	of	ADP
dpc-2939	66	26	adverse	adverse	ADJ
dpc-2939	66	27	events	event	NOUN
dpc-2939	66	28	leading	lead	VERB
dpc-2939	66	29	to	to	ADP
dpc-2939	66	30	treatment	treatment	NOUN
dpc-2939	66	31	discontinuation	discontinuation	NOUN
dpc-2939	66	32	(	(	PUNCT
dpc-2939	66	33	10.1	10.1	NUM
dpc-2939	66	34	%	%	NOUN
dpc-2939	66	35	versus	versus	ADP
dpc-2939	66	36	14.9	14.9	NUM
dpc-2939	66	37	%	%	NOUN
dpc-2939	66	38	,	,	PUNCT
dpc-2939	66	39	respectively	respectively	ADV
dpc-2939	66	40	)	)	PUNCT
dpc-2939	67	1	[	[	X
dpc-2939	67	2	11,13	11,13	NUM
dpc-2939	67	3	]	]	PUNCT
dpc-2939	67	4	.	.	PUNCT
dpc-2939	68	1	these	these	DET
dpc-2939	68	2	results	result	NOUN
dpc-2939	68	3	were	be	AUX
dpc-2939	68	4	confirmed	confirm	VERB
dpc-2939	68	5	by	by	ADP
dpc-2939	68	6	a	a	DET
dpc-2939	68	7	recently	recently	ADV
dpc-2939	68	8	published	publish	VERB
dpc-2939	68	9	network	network	NOUN
dpc-2939	68	10	meta	meta	NOUN
dpc-2939	68	11	-	-	PUNCT
dpc-2939	68	12	analysis	analysis	NOUN
dpc-2939	68	13	which	which	PRON
dpc-2939	68	14	included	include	VERB
dpc-2939	68	15	75	75	NUM
dpc-2939	68	16	randomized	randomized	ADJ
dpc-2939	68	17	clinical	clinical	ADJ
dpc-2939	68	18	trials	trial	NOUN
dpc-2939	68	19	[	[	X
dpc-2939	68	20	14	14	NUM
dpc-2939	68	21	]	]	PUNCT
dpc-2939	68	22	.	.	PUNCT
dpc-2939	69	1	in	in	ADP
dpc-2939	69	2	this	this	DET
dpc-2939	69	3	analysis	analysis	NOUN
dpc-2939	69	4	,	,	PUNCT
dpc-2939	69	5	4	4	NUM
dpc-2939	69	6	%	%	NOUN
dpc-2939	69	7	5	5	NUM
dpc-2939	69	8	-	-	PUNCT
dpc-2939	69	9	fu	fu	NOUN
dpc-2939	69	10	was	be	AUX
dpc-2939	69	11	compared	compare	VERB
dpc-2939	69	12	with	with	ADP
dpc-2939	69	13	5	5	NUM
dpc-2939	69	14	%	%	NOUN
dpc-2939	69	15	formulation	formulation	NOUN
dpc-2939	69	16	,	,	PUNCT
dpc-2939	69	17	placebo	placebo	NOUN
dpc-2939	69	18	and	and	CCONJ
dpc-2939	69	19	several	several	ADJ
dpc-2939	69	20	other	other	ADJ
dpc-2939	69	21	topical	topical	ADJ
dpc-2939	69	22	treatments	treatment	NOUN
dpc-2939	69	23	for	for	ADP
dpc-2939	69	24	ak	ak	PROPN
dpc-2939	69	25	(	(	PUNCT
dpc-2939	69	26	diclofenac	diclofenac	NOUN
dpc-2939	69	27	sodium	sodium	NOUN
dpc-2939	69	28	,	,	PUNCT
dpc-2939	69	29	imiquimod	imiquimod	ADJ
dpc-2939	69	30	,	,	PUNCT
dpc-2939	69	31	ingenol	ingenol	ADJ
dpc-2939	69	32	mebutate	mebutate	NOUN
dpc-2939	69	33	,	,	PUNCT
dpc-2939	69	34	and	and	CCONJ
dpc-2939	69	35	pdt	pdt	PROPN
dpc-2939	69	36	)	)	PUNCT
dpc-2939	69	37	.	.	PUNCT
dpc-2939	70	1	the	the	DET
dpc-2939	70	2	surface	surface	NOUN
dpc-2939	70	3	under	under	ADP
dpc-2939	70	4	the	the	DET
dpc-2939	70	5	cumulative	cumulative	ADJ
dpc-2939	70	6	ranking	ranking	ADJ
dpc-2939	70	7	(	(	PUNCT
dpc-2939	70	8	sucra	sucra	NOUN
dpc-2939	70	9	)	)	PUNCT
dpc-2939	70	10	values	value	NOUN
dpc-2939	70	11	ranked	rank	VERB
dpc-2939	70	12	4	4	NUM
dpc-2939	70	13	%	%	NOUN
dpc-2939	70	14	5	5	NUM
dpc-2939	70	15	-	-	PUNCT
dpc-2939	70	16	fu	fu	NOUN
dpc-2939	70	17	as	as	ADP
dpc-2939	70	18	having	have	VERB
dpc-2939	70	19	the	the	DET
dpc-2939	70	20	probability	probability	NOUN
dpc-2939	70	21	of	of	ADP
dpc-2939	70	22	being	be	AUX
dpc-2939	70	23	the	the	DET
dpc-2939	70	24	best	good	ADJ
dpc-2939	70	25	treatment	treatment	NOUN
dpc-2939	70	26	in	in	ADP
dpc-2939	70	27	achieving	achieve	VERB
dpc-2939	70	28	≥75	≥75	NOUN
dpc-2939	70	29	%	%	NOUN
dpc-2939	70	30	clearance	clearance	NOUN
dpc-2939	70	31	of	of	ADP
dpc-2939	70	32	ak	ak	PROPN
dpc-2939	70	33	lesions	lesion	NOUN
dpc-2939	70	34	,	,	PUNCT
dpc-2939	70	35	followed	follow	VERB
dpc-2939	70	36	by	by	ADP
dpc-2939	70	37	5	5	NUM
dpc-2939	70	38	%	%	NOUN
dpc-2939	70	39	5	5	NUM
dpc-2939	70	40	-	-	PUNCT
dpc-2939	70	41	fu	fu	NOUN
dpc-2939	70	42	(	(	PUNCT
dpc-2939	70	43	sucra	sucra	NOUN
dpc-2939	70	44	89.98	89.98	NUM
dpc-2939	70	45	versus	versus	ADP
dpc-2939	70	46	original	original	ADJ
dpc-2939	70	47	article	article	NOUN
dpc-2939	70	48	|	|	ADV
dpc-2939	70	49	dermatol	dermatol	ADJ
dpc-2939	70	50	pract	pract	NOUN
dpc-2939	70	51	concept	concept	NOUN
dpc-2939	70	52	.	.	PUNCT
dpc-2939	71	1	2023;13(2):e2023151	2023;13(2):e2023151	NUM
dpc-2939	71	2	3	3	NUM
dpc-2939	71	3	88.95	88.95	NUM
dpc-2939	71	4	,	,	PUNCT
dpc-2939	71	5	respectively	respectively	ADV
dpc-2939	71	6	)	)	PUNCT
dpc-2939	71	7	;	;	PUNCT
dpc-2939	71	8	moreover	moreover	ADV
dpc-2939	71	9	,	,	PUNCT
dpc-2939	71	10	4	4	NUM
dpc-2939	71	11	%	%	NOUN
dpc-2939	71	12	5	5	NUM
dpc-2939	71	13	-	-	PUNCT
dpc-2939	71	14	fu	fu	NOUN
dpc-2939	71	15	ranked	rank	VERB
dpc-2939	71	16	second	second	ADV
dpc-2939	71	17	,	,	PUNCT
dpc-2939	71	18	following	follow	VERB
dpc-2939	71	19	5	5	NUM
dpc-2939	71	20	%	%	NOUN
dpc-2939	71	21	5	5	NUM
dpc-2939	71	22	-	-	PUNCT
dpc-2939	71	23	fu	fu	NOUN
dpc-2939	71	24	,	,	PUNCT
dpc-2939	71	25	in	in	ADP
dpc-2939	71	26	the	the	DET
dpc-2939	71	27	probability	probability	NOUN
dpc-2939	71	28	of	of	ADP
dpc-2939	71	29	being	be	AUX
dpc-2939	71	30	the	the	DET
dpc-2939	71	31	best	good	ADJ
dpc-2939	71	32	treatment	treatment	NOUN
dpc-2939	71	33	for	for	ADP
dpc-2939	71	34	complete	complete	ADJ
dpc-2939	71	35	ak	ak	PROPN
dpc-2939	71	36	lesions	lesion	NOUN
dpc-2939	71	37	clearance	clearance	NOUN
dpc-2939	71	38	(	(	PUNCT
dpc-2939	71	39	sucra	sucra	NOUN
dpc-2939	71	40	78.26	78.26	NUM
dpc-2939	71	41	versus	versus	ADP
dpc-2939	71	42	84.74	84.74	NUM
dpc-2939	71	43	)	)	PUNCT
dpc-2939	71	44	.	.	PUNCT
dpc-2939	72	1	notably	notably	ADV
dpc-2939	72	2	,	,	PUNCT
dpc-2939	72	3	sucra	sucra	NOUN
dpc-2939	72	4	values	value	NOUN
dpc-2939	72	5	showed	show	VERB
dpc-2939	72	6	a	a	DET
dpc-2939	72	7	lower	low	ADJ
dpc-2939	72	8	risk	risk	NOUN
dpc-2939	72	9	of	of	ADP
dpc-2939	72	10	withdrawal	withdrawal	NOUN
dpc-2939	72	11	due	due	ADP
dpc-2939	72	12	to	to	ADP
dpc-2939	72	13	adverse	adverse	ADJ
dpc-2939	72	14	events	event	NOUN
dpc-2939	72	15	associated	associate	VERB
dpc-2939	72	16	with	with	ADP
dpc-2939	72	17	4	4	NUM
dpc-2939	72	18	%	%	NOUN
dpc-2939	72	19	5	5	NUM
dpc-2939	72	20	-	-	PUNCT
dpc-2939	72	21	fu	fu	NOUN
dpc-2939	72	22	treatment	treatment	NOUN
dpc-2939	72	23	compared	compare	VERB
dpc-2939	72	24	with	with	ADP
dpc-2939	72	25	5	5	NUM
dpc-2939	72	26	%	%	NOUN
dpc-2939	72	27	5	5	NUM
dpc-2939	72	28	-	-	PUNCT
dpc-2939	72	29	fu	fu	NOUN
dpc-2939	72	30	(	(	PUNCT
dpc-2939	72	31	sucra	sucra	PROPN
dpc-2939	72	32	70.89	70.89	NUM
dpc-2939	72	33	versus	versus	ADP
dpc-2939	72	34	70.89	70.89	NUM
dpc-2939	72	35	respectively	respectively	ADV
dpc-2939	72	36	)	)	PUNCT
dpc-2939	73	1	[	[	X
dpc-2939	73	2	14	14	NUM
dpc-2939	73	3	]	]	PUNCT
dpc-2939	73	4	.	.	PUNCT
dpc-2939	74	1	objectives	objective	NOUN
dpc-2939	74	2	due	due	ADJ
dpc-2939	74	3	to	to	PART
dpc-2939	74	4	4	4	NUM
dpc-2939	74	5	%	%	NOUN
dpc-2939	74	6	5	5	NUM
dpc-2939	74	7	-	-	PUNCT
dpc-2939	74	8	fu	fu	NOUN
dpc-2939	74	9	formulation	formulation	NOUN
dpc-2939	74	10	recent	recent	ADJ
dpc-2939	74	11	approval	approval	NOUN
dpc-2939	74	12	,	,	PUNCT
dpc-2939	74	13	real	real	ADJ
dpc-2939	74	14	-	-	PUNCT
dpc-2939	74	15	world	world	NOUN
dpc-2939	74	16	evidence	evidence	NOUN
dpc-2939	74	17	on	on	ADP
dpc-2939	74	18	this	this	DET
dpc-2939	74	19	treatment	treatment	NOUN
dpc-2939	74	20	in	in	ADP
dpc-2939	74	21	ak	ak	PROPN
dpc-2939	74	22	is	be	AUX
dpc-2939	74	23	lacking	lack	VERB
dpc-2939	74	24	.	.	PUNCT
dpc-2939	75	1	this	this	DET
dpc-2939	75	2	study	study	NOUN
dpc-2939	75	3	aimed	aim	VERB
dpc-2939	75	4	to	to	PART
dpc-2939	75	5	fill	fill	VERB
dpc-2939	75	6	this	this	DET
dpc-2939	75	7	gap	gap	NOUN
dpc-2939	75	8	,	,	PUNCT
dpc-2939	75	9	reporting	report	VERB
dpc-2939	75	10	the	the	DET
dpc-2939	75	11	experience	experience	NOUN
dpc-2939	75	12	of	of	ADP
dpc-2939	75	13	an	an	DET
dpc-2939	75	14	italian	italian	ADJ
dpc-2939	75	15	dermatology	dermatology	NOUN
dpc-2939	75	16	centre	centre	NOUN
dpc-2939	75	17	using	use	VERB
dpc-2939	75	18	4	4	NUM
dpc-2939	75	19	%	%	NOUN
dpc-2939	75	20	5	5	NUM
dpc-2939	75	21	-	-	PUNCT
dpc-2939	75	22	fu	fu	NOUN
dpc-2939	75	23	to	to	PART
dpc-2939	75	24	treat	treat	VERB
dpc-2939	75	25	subjects	subject	NOUN
dpc-2939	75	26	with	with	ADP
dpc-2939	75	27	ak	ak	PROPN
dpc-2939	75	28	in	in	ADP
dpc-2939	75	29	routine	routine	ADJ
dpc-2939	75	30	clinical	clinical	ADJ
dpc-2939	75	31	practice	practice	NOUN
dpc-2939	75	32	.	.	PUNCT
dpc-2939	76	1	methods	method	NOUN
dpc-2939	76	2	this	this	DET
dpc-2939	76	3	study	study	NOUN
dpc-2939	76	4	was	be	AUX
dpc-2939	76	5	a	a	DET
dpc-2939	76	6	retrospective	retrospective	ADJ
dpc-2939	76	7	analysis	analysis	NOUN
dpc-2939	76	8	of	of	ADP
dpc-2939	76	9	the	the	DET
dpc-2939	76	10	university	university	PROPN
dpc-2939	76	11	of	of	ADP
dpc-2939	76	12	campania	campania	PROPN
dpc-2939	76	13	dermatology	dermatology	PROPN
dpc-2939	76	14	unit	unit	NOUN
dpc-2939	76	15	(	(	PUNCT
dpc-2939	76	16	naples	naples	PROPN
dpc-2939	76	17	,	,	PUNCT
dpc-2939	76	18	italy	italy	PROPN
dpc-2939	76	19	)	)	PUNCT
dpc-2939	76	20	patient	patient	NOUN
dpc-2939	76	21	database	database	NOUN
dpc-2939	76	22	.	.	PUNCT
dpc-2939	77	1	adult	adult	NOUN
dpc-2939	77	2	subjects	subject	NOUN
dpc-2939	77	3	with	with	ADP
dpc-2939	77	4	a	a	DET
dpc-2939	77	5	diagnosis	diagnosis	NOUN
dpc-2939	77	6	of	of	ADP
dpc-2939	77	7	grade	grade	NOUN
dpc-2939	77	8	i	i	PROPN
dpc-2939	77	9	or	or	CCONJ
dpc-2939	77	10	ii	ii	PROPN
dpc-2939	77	11	ak	ak	PROPN
dpc-2939	77	12	(	(	PUNCT
dpc-2939	77	13	based	base	VERB
dpc-2939	77	14	on	on	ADP
dpc-2939	77	15	the	the	DET
dpc-2939	77	16	4	4	NUM
dpc-2939	77	17	-	-	PUNCT
dpc-2939	77	18	point	point	NOUN
dpc-2939	77	19	olsen	olsen	NOUN
dpc-2939	77	20	scale	scale	NOUN
dpc-2939	77	21	)	)	PUNCT
dpc-2939	77	22	,	,	PUNCT
dpc-2939	77	23	localized	localize	VERB
dpc-2939	77	24	on	on	ADP
dpc-2939	77	25	the	the	DET
dpc-2939	77	26	face	face	NOUN
dpc-2939	77	27	,	,	PUNCT
dpc-2939	77	28	ears	ear	NOUN
dpc-2939	77	29	,	,	PUNCT
dpc-2939	77	30	and/or	and/or	CCONJ
dpc-2939	77	31	scalp	scalp	NOUN
dpc-2939	77	32	,	,	PUNCT
dpc-2939	77	33	consisting	consist	VERB
dpc-2939	77	34	of	of	ADP
dpc-2939	77	35	visible	visible	ADJ
dpc-2939	77	36	and	and	CCONJ
dpc-2939	77	37	palpable	palpable	ADJ
dpc-2939	77	38	lesions	lesion	NOUN
dpc-2939	77	39	neither	neither	CCONJ
dpc-2939	77	40	hypertrophic	hypertrophic	ADJ
dpc-2939	77	41	nor	nor	CCONJ
dpc-2939	77	42	hyperkeratotic	hyperkeratotic	ADJ
dpc-2939	77	43	,	,	PUNCT
dpc-2939	77	44	treated	treat	VERB
dpc-2939	77	45	with	with	ADP
dpc-2939	77	46	5	5	NUM
dpc-2939	77	47	-	-	PUNCT
dpc-2939	77	48	fu	fu	NOUN
dpc-2939	77	49	4	4	NUM
dpc-2939	77	50	%	%	NOUN
dpc-2939	77	51	cream	cream	NOUN
dpc-2939	77	52	(	(	PUNCT
dpc-2939	77	53	tolerak	tolerak	PROPN
dpc-2939	77	54	®	®	PROPN
dpc-2939	77	55	,	,	PUNCT
dpc-2939	77	56	pierre	pierre	PROPN
dpc-2939	77	57	fabre	fabre	PROPN
dpc-2939	77	58	)	)	PUNCT
dpc-2939	77	59	once	once	ADV
dpc-2939	77	60	daily	daily	ADV
dpc-2939	77	61	for	for	ADP
dpc-2939	77	62	4	4	NUM
dpc-2939	77	63	weeks	week	NOUN
dpc-2939	77	64	from	from	ADP
dpc-2939	77	65	september	september	PROPN
dpc-2939	77	66	2021	2021	NUM
dpc-2939	77	67	to	to	ADP
dpc-2939	77	68	november	november	PROPN
dpc-2939	77	69	2021	2021	NUM
dpc-2939	77	70	were	be	AUX
dpc-2939	77	71	selected	select	VERB
dpc-2939	77	72	.	.	PUNCT
dpc-2939	78	1	only	only	ADV
dpc-2939	78	2	patients	patient	NOUN
dpc-2939	78	3	with	with	ADP
dpc-2939	78	4	at	at	ADV
dpc-2939	78	5	least	least	ADV
dpc-2939	78	6	3	3	NUM
dpc-2939	78	7	follow	follow	VERB
dpc-2939	78	8	-	-	PUNCT
dpc-2939	78	9	up	up	ADP
dpc-2939	78	10	visits	visit	NOUN
dpc-2939	78	11	were	be	AUX
dpc-2939	78	12	included	include	VERB
dpc-2939	78	13	:	:	PUNCT
dpc-2939	78	14	the	the	DET
dpc-2939	78	15	first	first	ADJ
dpc-2939	78	16	and	and	CCONJ
dpc-2939	78	17	the	the	DET
dpc-2939	78	18	second	second	ADJ
dpc-2939	78	19	one	one	NUM
dpc-2939	78	20	after	after	ADP
dpc-2939	78	21	4	4	NUM
dpc-2939	78	22	and	and	CCONJ
dpc-2939	78	23	8	8	NUM
dpc-2939	78	24	weeks	week	NOUN
dpc-2939	78	25	from	from	ADP
dpc-2939	78	26	treatment	treatment	NOUN
dpc-2939	78	27	initiation	initiation	NOUN
dpc-2939	78	28	respectively	respectively	ADV
dpc-2939	78	29	;	;	PUNCT
dpc-2939	78	30	the	the	DET
dpc-2939	78	31	third	third	ADJ
dpc-2939	78	32	one	one	NUM
dpc-2939	78	33	6	6	NUM
dpc-2939	78	34	months	month	NOUN
dpc-2939	78	35	after	after	ADP
dpc-2939	78	36	the	the	DET
dpc-2939	78	37	second	second	ADJ
dpc-2939	78	38	visit	visit	NOUN
dpc-2939	78	39	.	.	PUNCT
dpc-2939	79	1	the	the	DET
dpc-2939	79	2	primary	primary	ADJ
dpc-2939	79	3	objective	objective	NOUN
dpc-2939	79	4	of	of	ADP
dpc-2939	79	5	the	the	DET
dpc-2939	79	6	study	study	NOUN
dpc-2939	79	7	was	be	AUX
dpc-2939	79	8	to	to	PART
dpc-2939	79	9	evaluate	evaluate	VERB
dpc-2939	79	10	the	the	DET
dpc-2939	79	11	4	4	NUM
dpc-2939	79	12	%	%	NOUN
dpc-2939	79	13	5	5	NUM
dpc-2939	79	14	-	-	PUNCT
dpc-2939	79	15	fu	fu	NOUN
dpc-2939	79	16	cream	cream	NOUN
dpc-2939	79	17	efficacy	efficacy	NOUN
dpc-2939	79	18	in	in	ADP
dpc-2939	79	19	terms	term	NOUN
dpc-2939	79	20	of	of	ADP
dpc-2939	79	21	ak	ak	PROPN
dpc-2939	79	22	lesions	lesion	NOUN
dpc-2939	79	23	improvement	improvement	NOUN
dpc-2939	79	24	at	at	ADP
dpc-2939	79	25	8	8	NUM
dpc-2939	79	26	weeks	week	NOUN
dpc-2939	79	27	and	and	CCONJ
dpc-2939	79	28	relapse	relapse	NOUN
dpc-2939	79	29	rate	rate	NOUN
dpc-2939	79	30	at	at	ADP
dpc-2939	79	31	6	6	NUM
dpc-2939	79	32	months	month	NOUN
dpc-2939	79	33	.	.	PUNCT
dpc-2939	80	1	ak	ak	PROPN
dpc-2939	80	2	lesions	lesion	NOUN
dpc-2939	80	3	improvement	improvement	NOUN
dpc-2939	80	4	is	be	AUX
dpc-2939	80	5	routinely	routinely	ADV
dpc-2939	80	6	assessed	assess	VERB
dpc-2939	80	7	at	at	ADP
dpc-2939	80	8	our	our	PRON
dpc-2939	80	9	centre	centre	NOUN
dpc-2939	80	10	with	with	ADP
dpc-2939	80	11	the	the	DET
dpc-2939	80	12	7	7	NUM
dpc-2939	80	13	-	-	PUNCT
dpc-2939	80	14	point	point	NOUN
dpc-2939	80	15	investigator	investigator	NOUN
dpc-2939	80	16	global	global	ADJ
dpc-2939	80	17	improvement	improvement	NOUN
dpc-2939	80	18	scale	scale	NOUN
dpc-2939	80	19	(	(	PUNCT
dpc-2939	80	20	igi	igi	NOUN
dpc-2939	80	21	;	;	PUNCT
dpc-2939	80	22	-2	-2	NUM
dpc-2939	80	23	,	,	PUNCT
dpc-2939	80	24	significantly	significantly	ADV
dpc-2939	80	25	worse	bad	ADJ
dpc-2939	80	26	;	;	PUNCT
dpc-2939	80	27	-1	-1	CCONJ
dpc-2939	80	28	,	,	PUNCT
dpc-2939	80	29	slightly	slightly	ADV
dpc-2939	80	30	worse	bad	ADJ
dpc-2939	80	31	;	;	PUNCT
dpc-2939	80	32	0	0	NUM
dpc-2939	80	33	,	,	PUNCT
dpc-2939	80	34	no	no	DET
dpc-2939	80	35	change	change	NOUN
dpc-2939	80	36	;	;	PUNCT
dpc-2939	80	37	+1	+1	X
dpc-2939	80	38	,	,	PUNCT
dpc-2939	80	39	slightly	slightly	ADV
dpc-2939	80	40	improved	improve	VERB
dpc-2939	80	41	;	;	PUNCT
dpc-2939	80	42	+2	+2	PROPN
dpc-2939	80	43	,	,	PUNCT
dpc-2939	80	44	moderately	moderately	ADV
dpc-2939	80	45	improved	improve	VERB
dpc-2939	80	46	;	;	PUNCT
dpc-2939	80	47	+3	+3	PROPN
dpc-2939	80	48	,	,	PUNCT
dpc-2939	80	49	significantly	significantly	ADV
dpc-2939	80	50	improved	improve	VERB
dpc-2939	80	51	;	;	PUNCT
dpc-2939	80	52	+4	+4	ADJ
dpc-2939	80	53	,	,	PUNCT
dpc-2939	80	54	completely	completely	ADV
dpc-2939	80	55	improved	improve	VERB
dpc-2939	80	56	)	)	PUNCT
dpc-2939	80	57	,	,	PUNCT
dpc-2939	80	58	and	and	CCONJ
dpc-2939	80	59	the	the	DET
dpc-2939	80	60	availability	availability	NOUN
dpc-2939	80	61	of	of	ADP
dpc-2939	80	62	this	this	DET
dpc-2939	80	63	measurement	measurement	NOUN
dpc-2939	80	64	was	be	AUX
dpc-2939	80	65	included	include	VERB
dpc-2939	80	66	in	in	ADP
dpc-2939	80	67	the	the	DET
dpc-2939	80	68	patients	patient	NOUN
dpc-2939	80	69	’	’	PART
dpc-2939	80	70	selection	selection	NOUN
dpc-2939	80	71	criteria	criterion	NOUN
dpc-2939	80	72	.	.	PUNCT
dpc-2939	81	1	the	the	DET
dpc-2939	81	2	secondary	secondary	ADJ
dpc-2939	81	3	objective	objective	NOUN
dpc-2939	81	4	was	be	AUX
dpc-2939	81	5	to	to	PART
dpc-2939	81	6	evaluate	evaluate	VERB
dpc-2939	81	7	the	the	DET
dpc-2939	81	8	safety	safety	NOUN
dpc-2939	81	9	of	of	ADP
dpc-2939	81	10	4	4	NUM
dpc-2939	81	11	%	%	NOUN
dpc-2939	81	12	5	5	NUM
dpc-2939	81	13	-	-	PUNCT
dpc-2939	81	14	fu	fu	NOUN
dpc-2939	81	15	cream	cream	NOUN
dpc-2939	81	16	in	in	ADP
dpc-2939	81	17	terms	term	NOUN
dpc-2939	81	18	of	of	ADP
dpc-2939	81	19	erythema	erythema	NOUN
dpc-2939	81	20	and	and	CCONJ
dpc-2939	81	21	burning	burn	VERB
dpc-2939	81	22	sensation	sensation	NOUN
dpc-2939	81	23	intensity	intensity	NOUN
dpc-2939	81	24	at	at	ADP
dpc-2939	81	25	4	4	NUM
dpc-2939	81	26	weeks	week	NOUN
dpc-2939	81	27	.	.	PUNCT
dpc-2939	82	1	these	these	DET
dpc-2939	82	2	adverse	adverse	ADJ
dpc-2939	82	3	events	event	NOUN
dpc-2939	82	4	are	be	AUX
dpc-2939	82	5	routinely	routinely	ADV
dpc-2939	82	6	assessed	assess	VERB
dpc-2939	82	7	at	at	ADP
dpc-2939	82	8	our	our	PRON
dpc-2939	82	9	centre	centre	NOUN
dpc-2939	82	10	with	with	ADP
dpc-2939	82	11	the	the	DET
dpc-2939	82	12	patient	patient	NOUN
dpc-2939	82	13	-	-	PUNCT
dpc-2939	82	14	reported	report	VERB
dpc-2939	82	15	scale	scale	NOUN
dpc-2939	82	16	for	for	ADP
dpc-2939	82	17	clinical	clinical	ADJ
dpc-2939	82	18	assessment	assessment	NOUN
dpc-2939	82	19	(	(	PUNCT
dpc-2939	82	20	sca	sca	PROPN
dpc-2939	82	21	;	;	PUNCT
dpc-2939	82	22	0	0	NUM
dpc-2939	82	23	,	,	PUNCT
dpc-2939	82	24	absent	absent	ADJ
dpc-2939	82	25	;	;	PUNCT
dpc-2939	82	26	1	1	NUM
dpc-2939	82	27	,	,	PUNCT
dpc-2939	82	28	light	light	ADJ
dpc-2939	82	29	;	;	PUNCT
dpc-2939	82	30	2	2	NUM
dpc-2939	82	31	,	,	PUNCT
dpc-2939	82	32	moderate	moderate	ADJ
dpc-2939	82	33	;	;	PUNCT
dpc-2939	82	34	3	3	NUM
dpc-2939	82	35	,	,	PUNCT
dpc-2939	82	36	severe	severe	ADJ
dpc-2939	82	37	)	)	PUNCT
dpc-2939	82	38	;	;	PUNCT
dpc-2939	82	39	only	only	ADV
dpc-2939	82	40	patients	patient	NOUN
dpc-2939	82	41	with	with	ADP
dpc-2939	82	42	these	these	DET
dpc-2939	82	43	measurements	measurement	NOUN
dpc-2939	82	44	available	available	ADJ
dpc-2939	82	45	were	be	AUX
dpc-2939	82	46	selected	select	VERB
dpc-2939	82	47	.	.	PUNCT
dpc-2939	83	1	statistical	statistical	ADJ
dpc-2939	83	2	analyses	analysis	NOUN
dpc-2939	83	3	were	be	AUX
dpc-2939	83	4	performed	perform	VERB
dpc-2939	83	5	with	with	ADP
dpc-2939	83	6	software	software	NOUN
dpc-2939	83	7	r.	r.	PROPN
dpc-2939	83	8	descriptive	descriptive	ADJ
dpc-2939	83	9	statistics	statistic	NOUN
dpc-2939	83	10	of	of	ADP
dpc-2939	83	11	the	the	DET
dpc-2939	83	12	cohort	cohort	NOUN
dpc-2939	83	13	are	be	AUX
dpc-2939	83	14	provided	provide	VERB
dpc-2939	83	15	with	with	ADP
dpc-2939	83	16	confidence	confidence	NOUN
dpc-2939	83	17	intervals	interval	NOUN
dpc-2939	83	18	.	.	PUNCT
dpc-2939	84	1	chi	chi	ADJ
dpc-2939	84	2	-	-	PUNCT
dpc-2939	84	3	squared	square	VERB
dpc-2939	84	4	test	test	NOUN
dpc-2939	84	5	for	for	ADP
dpc-2939	84	6	categorical	categorical	ADJ
dpc-2939	84	7	variables	variable	NOUN
dpc-2939	84	8	and	and	CCONJ
dpc-2939	84	9	the	the	DET
dpc-2939	84	10	t	t	NOUN
dpc-2939	84	11	-	-	PUNCT
dpc-2939	84	12	test	test	NOUN
dpc-2939	84	13	for	for	ADP
dpc-2939	84	14	continuous	continuous	ADJ
dpc-2939	84	15	variables	variable	NOUN
dpc-2939	84	16	were	be	AUX
dpc-2939	84	17	used	use	VERB
dpc-2939	84	18	.	.	PUNCT
dpc-2939	85	1	statistical	statistical	ADJ
dpc-2939	85	2	significance	significance	NOUN
dpc-2939	85	3	was	be	AUX
dpc-2939	85	4	set	set	VERB
dpc-2939	85	5	at	at	ADP
dpc-2939	85	6	p	p	NOUN
dpc-2939	85	7	<	<	NOUN
dpc-2939	85	8	0.05	0.05	NUM
dpc-2939	85	9	.	.	PUNCT
dpc-2939	86	1	results	result	NOUN
dpc-2939	86	2	overall	overall	ADV
dpc-2939	86	3	,	,	PUNCT
dpc-2939	86	4	98	98	NUM
dpc-2939	86	5	patients	patient	NOUN
dpc-2939	86	6	satisfied	satisfy	VERB
dpc-2939	86	7	the	the	DET
dpc-2939	86	8	inclusion	inclusion	NOUN
dpc-2939	86	9	criteria	criterion	NOUN
dpc-2939	86	10	and	and	CCONJ
dpc-2939	86	11	were	be	AUX
dpc-2939	86	12	selected	select	VERB
dpc-2939	86	13	for	for	ADP
dpc-2939	86	14	the	the	DET
dpc-2939	86	15	study	study	NOUN
dpc-2939	86	16	.	.	PUNCT
dpc-2939	87	1	most	most	ADJ
dpc-2939	87	2	of	of	ADP
dpc-2939	87	3	these	these	DET
dpc-2939	87	4	patients	patient	NOUN
dpc-2939	87	5	were	be	AUX
dpc-2939	87	6	males	male	NOUN
dpc-2939	87	7	(	(	PUNCT
dpc-2939	87	8	n	n	CCONJ
dpc-2939	87	9	 	 	SPACE
dpc-2939	87	10	=	=	NOUN
dpc-2939	87	11	 	 	SPACE
dpc-2939	87	12	80/98	80/98	NUM
dpc-2939	87	13	;	;	PUNCT
dpc-2939	87	14	81	81	NUM
dpc-2939	87	15	%	%	NOUN
dpc-2939	87	16	)	)	PUNCT
dpc-2939	87	17	and	and	CCONJ
dpc-2939	87	18	the	the	DET
dpc-2939	87	19	mean	mean	ADJ
dpc-2939	87	20	age	age	NOUN
dpc-2939	87	21	at	at	ADP
dpc-2939	87	22	first	first	ADJ
dpc-2939	87	23	visit	visit	NOUN
dpc-2939	87	24	was	be	AUX
dpc-2939	87	25	74.7	74.7	NUM
dpc-2939	87	26	  	  	SPACE
dpc-2939	87	27	years	year	NOUN
dpc-2939	87	28	.	.	PUNCT
dpc-2939	88	1	the	the	DET
dpc-2939	88	2	mean	mean	ADJ
dpc-2939	88	3	number	number	NOUN
dpc-2939	88	4	of	of	ADP
dpc-2939	88	5	follow	follow	NOUN
dpc-2939	88	6	-	-	PUNCT
dpc-2939	88	7	up	up	ADP
dpc-2939	88	8	visits	visit	NOUN
dpc-2939	88	9	resulted	result	VERB
dpc-2939	88	10	slightly	slightly	ADV
dpc-2939	88	11	higher	high	ADJ
dpc-2939	88	12	than	than	ADP
dpc-2939	88	13	the	the	DET
dpc-2939	88	14	number	number	NOUN
dpc-2939	88	15	required	require	VERB
dpc-2939	88	16	for	for	ADP
dpc-2939	88	17	the	the	DET
dpc-2939	88	18	inclusion	inclusion	NOUN
dpc-2939	88	19	in	in	ADP
dpc-2939	88	20	the	the	DET
dpc-2939	88	21	study	study	NOUN
dpc-2939	88	22	(	(	PUNCT
dpc-2939	88	23	3.05	3.05	NUM
dpc-2939	88	24	versus	versus	ADP
dpc-2939	88	25	3	3	NUM
dpc-2939	88	26	)	)	PUNCT
dpc-2939	88	27	since	since	SCONJ
dpc-2939	88	28	5	5	NUM
dpc-2939	88	29	patients	patient	NOUN
dpc-2939	88	30	required	require	VERB
dpc-2939	88	31	1	1	NUM
dpc-2939	88	32	or	or	CCONJ
dpc-2939	88	33	2	2	NUM
dpc-2939	88	34	additional	additional	ADJ
dpc-2939	88	35	consultations	consultation	NOUN
dpc-2939	88	36	because	because	SCONJ
dpc-2939	88	37	of	of	ADP
dpc-2939	88	38	side	side	NOUN
dpc-2939	88	39	effects	effect	NOUN
dpc-2939	88	40	.	.	PUNCT
dpc-2939	89	1	the	the	DET
dpc-2939	89	2	mean	mean	ADJ
dpc-2939	89	3	follow	follow	VERB
dpc-2939	89	4	-	-	PUNCT
dpc-2939	89	5	up	up	ADP
dpc-2939	89	6	duration	duration	NOUN
dpc-2939	89	7	in	in	ADP
dpc-2939	89	8	our	our	PRON
dpc-2939	89	9	sample	sample	NOUN
dpc-2939	89	10	was	be	AUX
dpc-2939	89	11	212	212	NUM
dpc-2939	89	12	days	day	NOUN
dpc-2939	89	13	.	.	PUNCT
dpc-2939	90	1	according	accord	VERB
dpc-2939	90	2	to	to	ADP
dpc-2939	90	3	the	the	DET
dpc-2939	90	4	igi	igi	PROPN
dpc-2939	90	5	scores	score	NOUN
dpc-2939	90	6	,	,	PUNCT
dpc-2939	90	7	after	after	ADP
dpc-2939	90	8	8	8	NUM
dpc-2939	90	9	weeks	week	NOUN
dpc-2939	90	10	from	from	ADP
dpc-2939	90	11	treatment	treatment	NOUN
dpc-2939	90	12	initiation	initiation	NOUN
dpc-2939	90	13	(	(	PUNCT
dpc-2939	90	14	4	4	NUM
dpc-2939	90	15	weeks	week	NOUN
dpc-2939	90	16	after	after	ADP
dpc-2939	90	17	the	the	DET
dpc-2939	90	18	end	end	NOUN
dpc-2939	90	19	of	of	ADP
dpc-2939	90	20	treatment	treatment	NOUN
dpc-2939	90	21	)	)	PUNCT
dpc-2939	90	22	ak	ak	PROPN
dpc-2939	90	23	lesions	lesion	NOUN
dpc-2939	90	24	were	be	AUX
dpc-2939	90	25	completely	completely	ADV
dpc-2939	90	26	or	or	CCONJ
dpc-2939	90	27	significantly	significantly	ADV
dpc-2939	90	28	improved	improve	VERB
dpc-2939	90	29	compared	compare	VERB
dpc-2939	90	30	with	with	ADP
dpc-2939	90	31	baseline	baseline	NOUN
dpc-2939	90	32	in	in	ADP
dpc-2939	90	33	the	the	DET
dpc-2939	90	34	vast	vast	ADJ
dpc-2939	90	35	majority	majority	NOUN
dpc-2939	90	36	of	of	ADP
dpc-2939	90	37	the	the	DET
dpc-2939	90	38	patients	patient	NOUN
dpc-2939	90	39	(	(	PUNCT
dpc-2939	90	40	74.5	74.5	NUM
dpc-2939	90	41	%	%	NOUN
dpc-2939	90	42	and	and	CCONJ
dpc-2939	90	43	20.4	20.4	NUM
dpc-2939	90	44	%	%	NOUN
dpc-2939	90	45	,	,	PUNCT
dpc-2939	90	46	respectively	respectively	ADV
dpc-2939	90	47	;	;	PUNCT
dpc-2939	90	48	figure	figure	NOUN
dpc-2939	90	49	1	1	NUM
dpc-2939	90	50	)	)	PUNCT
dpc-2939	90	51	.	.	PUNCT
dpc-2939	91	1	in	in	ADP
dpc-2939	91	2	only	only	ADV
dpc-2939	91	3	4	4	NUM
dpc-2939	91	4	patients	patient	NOUN
dpc-2939	91	5	the	the	DET
dpc-2939	91	6	investigators	investigator	NOUN
dpc-2939	91	7	graded	grade	VERB
dpc-2939	91	8	the	the	DET
dpc-2939	91	9	improvement	improvement	NOUN
dpc-2939	91	10	as	as	ADP
dpc-2939	91	11	moderate	moderate	ADJ
dpc-2939	91	12	or	or	CCONJ
dpc-2939	91	13	slight	slight	ADJ
dpc-2939	91	14	(	(	PUNCT
dpc-2939	91	15	4.1	4.1	NUM
dpc-2939	91	16	%	%	NOUN
dpc-2939	91	17	)	)	PUNCT
dpc-2939	91	18	and	and	CCONJ
dpc-2939	91	19	1	1	NUM
dpc-2939	91	20	patient	patient	NOUN
dpc-2939	91	21	(	(	PUNCT
dpc-2939	91	22	1	1	NUM
dpc-2939	91	23	%	%	NOUN
dpc-2939	91	24	)	)	PUNCT
dpc-2939	91	25	showed	show	VERB
dpc-2939	91	26	no	no	DET
dpc-2939	91	27	change	change	NOUN
dpc-2939	91	28	in	in	ADP
dpc-2939	91	29	ak	ak	PROPN
dpc-2939	91	30	severity	severity	NOUN
dpc-2939	91	31	.	.	PUNCT
dpc-2939	92	1	moreover	moreover	ADV
dpc-2939	92	2	,	,	PUNCT
dpc-2939	92	3	no	no	DET
dpc-2939	92	4	patient	patient	NOUN
dpc-2939	92	5	showed	show	VERB
dpc-2939	92	6	a	a	DET
dpc-2939	92	7	worsening	worsening	NOUN
dpc-2939	92	8	of	of	ADP
dpc-2939	92	9	the	the	DET
dpc-2939	92	10	disease	disease	NOUN
dpc-2939	92	11	.	.	PUNCT
dpc-2939	93	1	4	4	NUM
dpc-2939	93	2	%	%	NOUN
dpc-2939	93	3	5	5	NUM
dpc-2939	93	4	-	-	PUNCT
dpc-2939	93	5	fu	fu	NOUN
dpc-2939	93	6	treatment	treatment	NOUN
dpc-2939	93	7	results	result	NOUN
dpc-2939	93	8	were	be	AUX
dpc-2939	93	9	sustained	sustain	VERB
dpc-2939	93	10	during	during	ADP
dpc-2939	93	11	follow	follow	NOUN
dpc-2939	93	12	-	-	PUNCT
dpc-2939	93	13	up	up	NOUN
dpc-2939	93	14	,	,	PUNCT
dpc-2939	93	15	and	and	CCONJ
dpc-2939	93	16	64	64	NUM
dpc-2939	93	17	patients	patient	NOUN
dpc-2939	93	18	(	(	PUNCT
dpc-2939	93	19	65.3	65.3	NUM
dpc-2939	93	20	%	%	NOUN
dpc-2939	93	21	)	)	PUNCT
dpc-2939	93	22	did	do	AUX
dpc-2939	93	23	not	not	PART
dpc-2939	93	24	show	show	VERB
dpc-2939	93	25	ak	ak	PROPN
dpc-2939	93	26	relapses	relapse	NOUN
dpc-2939	93	27	at	at	ADP
dpc-2939	93	28	the	the	DET
dpc-2939	93	29	6	6	NUM
dpc-2939	93	30	months	month	NOUN
dpc-2939	93	31	visit	visit	NOUN
dpc-2939	93	32	.	.	PUNCT
dpc-2939	94	1	patients	patient	NOUN
dpc-2939	94	2	-	-	PUNCT
dpc-2939	94	3	reported	report	VERB
dpc-2939	94	4	burning	burning	NOUN
dpc-2939	94	5	sensation	sensation	NOUN
dpc-2939	94	6	after	after	ADP
dpc-2939	94	7	4	4	NUM
dpc-2939	94	8	weeks	week	NOUN
dpc-2939	94	9	from	from	ADP
dpc-2939	94	10	treatment	treatment	NOUN
dpc-2939	94	11	initiation	initiation	NOUN
dpc-2939	94	12	was	be	AUX
dpc-2939	94	13	generally	generally	ADV
dpc-2939	94	14	light	light	ADJ
dpc-2939	94	15	(	(	PUNCT
dpc-2939	94	16	n	n	NOUN
dpc-2939	94	17	=	=	SYM
dpc-2939	94	18	43	43	NUM
dpc-2939	94	19	,	,	PUNCT
dpc-2939	94	20	43.9	43.9	NUM
dpc-2939	94	21	%	%	NOUN
dpc-2939	94	22	)	)	PUNCT
dpc-2939	94	23	or	or	CCONJ
dpc-2939	94	24	moderate	moderate	ADJ
dpc-2939	94	25	(	(	PUNCT
dpc-2939	94	26	n	n	NOUN
dpc-2939	94	27	=	=	SYM
dpc-2939	94	28	22	22	NUM
dpc-2939	94	29	,	,	PUNCT
dpc-2939	94	30	22.4	22.4	NUM
dpc-2939	94	31	%	%	NOUN
dpc-2939	94	32	;	;	PUNCT
dpc-2939	94	33	figure	figure	NOUN
dpc-2939	94	34	2a	2a	NUM
dpc-2939	94	35	)	)	PUNCT
dpc-2939	94	36	.	.	PUNCT
dpc-2939	95	1	only	only	ADV
dpc-2939	95	2	1	1	NUM
dpc-2939	95	3	patient	patient	NOUN
dpc-2939	95	4	(	(	PUNCT
dpc-2939	95	5	1	1	NUM
dpc-2939	95	6	%	%	NOUN
dpc-2939	95	7	)	)	PUNCT
dpc-2939	95	8	reported	report	VERB
dpc-2939	95	9	severe	severe	ADJ
dpc-2939	95	10	burning	burning	NOUN
dpc-2939	95	11	sensation	sensation	NOUN
dpc-2939	95	12	,	,	PUNCT
dpc-2939	95	13	and	and	CCONJ
dpc-2939	95	14	31	31	NUM
dpc-2939	95	15	patients	patient	NOUN
dpc-2939	95	16	(	(	PUNCT
dpc-2939	95	17	31.6	31.6	NUM
dpc-2939	95	18	%	%	NOUN
dpc-2939	95	19	)	)	PUNCT
dpc-2939	95	20	did	do	AUX
dpc-2939	95	21	not	not	PART
dpc-2939	95	22	report	report	VERB
dpc-2939	95	23	this	this	DET
dpc-2939	95	24	adverse	adverse	ADJ
dpc-2939	95	25	event	event	NOUN
dpc-2939	95	26	.	.	PUNCT
dpc-2939	96	1	similar	similar	ADJ
dpc-2939	96	2	results	result	NOUN
dpc-2939	96	3	were	be	AUX
dpc-2939	96	4	obtained	obtain	VERB
dpc-2939	96	5	for	for	ADP
dpc-2939	96	6	patients	patient	NOUN
dpc-2939	96	7	-	-	PUNCT
dpc-2939	96	8	reported	report	VERB
dpc-2939	96	9	erythema	erythema	NOUN
dpc-2939	96	10	at	at	ADP
dpc-2939	96	11	4	4	NUM
dpc-2939	96	12	weeks	week	NOUN
dpc-2939	96	13	(	(	PUNCT
dpc-2939	96	14	figure	figure	NOUN
dpc-2939	96	15	 	 	SPACE
dpc-2939	96	16	2b	2b	NOUN
dpc-2939	96	17	)	)	PUNCT
dpc-2939	96	18	,	,	PUNCT
dpc-2939	96	19	which	which	PRON
dpc-2939	96	20	was	be	AUX
dpc-2939	96	21	generally	generally	ADV
dpc-2939	96	22	graded	grade	VERB
dpc-2939	96	23	as	as	ADP
dpc-2939	96	24	light	light	NOUN
dpc-2939	96	25	(	(	PUNCT
dpc-2939	96	26	n	n	NOUN
dpc-2939	96	27	=	=	SYM
dpc-2939	96	28	37	37	NUM
dpc-2939	96	29	,	,	PUNCT
dpc-2939	96	30	37.8	37.8	NUM
dpc-2939	96	31	%	%	NOUN
dpc-2939	96	32	)	)	PUNCT
dpc-2939	96	33	or	or	CCONJ
dpc-2939	96	34	moderate	moderate	ADJ
dpc-2939	96	35	(	(	PUNCT
dpc-2939	96	36	n	n	NOUN
dpc-2939	96	37	=	=	SYM
dpc-2939	96	38	50	50	NUM
dpc-2939	96	39	,	,	PUNCT
dpc-2939	96	40	51	51	NUM
dpc-2939	96	41	%	%	NOUN
dpc-2939	96	42	)	)	PUNCT
dpc-2939	96	43	.	.	PUNCT
dpc-2939	97	1	only	only	ADV
dpc-2939	97	2	1	1	NUM
dpc-2939	97	3	patient	patient	NOUN
dpc-2939	97	4	(	(	PUNCT
dpc-2939	97	5	1	1	NUM
dpc-2939	97	6	%	%	NOUN
dpc-2939	97	7	)	)	PUNCT
dpc-2939	97	8	reported	report	VERB
dpc-2939	97	9	a	a	DET
dpc-2939	97	10	severe	severe	ADJ
dpc-2939	97	11	erythema	erythema	NOUN
dpc-2939	97	12	,	,	PUNCT
dpc-2939	97	13	while	while	SCONJ
dpc-2939	97	14	10	10	NUM
dpc-2939	97	15	patients	patient	NOUN
dpc-2939	97	16	(	(	PUNCT
dpc-2939	97	17	10.2	10.2	NUM
dpc-2939	97	18	%	%	NOUN
dpc-2939	97	19	)	)	PUNCT
dpc-2939	97	20	did	do	AUX
dpc-2939	97	21	not	not	PART
dpc-2939	97	22	report	report	VERB
dpc-2939	97	23	this	this	DET
dpc-2939	97	24	adverse	adverse	ADJ
dpc-2939	97	25	event	event	NOUN
dpc-2939	97	26	.	.	PUNCT
dpc-2939	98	1	in	in	ADP
dpc-2939	98	2	patients	patient	NOUN
dpc-2939	98	3	with	with	ADP
dpc-2939	98	4	burning	burn	VERB
dpc-2939	98	5	sensation	sensation	NOUN
dpc-2939	98	6	and/or	and/or	CCONJ
dpc-2939	98	7	erythema	erythema	ADJ
dpc-2939	98	8	,	,	PUNCT
dpc-2939	98	9	these	these	DET
dpc-2939	98	10	adverse	adverse	ADJ
dpc-2939	98	11	events	event	NOUN
dpc-2939	98	12	disappeared	disappear	VERB
dpc-2939	98	13	gradually	gradually	ADV
dpc-2939	98	14	during	during	ADP
dpc-2939	98	15	follow	follow	NOUN
dpc-2939	98	16	-	-	PUNCT
dpc-2939	98	17	up	up	NOUN
dpc-2939	98	18	,	,	PUNCT
dpc-2939	98	19	and	and	CCONJ
dpc-2939	98	20	they	they	PRON
dpc-2939	98	21	could	could	AUX
dpc-2939	98	22	be	be	AUX
dpc-2939	98	23	managed	manage	VERB
dpc-2939	98	24	with	with	ADP
dpc-2939	98	25	moisturizing	moisturizing	NOUN
dpc-2939	98	26	and/or	and/or	CCONJ
dpc-2939	98	27	topical	topical	ADJ
dpc-2939	98	28	antibiotics	antibiotic	NOUN
dpc-2939	98	29	on	on	ADP
dpc-2939	98	30	the	the	DET
dpc-2939	98	31	basis	basis	NOUN
dpc-2939	98	32	of	of	ADP
dpc-2939	98	33	the	the	DET
dpc-2939	98	34	investigator	investigator	NOUN
dpc-2939	98	35	clinical	clinical	ADJ
dpc-2939	98	36	judgment	judgment	NOUN
dpc-2939	98	37	.	.	PUNCT
dpc-2939	99	1	no	no	DET
dpc-2939	99	2	other	other	ADJ
dpc-2939	99	3	side	side	NOUN
dpc-2939	99	4	effects	effect	NOUN
dpc-2939	99	5	were	be	AUX
dpc-2939	99	6	reported	report	VERB
dpc-2939	99	7	.	.	PUNCT
dpc-2939	100	1	conclusions	conclusion	NOUN
dpc-2939	100	2	in	in	ADP
dpc-2939	100	3	our	our	PRON
dpc-2939	100	4	study	study	NOUN
dpc-2939	100	5	,	,	PUNCT
dpc-2939	100	6	4	4	NUM
dpc-2939	100	7	%	%	NOUN
dpc-2939	100	8	5	5	NUM
dpc-2939	100	9	-	-	PUNCT
dpc-2939	100	10	fu	fu	NOUN
dpc-2939	100	11	proved	prove	VERB
dpc-2939	100	12	to	to	PART
dpc-2939	100	13	be	be	AUX
dpc-2939	100	14	an	an	DET
dpc-2939	100	15	effective	effective	ADJ
dpc-2939	100	16	and	and	CCONJ
dpc-2939	100	17	safe	safe	ADJ
dpc-2939	100	18	topical	topical	ADJ
dpc-2939	100	19	treatment	treatment	NOUN
dpc-2939	100	20	for	for	ADP
dpc-2939	100	21	adults	adult	NOUN
dpc-2939	100	22	with	with	ADP
dpc-2939	100	23	non	non	ADJ
dpc-2939	100	24	-	-	ADJ
dpc-2939	100	25	hyperkeratotic	hyperkeratotic	ADJ
dpc-2939	100	26	,	,	PUNCT
dpc-2939	100	27	non	non	ADJ
dpc-2939	100	28	-	-	ADJ
dpc-2939	100	29	hypertrophic	hypertrophic	ADJ
dpc-2939	100	30	ak	ak	PROPN
dpc-2939	100	31	(	(	PUNCT
dpc-2939	100	32	olsen	olsen	NOUN
dpc-2939	100	33	grade	grade	NOUN
dpc-2939	100	34	i	i	PROPN
dpc-2939	100	35	and	and	CCONJ
dpc-2939	100	36	ii	ii	NOUN
dpc-2939	100	37	)	)	PUNCT
dpc-2939	100	38	of	of	ADP
dpc-2939	100	39	the	the	DET
dpc-2939	100	40	face	face	NOUN
dpc-2939	100	41	,	,	PUNCT
dpc-2939	100	42	ears	ear	NOUN
dpc-2939	100	43	,	,	PUNCT
dpc-2939	100	44	and/or	and/or	CCONJ
dpc-2939	100	45	scalp	scalp	NOUN
dpc-2939	100	46	,	,	PUNCT
dpc-2939	100	47	in	in	ADP
dpc-2939	100	48	a	a	DET
dpc-2939	100	49	real	real	ADJ
dpc-2939	100	50	-	-	PUNCT
dpc-2939	100	51	world	world	NOUN
dpc-2939	100	52	clinical	clinical	ADJ
dpc-2939	100	53	setting	setting	NOUN
dpc-2939	100	54	.	.	PUNCT
dpc-2939	101	1	almost	almost	ADV
dpc-2939	101	2	the	the	DET
dpc-2939	101	3	totality	totality	NOUN
dpc-2939	101	4	of	of	ADP
dpc-2939	101	5	our	our	PRON
dpc-2939	101	6	patients	patient	NOUN
dpc-2939	101	7	(	(	PUNCT
dpc-2939	101	8	99	99	NUM
dpc-2939	101	9	%	%	NOUN
dpc-2939	101	10	)	)	PUNCT
dpc-2939	101	11	showed	show	VERB
dpc-2939	101	12	a	a	DET
dpc-2939	101	13	clinical	clinical	ADJ
dpc-2939	101	14	improvement	improvement	NOUN
dpc-2939	101	15	after	after	ADP
dpc-2939	101	16	8	8	NUM
dpc-2939	101	17	weeks	week	NOUN
dpc-2939	101	18	from	from	ADP
dpc-2939	101	19	treatment	treatment	NOUN
dpc-2939	101	20	initiation	initiation	NOUN
dpc-2939	101	21	,	,	PUNCT
dpc-2939	101	22	which	which	PRON
dpc-2939	101	23	was	be	AUX
dpc-2939	101	24	considered	consider	VERB
dpc-2939	101	25	significant	significant	ADJ
dpc-2939	101	26	or	or	CCONJ
dpc-2939	101	27	complete	complete	ADJ
dpc-2939	101	28	in	in	ADP
dpc-2939	101	29	94.4	94.4	NUM
dpc-2939	101	30	%	%	NOUN
dpc-2939	101	31	of	of	ADP
dpc-2939	101	32	the	the	DET
dpc-2939	101	33	cases	case	NOUN
dpc-2939	101	34	(	(	PUNCT
dpc-2939	101	35	figure	figure	NOUN
dpc-2939	101	36	3	3	NUM
dpc-2939	101	37	)	)	PUNCT
dpc-2939	101	38	.	.	PUNCT
dpc-2939	102	1	moreover	moreover	ADV
dpc-2939	102	2	,	,	PUNCT
dpc-2939	102	3	although	although	SCONJ
dpc-2939	102	4	the	the	DET
dpc-2939	102	5	natural	natural	ADJ
dpc-2939	102	6	course	course	NOUN
dpc-2939	102	7	of	of	ADP
dpc-2939	102	8	ak	ak	PROPN
dpc-2939	102	9	is	be	AUX
dpc-2939	102	10	characterized	characterize	VERB
dpc-2939	102	11	by	by	ADP
dpc-2939	102	12	the	the	DET
dpc-2939	102	13	recurrence	recurrence	NOUN
dpc-2939	102	14	of	of	ADP
dpc-2939	102	15	lesions	lesion	NOUN
dpc-2939	102	16	,	,	PUNCT
dpc-2939	102	17	the	the	DET
dpc-2939	102	18	clearance	clearance	NOUN
dpc-2939	102	19	obtained	obtain	VERB
dpc-2939	102	20	with	with	ADP
dpc-2939	102	21	4	4	NUM
dpc-2939	102	22	%	%	NOUN
dpc-2939	102	23	5	5	NUM
dpc-2939	102	24	-	-	PUNCT
dpc-2939	102	25	fu	fu	NOUN
dpc-2939	102	26	was	be	AUX
dpc-2939	102	27	sustained	sustain	VERB
dpc-2939	102	28	during	during	ADP
dpc-2939	102	29	follow	follow	NOUN
dpc-2939	102	30	-	-	PUNCT
dpc-2939	102	31	up	up	NOUN
dpc-2939	102	32	,	,	PUNCT
dpc-2939	102	33	with	with	ADP
dpc-2939	102	34	more	more	ADJ
dpc-2939	102	35	than	than	ADP
dpc-2939	102	36	64	64	NUM
dpc-2939	102	37	%	%	NOUN
dpc-2939	102	38	of	of	ADP
dpc-2939	102	39	the	the	DET
dpc-2939	102	40	patients	patient	NOUN
dpc-2939	102	41	free	free	ADJ
dpc-2939	102	42	from	from	ADP
dpc-2939	102	43	ak	ak	PROPN
dpc-2939	102	44	recurrences	recurrence	NOUN
dpc-2939	102	45	at	at	ADP
dpc-2939	102	46	6	6	NUM
dpc-2939	102	47	months	month	NOUN
dpc-2939	103	1	[	[	X
dpc-2939	103	2	15	15	NUM
dpc-2939	103	3	]	]	SYM
dpc-2939	103	4	.	.	PUNCT
dpc-2939	103	5	4	4	NUM
dpc-2939	103	6	original	original	ADJ
dpc-2939	103	7	article	article	NOUN
dpc-2939	103	8	|	|	ADV
dpc-2939	103	9	dermatol	dermatol	ADJ
dpc-2939	103	10	pract	pract	NOUN
dpc-2939	103	11	concept	concept	NOUN
dpc-2939	103	12	.	.	PUNCT
dpc-2939	104	1	2023;13(2):e2023151	2023;13(2):e2023151	NUM
dpc-2939	104	2	4	4	NUM
dpc-2939	104	3	%	%	NOUN
dpc-2939	104	4	5	5	NUM
dpc-2939	104	5	-	-	PUNCT
dpc-2939	104	6	fu	fu	NOUN
dpc-2939	104	7	was	be	AUX
dpc-2939	104	8	well	well	ADV
dpc-2939	104	9	tolerated	tolerate	VERB
dpc-2939	104	10	in	in	ADP
dpc-2939	104	11	our	our	PRON
dpc-2939	104	12	patient	patient	ADJ
dpc-2939	104	13	population	population	NOUN
dpc-2939	104	14	,	,	PUNCT
dpc-2939	104	15	with	with	SCONJ
dpc-2939	104	16	no	no	DET
dpc-2939	104	17	side	side	NOUN
dpc-2939	104	18	effects	effect	NOUN
dpc-2939	104	19	reported	report	VERB
dpc-2939	104	20	other	other	ADJ
dpc-2939	104	21	than	than	ADP
dpc-2939	104	22	erythema	erythema	ADJ
dpc-2939	104	23	and	and	CCONJ
dpc-2939	104	24	burning	burn	VERB
dpc-2939	104	25	sensation	sensation	NOUN
dpc-2939	104	26	.	.	PUNCT
dpc-2939	105	1	after	after	ADP
dpc-2939	105	2	4	4	NUM
dpc-2939	105	3	weeks	week	NOUN
dpc-2939	105	4	of	of	ADP
dpc-2939	105	5	treatment	treatment	NOUN
dpc-2939	105	6	,	,	PUNCT
dpc-2939	105	7	erythema	erythema	ADV
dpc-2939	105	8	was	be	AUX
dpc-2939	105	9	light	light	ADJ
dpc-2939	105	10	or	or	CCONJ
dpc-2939	105	11	moderate	moderate	ADJ
dpc-2939	105	12	in	in	ADP
dpc-2939	105	13	almost	almost	ADV
dpc-2939	105	14	90	90	NUM
dpc-2939	105	15	%	%	NOUN
dpc-2939	105	16	of	of	ADP
dpc-2939	105	17	the	the	DET
dpc-2939	105	18	subjects	subject	NOUN
dpc-2939	105	19	,	,	PUNCT
dpc-2939	105	20	and	and	CCONJ
dpc-2939	105	21	only	only	ADV
dpc-2939	105	22	1	1	NUM
dpc-2939	105	23	patient	patient	NOUN
dpc-2939	105	24	graded	grade	VERB
dpc-2939	105	25	it	it	PRON
dpc-2939	105	26	as	as	ADP
dpc-2939	105	27	severe	severe	ADJ
dpc-2939	105	28	.	.	PUNCT
dpc-2939	106	1	31.6	31.6	NUM
dpc-2939	106	2	%	%	NOUN
dpc-2939	106	3	of	of	ADP
dpc-2939	106	4	patients	patient	NOUN
dpc-2939	106	5	did	do	AUX
dpc-2939	106	6	not	not	PART
dpc-2939	106	7	report	report	VERB
dpc-2939	106	8	any	any	DET
dpc-2939	106	9	burning	burn	VERB
dpc-2939	106	10	sensation	sensation	NOUN
dpc-2939	106	11	,	,	PUNCT
dpc-2939	106	12	which	which	PRON
dpc-2939	106	13	was	be	AUX
dpc-2939	106	14	severe	severe	ADJ
dpc-2939	106	15	in	in	ADP
dpc-2939	106	16	only	only	ADV
dpc-2939	106	17	1	1	NUM
dpc-2939	106	18	patient	patient	NOUN
dpc-2939	106	19	.	.	PUNCT
dpc-2939	107	1	in	in	ADP
dpc-2939	107	2	all	all	DET
dpc-2939	107	3	the	the	DET
dpc-2939	107	4	patients	patient	NOUN
dpc-2939	107	5	both	both	CCONJ
dpc-2939	107	6	erythema	erythema	VERB
dpc-2939	107	7	and	and	CCONJ
dpc-2939	107	8	burning	burn	VERB
dpc-2939	107	9	sensation	sensation	NOUN
dpc-2939	107	10	were	be	AUX
dpc-2939	107	11	these	these	DET
dpc-2939	107	12	results	result	NOUN
dpc-2939	107	13	confirm	confirm	VERB
dpc-2939	107	14	previously	previously	ADV
dpc-2939	107	15	published	publish	VERB
dpc-2939	107	16	evidence	evidence	NOUN
dpc-2939	107	17	on	on	ADP
dpc-2939	107	18	5	5	NUM
dpc-2939	107	19	-	-	PUNCT
dpc-2939	107	20	fu	fu	NOUN
dpc-2939	107	21	,	,	PUNCT
dpc-2939	107	22	which	which	PRON
dpc-2939	107	23	is	be	AUX
dpc-2939	107	24	currently	currently	ADV
dpc-2939	107	25	considered	consider	VERB
dpc-2939	107	26	one	one	NUM
dpc-2939	107	27	of	of	ADP
dpc-2939	107	28	the	the	DET
dpc-2939	107	29	most	most	ADV
dpc-2939	107	30	effective	effective	ADJ
dpc-2939	107	31	topical	topical	ADJ
dpc-2939	107	32	treatments	treatment	NOUN
dpc-2939	107	33	for	for	ADP
dpc-2939	107	34	ak	ak	PROPN
dpc-2939	107	35	lesion	lesion	NOUN
dpc-2939	107	36	clearance	clearance	NOUN
dpc-2939	107	37	based	base	VERB
dpc-2939	107	38	on	on	ADP
dpc-2939	107	39	several	several	ADJ
dpc-2939	107	40	randomized	randomized	ADJ
dpc-2939	107	41	clinical	clinical	ADJ
dpc-2939	107	42	trials	trial	NOUN
dpc-2939	107	43	and	and	CCONJ
dpc-2939	107	44	meta	meta	NOUN
dpc-2939	107	45	-	-	PUNCT
dpc-2939	107	46	analyses	analyse	VERB
dpc-2939	108	1	[	[	X
dpc-2939	108	2	7,9,13,14	7,9,13,14	X
dpc-2939	108	3	]	]	PUNCT
dpc-2939	108	4	.	.	PUNCT
dpc-2939	109	1	furthermore	furthermore	ADV
dpc-2939	109	2	,	,	PUNCT
dpc-2939	109	3	our	our	PRON
dpc-2939	109	4	study	study	NOUN
dpc-2939	109	5	confirms	confirm	VERB
dpc-2939	109	6	that	that	SCONJ
dpc-2939	109	7	reducing	reduce	VERB
dpc-2939	109	8	5	5	NUM
dpc-2939	109	9	-	-	PUNCT
dpc-2939	109	10	fu	fu	NOUN
dpc-2939	109	11	concentration	concentration	NOUN
dpc-2939	109	12	from	from	ADP
dpc-2939	109	13	5	5	NUM
dpc-2939	109	14	%	%	NOUN
dpc-2939	109	15	to	to	PART
dpc-2939	109	16	4	4	NUM
dpc-2939	109	17	%	%	NOUN
dpc-2939	109	18	does	do	AUX
dpc-2939	109	19	not	not	PART
dpc-2939	109	20	affect	affect	VERB
dpc-2939	109	21	its	its	PRON
dpc-2939	109	22	efficacy	efficacy	NOUN
dpc-2939	109	23	,	,	PUNCT
dpc-2939	109	24	even	even	ADV
dpc-2939	109	25	when	when	SCONJ
dpc-2939	109	26	used	use	VERB
dpc-2939	109	27	in	in	ADP
dpc-2939	109	28	real	real	ADJ
dpc-2939	109	29	-	-	PUNCT
dpc-2939	109	30	world	world	NOUN
dpc-2939	109	31	clinical	clinical	ADJ
dpc-2939	109	32	practice	practice	NOUN
dpc-2939	109	33	.	.	PUNCT
dpc-2939	110	1	90	90	NUM
dpc-2939	110	2	80	80	NUM
dpc-2939	110	3	70	70	NUM
dpc-2939	110	4	60	60	NUM
dpc-2939	110	5	50	50	NUM
dpc-2939	110	6	40	40	NUM
dpc-2939	110	7	pa	pa	NOUN
dpc-2939	110	8	ti	ti	X
dpc-2939	110	9	en	en	ADP
dpc-2939	110	10	ts	ts	X
dpc-2939	110	11	,	,	PUNCT
dpc-2939	110	12	%	%	NOUN
dpc-2939	110	13	30	30	NUM
dpc-2939	110	14	20	20	NUM
dpc-2939	110	15	10	10	NUM
dpc-2939	110	16	0	0	NUM
dpc-2939	110	17	0	0	NUM
dpc-2939	110	18	0	0	NUM
dpc-2939	110	19	1	1	NUM
dpc-2939	110	20	*	*	SYM
dpc-2939	110	21	3.1	3.1	NUM
dpc-2939	110	22	*	*	SYM
dpc-2939	110	23	1	1	NUM
dpc-2939	110	24	*	*	SYM
dpc-2939	110	25	20.4	20.4	NUM
dpc-2939	110	26	*	*	SYM
dpc-2939	111	1	74.5	74.5	NUM
dpc-2939	111	2	*	*	PUNCT
dpc-2939	111	3	igi	igi	NOUN
dpc-2939	111	4	score	score	NOUN
dpc-2939	111	5	(	(	PUNCT
dpc-2939	111	6	significantly	significantly	ADV
dpc-2939	111	7	worse	bad	ADJ
dpc-2939	111	8	)	)	PUNCT
dpc-2939	111	9	-2	-2	INTJ
dpc-2939	112	1	-1	-1	NOUN
dpc-2939	112	2	0	0	PUNCT
dpc-2939	113	1	+1	+1	ADJ
dpc-2939	113	2	+2	+2	PROPN
dpc-2939	113	3	+3	+3	PROPN
dpc-2939	113	4	+4	+4	PROPN
dpc-2939	113	5	(	(	PUNCT
dpc-2939	113	6	sligthly	sligthly	ADV
dpc-2939	113	7	worse	bad	ADJ
dpc-2939	113	8	)	)	PUNCT
dpc-2939	113	9	(	(	PUNCT
dpc-2939	113	10	no	no	DET
dpc-2939	113	11	change	change	NOUN
dpc-2939	113	12	)	)	PUNCT
dpc-2939	113	13	(	(	PUNCT
dpc-2939	113	14	sligthly	sligthly	ADV
dpc-2939	113	15	improved	improve	VERB
dpc-2939	113	16	)	)	PUNCT
dpc-2939	113	17	(	(	PUNCT
dpc-2939	113	18	moderately	moderately	ADV
dpc-2939	113	19	improved	improve	VERB
dpc-2939	113	20	)	)	PUNCT
dpc-2939	113	21	(	(	PUNCT
dpc-2939	113	22	significantly	significantly	ADV
dpc-2939	113	23	improved	improve	VERB
dpc-2939	113	24	)	)	PUNCT
dpc-2939	113	25	(	(	PUNCT
dpc-2939	113	26	completely	completely	ADV
dpc-2939	113	27	improved	improve	VERB
dpc-2939	113	28	)	)	PUNCT
dpc-2939	113	29	n	n	CCONJ
dpc-2939	113	30	/	/	SYM
dpc-2939	113	31	n	n	ADP
dpc-2939	113	32	1/98	1/98	NUM
dpc-2939	113	33	3/98	3/98	NUM
dpc-2939	113	34	1/98	1/98	NUM
dpc-2939	113	35	20/98	20/98	NUM
dpc-2939	113	36	73/980/98	73/980/98	NUM
dpc-2939	113	37	0/98	0/98	NUM
dpc-2939	113	38	figure	figure	NOUN
dpc-2939	113	39	1	1	NUM
dpc-2939	113	40	.	.	PUNCT
dpc-2939	113	41	ak	ak	PROPN
dpc-2939	113	42	lesions	lesion	NOUN
dpc-2939	113	43	improvement	improvement	NOUN
dpc-2939	113	44	from	from	ADP
dpc-2939	113	45	baseline	baseline	NOUN
dpc-2939	113	46	at	at	ADP
dpc-2939	113	47	8	8	NUM
dpc-2939	113	48	weeks	week	NOUN
dpc-2939	113	49	.	.	PUNCT
dpc-2939	114	1	percentages	percentage	NOUN
dpc-2939	114	2	of	of	ADP
dpc-2939	114	3	patients	patient	NOUN
dpc-2939	114	4	with	with	ADP
dpc-2939	114	5	ak	ak	PROPN
dpc-2939	114	6	lesion	lesion	NOUN
dpc-2939	114	7	improvement	improvement	NOUN
dpc-2939	114	8	assessed	assess	VERB
dpc-2939	114	9	with	with	ADP
dpc-2939	114	10	igi	igi	NOUN
dpc-2939	114	11	scale	scale	NOUN
dpc-2939	114	12	after	after	ADP
dpc-2939	114	13	8	8	NUM
dpc-2939	114	14	weeks	week	NOUN
dpc-2939	114	15	from	from	ADP
dpc-2939	114	16	8	8	NUM
dpc-2939	114	17	weeks	week	NOUN
dpc-2939	114	18	after	after	ADP
dpc-2939	114	19	treatment	treatment	NOUN
dpc-2939	114	20	initiation	initiation	NOUN
dpc-2939	114	21	.	.	PUNCT
dpc-2939	115	1	error	error	NOUN
dpc-2939	115	2	bars	bar	NOUN
dpc-2939	115	3	show	show	VERB
dpc-2939	115	4	95	95	NUM
dpc-2939	115	5	%	%	NOUN
dpc-2939	115	6	cis	cis	NOUN
dpc-2939	115	7	.	.	PUNCT
dpc-2939	116	1	*	*	PUNCT
dpc-2939	116	2	p	p	X
dpc-2939	116	3	<	<	X
dpc-2939	116	4	0.001	0.001	NUM
dpc-2939	116	5	.	.	PUNCT
dpc-2939	116	6	ak	ak	PROPN
dpc-2939	116	7	=	=	PROPN
dpc-2939	116	8	actinic	actinic	ADJ
dpc-2939	116	9	keratosis	keratosis	NOUN
dpc-2939	116	10	;	;	PUNCT
dpc-2939	116	11	igi	igi	NOUN
dpc-2939	116	12	=	=	NOUN
dpc-2939	116	13	investigator	investigator	NOUN
dpc-2939	116	14	global	global	ADJ
dpc-2939	116	15	improvement	improvement	NOUN
dpc-2939	116	16	;	;	PUNCT
dpc-2939	116	17	ci	ci	NOUN
dpc-2939	116	18	=	=	NOUN
dpc-2939	116	19	confidence	confidence	NOUN
dpc-2939	116	20	interval	interval	NOUN
dpc-2939	116	21	.	.	PUNCT
dpc-2939	117	1	60	60	NUM
dpc-2939	117	2	50	50	NUM
dpc-2939	117	3	40	40	NUM
dpc-2939	117	4	30	30	NUM
dpc-2939	117	5	31.6	31.6	NUM
dpc-2939	117	6	*	*	NUM
dpc-2939	117	7	22.4	22.4	NUM
dpc-2939	117	8	*	*	PUNCT
dpc-2939	117	9	1.0	1.0	NUM
dpc-2939	117	10	*	*	SYM
dpc-2939	117	11	10.2	10.2	NUM
dpc-2939	117	12	37.8	37.8	NUM
dpc-2939	117	13	51.0	51.0	NUM
dpc-2939	117	14	*	*	SYM
dpc-2939	117	15	1.0	1.0	NUM
dpc-2939	117	16	*	*	SYM
dpc-2939	117	17	43.9	43.9	NUM
dpc-2939	117	18	a.	a.	NOUN
dpc-2939	117	19	burning	burn	VERB
dpc-2939	117	20	sensation	sensation	NOUN
dpc-2939	117	21	b.	b.	PROPN
dpc-2939	117	22	erythema	erythema	PROPN
dpc-2939	117	23	pa	pa	PROPN
dpc-2939	117	24	ti	ti	PROPN
dpc-2939	117	25	en	en	ADP
dpc-2939	117	26	ts	ts	X
dpc-2939	117	27	,	,	PUNCT
dpc-2939	117	28	%	%	INTJ
dpc-2939	117	29	pa	pa	PROPN
dpc-2939	117	30	ti	ti	PROPN
dpc-2939	117	31	en	en	ADP
dpc-2939	117	32	ts	ts	X
dpc-2939	117	33	,	,	PUNCT
dpc-2939	117	34	%	%	NOUN
dpc-2939	117	35	20	20	NUM
dpc-2939	117	36	10	10	NUM
dpc-2939	117	37	0	0	NUM
dpc-2939	117	38	0	0	NUM
dpc-2939	117	39	10	10	NUM
dpc-2939	117	40	20	20	NUM
dpc-2939	117	41	30	30	NUM
dpc-2939	117	42	40	40	NUM
dpc-2939	117	43	50	50	NUM
dpc-2939	117	44	60	60	NUM
dpc-2939	117	45	70	70	NUM
dpc-2939	117	46	sca	sca	NOUN
dpc-2939	117	47	score	score	NOUN
dpc-2939	117	48	n	n	CCONJ
dpc-2939	117	49	/	/	SYM
dpc-2939	117	50	n	n	NOUN
dpc-2939	117	51	0	0	NUM
dpc-2939	117	52	(	(	PUNCT
dpc-2939	117	53	absent	absent	ADJ
dpc-2939	117	54	)	)	PUNCT
dpc-2939	117	55	31/98	31/98	NUM
dpc-2939	117	56	1	1	NUM
dpc-2939	117	57	(	(	PUNCT
dpc-2939	117	58	light	light	NOUN
dpc-2939	117	59	)	)	PUNCT
dpc-2939	117	60	43/98	43/98	NUM
dpc-2939	117	61	2	2	NUM
dpc-2939	117	62	(	(	PUNCT
dpc-2939	117	63	moderate	moderate	ADJ
dpc-2939	117	64	)	)	PUNCT
dpc-2939	117	65	22/98	22/98	NUM
dpc-2939	117	66	3	3	NUM
dpc-2939	117	67	(	(	PUNCT
dpc-2939	117	68	severe	severe	ADJ
dpc-2939	117	69	)	)	PUNCT
dpc-2939	117	70	1/98	1/98	NUM
dpc-2939	117	71	sca	sca	NOUN
dpc-2939	117	72	score	score	NOUN
dpc-2939	117	73	n	n	CCONJ
dpc-2939	117	74	/	/	SYM
dpc-2939	117	75	n	n	NOUN
dpc-2939	117	76	0	0	NUM
dpc-2939	117	77	(	(	PUNCT
dpc-2939	117	78	absent	absent	ADJ
dpc-2939	117	79	)	)	PUNCT
dpc-2939	117	80	10/98	10/98	NUM
dpc-2939	117	81	1	1	NUM
dpc-2939	117	82	(	(	PUNCT
dpc-2939	117	83	light	light	NOUN
dpc-2939	117	84	)	)	PUNCT
dpc-2939	117	85	37/98	37/98	NUM
dpc-2939	117	86	2	2	NUM
dpc-2939	117	87	(	(	PUNCT
dpc-2939	117	88	moderate	moderate	ADJ
dpc-2939	117	89	)	)	PUNCT
dpc-2939	117	90	50/98	50/98	NUM
dpc-2939	117	91	3	3	NUM
dpc-2939	117	92	(	(	PUNCT
dpc-2939	117	93	severe	severe	ADJ
dpc-2939	117	94	)	)	PUNCT
dpc-2939	117	95	1/98	1/98	NUM
dpc-2939	117	96	figure	figure	NOUN
dpc-2939	117	97	2	2	NUM
dpc-2939	117	98	.	.	PUNCT
dpc-2939	117	99	safety	safety	NOUN
dpc-2939	117	100	assessment	assessment	NOUN
dpc-2939	117	101	at	at	ADP
dpc-2939	117	102	4	4	NUM
dpc-2939	117	103	weeks	week	NOUN
dpc-2939	117	104	.	.	PUNCT
dpc-2939	118	1	(	(	PUNCT
dpc-2939	118	2	a	a	X
dpc-2939	118	3	)	)	PUNCT
dpc-2939	118	4	burning	burn	VERB
dpc-2939	118	5	sensation	sensation	NOUN
dpc-2939	118	6	assessed	assess	VERB
dpc-2939	118	7	with	with	ADP
dpc-2939	118	8	sca	sca	PROPN
dpc-2939	118	9	after	after	ADP
dpc-2939	118	10	4	4	NUM
dpc-2939	118	11	weeks	week	NOUN
dpc-2939	118	12	from	from	ADP
dpc-2939	118	13	4	4	NUM
dpc-2939	118	14	weeks	week	NOUN
dpc-2939	118	15	after	after	ADP
dpc-2939	118	16	treatment	treatment	NOUN
dpc-2939	118	17	initiation	initiation	NOUN
dpc-2939	118	18	.	.	PUNCT
dpc-2939	119	1	(	(	PUNCT
dpc-2939	119	2	b	b	X
dpc-2939	119	3	)	)	PUNCT
dpc-2939	119	4	erythema	erythema	NOUN
dpc-2939	119	5	assessed	assess	VERB
dpc-2939	119	6	with	with	ADP
dpc-2939	119	7	sca	sca	PROPN
dpc-2939	119	8	after	after	ADP
dpc-2939	119	9	4	4	NUM
dpc-2939	119	10	weeks	week	NOUN
dpc-2939	119	11	from	from	ADP
dpc-2939	119	12	4	4	NUM
dpc-2939	119	13	weeks	week	NOUN
dpc-2939	119	14	after	after	ADP
dpc-2939	119	15	treatment	treatment	NOUN
dpc-2939	119	16	initiation	initiation	NOUN
dpc-2939	119	17	.	.	PUNCT
dpc-2939	120	1	error	error	NOUN
dpc-2939	120	2	bars	bar	NOUN
dpc-2939	120	3	show	show	VERB
dpc-2939	120	4	95	95	NUM
dpc-2939	120	5	%	%	NOUN
dpc-2939	120	6	cis	cis	NOUN
dpc-2939	120	7	.	.	PUNCT
dpc-2939	121	1	*	*	PUNCT
dpc-2939	121	2	p	p	X
dpc-2939	121	3	<	<	X
dpc-2939	121	4	0.001	0.001	NUM
dpc-2939	121	5	.	.	PUNCT
dpc-2939	122	1	sca	sca	NOUN
dpc-2939	122	2	=	=	NOUN
dpc-2939	122	3	scale	scale	NOUN
dpc-2939	122	4	for	for	ADP
dpc-2939	122	5	clinical	clinical	ADJ
dpc-2939	122	6	assessment	assessment	NOUN
dpc-2939	122	7	;	;	PUNCT
dpc-2939	122	8	ci	ci	NOUN
dpc-2939	122	9	=	=	NOUN
dpc-2939	122	10	confidence	confidence	NOUN
dpc-2939	122	11	interval	interval	NOUN
dpc-2939	122	12	.	.	PUNCT
dpc-2939	123	1	original	original	ADJ
dpc-2939	123	2	article	article	NOUN
dpc-2939	123	3	|	|	ADV
dpc-2939	123	4	dermatol	dermatol	ADJ
dpc-2939	123	5	pract	pract	NOUN
dpc-2939	123	6	concept	concept	NOUN
dpc-2939	123	7	.	.	PUNCT
dpc-2939	124	1	2023;13(2):e2023151	2023;13(2):e2023151	NUM
dpc-2939	124	2	5	5	NUM
dpc-2939	124	3	figure	figure	NOUN
dpc-2939	124	4	3	3	NUM
dpc-2939	124	5	.	.	PUNCT
dpc-2939	124	6	effects	effect	NOUN
dpc-2939	124	7	of	of	ADP
dpc-2939	124	8	4	4	NUM
dpc-2939	124	9	%	%	NOUN
dpc-2939	124	10	5	5	NUM
dpc-2939	124	11	-	-	PUNCT
dpc-2939	124	12	fu	fu	NOUN
dpc-2939	124	13	treatment	treatment	NOUN
dpc-2939	124	14	.	.	PUNCT
dpc-2939	125	1	these	these	DET
dpc-2939	125	2	pictures	picture	NOUN
dpc-2939	125	3	show	show	VERB
dpc-2939	125	4	4	4	NUM
dpc-2939	125	5	patients	patient	NOUN
dpc-2939	125	6	with	with	ADP
dpc-2939	125	7	diffuse	diffuse	PROPN
dpc-2939	125	8	ak	ak	PROPN
dpc-2939	125	9	of	of	ADP
dpc-2939	125	10	the	the	DET
dpc-2939	125	11	scalp	scalp	NOUN
dpc-2939	125	12	,	,	PUNCT
dpc-2939	125	13	forehead	forehead	NOUN
dpc-2939	125	14	and/or	and/or	CCONJ
dpc-2939	125	15	face	face	NOUN
dpc-2939	125	16	at	at	ADP
dpc-2939	125	17	baseline	baseline	NOUN
dpc-2939	125	18	,	,	PUNCT
dpc-2939	125	19	treated	treat	VERB
dpc-2939	125	20	for	for	ADP
dpc-2939	125	21	4	4	NUM
dpc-2939	125	22	weeks	week	NOUN
dpc-2939	125	23	with	with	ADP
dpc-2939	125	24	4	4	NUM
dpc-2939	125	25	%	%	NOUN
dpc-2939	125	26	5	5	NUM
dpc-2939	125	27	-	-	PUNCT
dpc-2939	125	28	fu	fu	NOUN
dpc-2939	125	29	.	.	PUNCT
dpc-2939	126	1	they	they	PRON
dpc-2939	126	2	confirm	confirm	VERB
dpc-2939	126	3	the	the	DET
dpc-2939	126	4	normal	normal	ADJ
dpc-2939	126	5	pattern	pattern	NOUN
dpc-2939	126	6	of	of	ADP
dpc-2939	126	7	response	response	NOUN
dpc-2939	126	8	to	to	ADP
dpc-2939	126	9	4	4	NUM
dpc-2939	126	10	%	%	NOUN
dpc-2939	126	11	5	5	NUM
dpc-2939	126	12	-	-	PUNCT
dpc-2939	126	13	fu	fu	NOUN
dpc-2939	126	14	:	:	PUNCT
dpc-2939	126	15	at	at	ADP
dpc-2939	126	16	the	the	DET
dpc-2939	126	17	end	end	NOUN
dpc-2939	126	18	of	of	ADP
dpc-2939	126	19	treatment	treatment	NOUN
dpc-2939	126	20	,	,	PUNCT
dpc-2939	126	21	the	the	DET
dpc-2939	126	22	inflammatory	inflammatory	ADJ
dpc-2939	126	23	response	response	NOUN
dpc-2939	126	24	associated	associate	VERB
dpc-2939	126	25	with	with	ADP
dpc-2939	126	26	5	5	NUM
dpc-2939	126	27	-	-	PUNCT
dpc-2939	126	28	fu	fu	NOUN
dpc-2939	126	29	pharmacological	pharmacological	ADJ
dpc-2939	126	30	action	action	NOUN
dpc-2939	126	31	on	on	ADP
dpc-2939	126	32	dysplastic	dysplastic	ADJ
dpc-2939	126	33	ak	ak	PROPN
dpc-2939	126	34	cells	cell	NOUN
dpc-2939	126	35	reaches	reach	VERB
dpc-2939	126	36	its	its	PRON
dpc-2939	126	37	peak	peak	NOUN
dpc-2939	126	38	,	,	PUNCT
dpc-2939	126	39	characterised	characterise	VERB
dpc-2939	126	40	by	by	ADP
dpc-2939	126	41	mild	mild	ADJ
dpc-2939	126	42	-	-	PUNCT
dpc-2939	126	43	moderate	moderate	ADJ
dpc-2939	126	44	erythema	erythema	NOUN
dpc-2939	126	45	(	(	PUNCT
dpc-2939	126	46	and	and	CCONJ
dpc-2939	126	47	burning	burn	VERB
dpc-2939	126	48	sensation	sensation	NOUN
dpc-2939	126	49	)	)	PUNCT
dpc-2939	126	50	;	;	PUNCT
dpc-2939	126	51	after	after	ADP
dpc-2939	126	52	8	8	NUM
dpc-2939	126	53	weeks	week	NOUN
dpc-2939	126	54	from	from	ADP
dpc-2939	126	55	8	8	NUM
dpc-2939	126	56	weeks	week	NOUN
dpc-2939	126	57	after	after	ADP
dpc-2939	126	58	treatment	treatment	NOUN
dpc-2939	126	59	initiation	initiation	NOUN
dpc-2939	126	60	,	,	PUNCT
dpc-2939	126	61	the	the	DET
dpc-2939	126	62	inflammatory	inflammatory	ADJ
dpc-2939	126	63	response	response	NOUN
dpc-2939	126	64	is	be	AUX
dpc-2939	126	65	resolved	resolve	VERB
dpc-2939	126	66	,	,	PUNCT
dpc-2939	126	67	and	and	CCONJ
dpc-2939	126	68	ak	ak	PROPN
dpc-2939	126	69	lesion	lesion	NOUN
dpc-2939	126	70	clearance	clearance	NOUN
dpc-2939	126	71	is	be	AUX
dpc-2939	126	72	noticeable	noticeable	ADJ
dpc-2939	126	73	.	.	PUNCT
dpc-2939	127	1	(	(	PUNCT
dpc-2939	127	2	a	a	X
dpc-2939	127	3	)	)	PUNCT
dpc-2939	127	4	86	86	NUM
dpc-2939	127	5	-	-	PUNCT
dpc-2939	127	6	year	year	NOUN
dpc-2939	127	7	-	-	PUNCT
dpc-2939	127	8	old	old	ADJ
dpc-2939	127	9	male	male	ADJ
dpc-2939	127	10	patient	patient	NOUN
dpc-2939	127	11	;	;	PUNCT
dpc-2939	127	12	(	(	PUNCT
dpc-2939	127	13	b	b	X
dpc-2939	127	14	)	)	PUNCT
dpc-2939	127	15	76	76	NUM
dpc-2939	127	16	-	-	PUNCT
dpc-2939	127	17	year	year	NOUN
dpc-2939	127	18	-	-	PUNCT
dpc-2939	127	19	old	old	ADJ
dpc-2939	127	20	male	male	ADJ
dpc-2939	127	21	patient	patient	NOUN
dpc-2939	127	22	,	,	PUNCT
dpc-2939	127	23	(	(	PUNCT
dpc-2939	127	24	c	c	NOUN
dpc-2939	127	25	)	)	PUNCT
dpc-2939	127	26	67	67	NUM
dpc-2939	127	27	-	-	PUNCT
dpc-2939	127	28	year	year	NOUN
dpc-2939	127	29	-	-	PUNCT
dpc-2939	127	30	old	old	ADJ
dpc-2939	127	31	male	male	ADJ
dpc-2939	127	32	patient	patient	NOUN
dpc-2939	127	33	;	;	PUNCT
dpc-2939	127	34	(	(	PUNCT
dpc-2939	127	35	d	d	X
dpc-2939	127	36	)	)	PUNCT
dpc-2939	127	37	76	76	NUM
dpc-2939	127	38	-	-	PUNCT
dpc-2939	127	39	year	year	NOUN
dpc-2939	127	40	-	-	PUNCT
dpc-2939	127	41	old	old	ADJ
dpc-2939	127	42	male	male	ADJ
dpc-2939	127	43	patient	patient	NOUN
dpc-2939	127	44	.	.	PUNCT
dpc-2939	128	1	5	5	NUM
dpc-2939	128	2	-	-	PUNCT
dpc-2939	128	3	fu	fu	NOUN
dpc-2939	128	4	=	=	ADJ
dpc-2939	128	5	5	5	NUM
dpc-2939	128	6	-	-	PUNCT
dpc-2939	128	7	fluorouracil	fluorouracil	NOUN
dpc-2939	128	8	.	.	PUNCT
dpc-2939	129	1	6	6	NUM
dpc-2939	129	2	original	original	ADJ
dpc-2939	129	3	article	article	NOUN
dpc-2939	129	4	|	|	ADV
dpc-2939	129	5	dermatol	dermatol	ADJ
dpc-2939	129	6	pract	pract	NOUN
dpc-2939	129	7	concept	concept	NOUN
dpc-2939	129	8	.	.	PUNCT
dpc-2939	130	1	2023;13(2):e2023151	2023;13(2):e2023151	NUM
dpc-2939	130	2	2020;83(3):709	2020;83(3):709	NUM
dpc-2939	130	3	-	-	PUNCT
dpc-2939	130	4	717	717	PROPN
dpc-2939	130	5	.	.	PUNCT
dpc-2939	131	1	doi:10.1016	doi:10.1016	PROPN
dpc-2939	131	2	/	/	SYM
dpc-2939	131	3	j.jaad.2020.03.126	j.jaad.2020.03.126	PROPN
dpc-2939	131	4	.	.	PUNCT
dpc-2939	132	1	pmid	pmid	NOUN
dpc-2939	132	2	:	:	PUNCT
dpc-2939	132	3	32387665	32387665	NUM
dpc-2939	132	4	.	.	PUNCT
dpc-2939	133	1	7	7	X
dpc-2939	133	2	.	.	X
dpc-2939	133	3	wu	wu	PROPN
dpc-2939	133	4	y	y	PROPN
dpc-2939	133	5	,	,	PUNCT
dpc-2939	133	6	tang	tang	PROPN
dpc-2939	133	7	n	n	CCONJ
dpc-2939	133	8	,	,	PUNCT
dpc-2939	133	9	cai	cai	PROPN
dpc-2939	133	10	l	l	PROPN
dpc-2939	133	11	,	,	PUNCT
dpc-2939	133	12	li	li	PROPN
dpc-2939	133	13	q.	q.	PROPN
dpc-2939	133	14	relative	relative	PROPN
dpc-2939	133	15	efficacy	efficacy	PROPN
dpc-2939	133	16	of	of	ADP
dpc-2939	133	17	5	5	NUM
dpc-2939	133	18	-	-	PUNCT
dpc-2939	133	19	fluorouracil	fluorouracil	NOUN
dpc-2939	133	20	compared	compare	VERB
dpc-2939	133	21	with	with	ADP
dpc-2939	133	22	other	other	ADJ
dpc-2939	133	23	treatments	treatment	NOUN
dpc-2939	133	24	among	among	ADP
dpc-2939	133	25	patients	patient	NOUN
dpc-2939	133	26	with	with	ADP
dpc-2939	133	27	actinic	actinic	ADJ
dpc-2939	133	28	keratosis	keratosis	NOUN
dpc-2939	133	29	:	:	PUNCT
dpc-2939	133	30	a	a	DET
dpc-2939	133	31	network	network	NOUN
dpc-2939	133	32	meta	meta	NOUN
dpc-2939	133	33	-	-	PUNCT
dpc-2939	133	34	analysis	analysis	NOUN
dpc-2939	133	35	.	.	PUNCT
dpc-2939	134	1	dermatol	dermatol	NOUN
dpc-2939	134	2	ther	ther	ADV
dpc-2939	134	3	.	.	PUNCT
dpc-2939	135	1	2019;32(3):e12822	2019;32(3):e12822	X
dpc-2939	135	2	.	.	PUNCT
dpc-2939	135	3	doi:10.1111	doi:10.1111	ADJ
dpc-2939	135	4	/	/	SYM
dpc-2939	135	5	dth.12822	dth.12822	NOUN
dpc-2939	135	6	.	.	PUNCT
dpc-2939	136	1	pmid	pmid	NOUN
dpc-2939	136	2	:	:	PUNCT
dpc-2939	136	3	30638294	30638294	NUM
dpc-2939	136	4	.	.	PUNCT
dpc-2939	137	1	8	8	NUM
dpc-2939	137	2	.	.	X
dpc-2939	137	3	reinehr	reinehr	PROPN
dpc-2939	137	4	cph	cph	PROPN
dpc-2939	137	5	,	,	PUNCT
dpc-2939	137	6	bakos	bakos	PROPN
dpc-2939	137	7	rm	rm	PROPN
dpc-2939	137	8	.	.	PUNCT
dpc-2939	137	9	actinic	actinic	ADJ
dpc-2939	137	10	keratoses	keratose	NOUN
dpc-2939	137	11	:	:	PUNCT
dpc-2939	137	12	review	review	NOUN
dpc-2939	137	13	of	of	ADP
dpc-2939	137	14	clinical	clinical	ADJ
dpc-2939	137	15	,	,	PUNCT
dpc-2939	137	16	dermoscopic	dermoscopic	NOUN
dpc-2939	137	17	,	,	PUNCT
dpc-2939	137	18	and	and	CCONJ
dpc-2939	137	19	therapeutic	therapeutic	ADJ
dpc-2939	137	20	aspects	aspect	NOUN
dpc-2939	137	21	.	.	PUNCT
dpc-2939	138	1	an	an	DET
dpc-2939	138	2	bras	bras	NOUN
dpc-2939	138	3	dermatol	dermatol	NOUN
dpc-2939	138	4	.	.	PUNCT
dpc-2939	139	1	2019;94(6):637	2019;94(6):637	NUM
dpc-2939	139	2	-	-	PUNCT
dpc-2939	139	3	657	657	NUM
dpc-2939	139	4	.	.	PUNCT
dpc-2939	140	1	doi:10.1016	doi:10.1016	PROPN
dpc-2939	140	2	/	/	SYM
dpc-2939	140	3	j.abd.2019.10.004	j.abd.2019.10.004	PROPN
dpc-2939	140	4	.	.	PUNCT
dpc-2939	141	1	pmid	pmid	NOUN
dpc-2939	141	2	:	:	PUNCT
dpc-2939	141	3	31789244	31789244	NUM
dpc-2939	141	4	.	.	PUNCT
dpc-2939	142	1	pmcid	pmcid	NOUN
dpc-2939	142	2	:	:	PUNCT
dpc-2939	142	3	pmc6939186	pmc6939186	ADJ
dpc-2939	142	4	.	.	PUNCT
dpc-2939	143	1	9	9	X
dpc-2939	143	2	.	.	X
dpc-2939	143	3	jansen	jansen	PROPN
dpc-2939	143	4	mhe	mhe	PROPN
dpc-2939	143	5	,	,	PUNCT
dpc-2939	143	6	kessels	kessels	PROPN
dpc-2939	143	7	jphm	jphm	PROPN
dpc-2939	143	8	,	,	PUNCT
dpc-2939	143	9	nelemans	nelemans	PROPN
dpc-2939	143	10	pj	pj	PROPN
dpc-2939	143	11	,	,	PUNCT
dpc-2939	143	12	et	et	PROPN
dpc-2939	143	13	al	al	PROPN
dpc-2939	143	14	.	.	PROPN
dpc-2939	143	15	randomized	randomize	VERB
dpc-2939	143	16	trial	trial	NOUN
dpc-2939	143	17	of	of	ADP
dpc-2939	143	18	four	four	NUM
dpc-2939	143	19	treatment	treatment	NOUN
dpc-2939	143	20	approaches	approach	NOUN
dpc-2939	143	21	for	for	ADP
dpc-2939	143	22	actinic	actinic	ADJ
dpc-2939	143	23	keratosis	keratosis	NOUN
dpc-2939	143	24	.	.	PUNCT
dpc-2939	144	1	n	n	PROPN
dpc-2939	144	2	engl	engl	PROPN
dpc-2939	144	3	j	j	PROPN
dpc-2939	144	4	med	med	PROPN
dpc-2939	144	5	.	.	PUNCT
dpc-2939	145	1	2019;380(10):935	2019;380(10):935	NUM
dpc-2939	145	2	-	-	SYM
dpc-2939	145	3	946	946	NUM
dpc-2939	145	4	.	.	PUNCT
dpc-2939	145	5	doi:10.1056	doi:10.1056	PROPN
dpc-2939	145	6	/	/	SYM
dpc-2939	145	7	nejmoa1811850	nejmoa1811850	PROPN
dpc-2939	145	8	.	.	PUNCT
dpc-2939	146	1	pmid	pmid	NOUN
dpc-2939	146	2	:	:	PUNCT
dpc-2939	146	3	30855743	30855743	NUM
dpc-2939	146	4	.	.	PUNCT
dpc-2939	147	1	10	10	NUM
dpc-2939	147	2	.	.	X
dpc-2939	148	1	ahmady	ahmady	PROPN
dpc-2939	148	2	s	s	PROPN
dpc-2939	148	3	,	,	PUNCT
dpc-2939	148	4	jansen	jansen	PROPN
dpc-2939	148	5	mhe	mhe	PROPN
dpc-2939	148	6	,	,	PUNCT
dpc-2939	148	7	nelemans	nelemans	PROPN
dpc-2939	148	8	pj	pj	PROPN
dpc-2939	148	9	,	,	PUNCT
dpc-2939	148	10	et	et	PROPN
dpc-2939	148	11	al	al	PROPN
dpc-2939	148	12	.	.	PROPN
dpc-2939	149	1	risk	risk	NOUN
dpc-2939	149	2	of	of	ADP
dpc-2939	149	3	invasive	invasive	ADJ
dpc-2939	149	4	cutaneous	cutaneous	ADJ
dpc-2939	149	5	squamous	squamous	ADJ
dpc-2939	149	6	cell	cell	NOUN
dpc-2939	149	7	carcinoma	carcinoma	NOUN
dpc-2939	149	8	after	after	ADP
dpc-2939	149	9	different	different	ADJ
dpc-2939	149	10	treatments	treatment	NOUN
dpc-2939	149	11	for	for	ADP
dpc-2939	149	12	actinic	actinic	ADJ
dpc-2939	149	13	keratosis	keratosis	NOUN
dpc-2939	149	14	:	:	PUNCT
dpc-2939	149	15	a	a	DET
dpc-2939	149	16	secondary	secondary	ADJ
dpc-2939	149	17	analysis	analysis	NOUN
dpc-2939	149	18	of	of	ADP
dpc-2939	149	19	a	a	DET
dpc-2939	149	20	randomized	randomized	ADJ
dpc-2939	149	21	clinical	clinical	ADJ
dpc-2939	149	22	trial	trial	NOUN
dpc-2939	149	23	.	.	PUNCT
dpc-2939	150	1	jama	jama	PROPN
dpc-2939	150	2	dermatol	dermatol	NOUN
dpc-2939	150	3	.	.	PUNCT
dpc-2939	151	1	2022;158(6	2022;158(6	NUM
dpc-2939	151	2	):	):	PUNCT
dpc-2939	151	3	634	634	NUM
dpc-2939	151	4	-	-	SYM
dpc-2939	151	5	640	640	NUM
dpc-2939	151	6	.	.	PUNCT
dpc-2939	152	1	doi:10.1001	doi:10.1001	NOUN
dpc-2939	152	2	/	/	SYM
dpc-2939	152	3	jamadermatol.2022.1034	jamadermatol.2022.1034	NOUN
dpc-2939	152	4	.	.	PUNCT
dpc-2939	153	1	pmid	pmid	NOUN
dpc-2939	153	2	:	:	PUNCT
dpc-2939	153	3	3547	3547	NUM
dpc-2939	153	4	5852	5852	NUM
dpc-2939	153	5	.	.	PUNCT
dpc-2939	154	1	pmcid	pmcid	NOUN
dpc-2939	154	2	:	:	PUNCT
dpc-2939	154	3	pmc9047727	pmc9047727	NOUN
dpc-2939	154	4	.	.	PUNCT
dpc-2939	155	1	11	11	NUM
dpc-2939	155	2	.	.	PUNCT
dpc-2939	155	3	tolerak	tolerak	PROPN
dpc-2939	155	4	®	®	NOUN
dpc-2939	155	5	40	40	NUM
dpc-2939	155	6	mg	mg	NUM
dpc-2939	155	7	/	/	SYM
dpc-2939	155	8	g	g	NOUN
dpc-2939	155	9	cream	cream	NOUN
dpc-2939	155	10	,	,	PUNCT
dpc-2939	155	11	summary	summary	NOUN
dpc-2939	155	12	of	of	ADP
dpc-2939	155	13	product	product	NOUN
dpc-2939	155	14	characteristics	characteristic	NOUN
dpc-2939	155	15	(	(	PUNCT
dpc-2939	155	16	pierre	pierre	PROPN
dpc-2939	155	17	fabre	fabre	PROPN
dpc-2939	155	18	italia	italia	PROPN
dpc-2939	155	19	)	)	PUNCT
dpc-2939	155	20	.	.	PUNCT
dpc-2939	156	1	12	12	NUM
dpc-2939	156	2	.	.	PUNCT
dpc-2939	156	3	del	del	PROPN
dpc-2939	156	4	regno	regno	PROPN
dpc-2939	156	5	l	l	PROPN
dpc-2939	156	6	,	,	PUNCT
dpc-2939	156	7	catapano	catapano	PROPN
dpc-2939	156	8	s	s	PART
dpc-2939	156	9	,	,	PUNCT
dpc-2939	156	10	di	di	PROPN
dpc-2939	156	11	stefani	stefani	PROPN
dpc-2939	156	12	a	a	PROPN
dpc-2939	156	13	,	,	PUNCT
dpc-2939	156	14	cappilli	cappilli	PROPN
dpc-2939	156	15	s	s	PART
dpc-2939	156	16	,	,	PUNCT
dpc-2939	156	17	peris	peris	PROPN
dpc-2939	156	18	k.	k.	PROPN
dpc-2939	157	1	a	a	DET
dpc-2939	157	2	review	review	NOUN
dpc-2939	157	3	of	of	ADP
dpc-2939	157	4	existing	exist	VERB
dpc-2939	157	5	therapies	therapy	NOUN
dpc-2939	157	6	for	for	ADP
dpc-2939	157	7	actinic	actinic	ADJ
dpc-2939	157	8	keratosis	keratosis	NOUN
dpc-2939	157	9	:	:	PUNCT
dpc-2939	157	10	current	current	ADJ
dpc-2939	157	11	status	status	NOUN
dpc-2939	157	12	and	and	CCONJ
dpc-2939	157	13	future	future	ADJ
dpc-2939	157	14	directions	direction	NOUN
dpc-2939	157	15	[	[	X
dpc-2939	157	16	published	publish	VERB
dpc-2939	157	17	correction	correction	NOUN
dpc-2939	157	18	appears	appear	VERB
dpc-2939	157	19	in	in	ADP
dpc-2939	157	20	am	am	PROPN
dpc-2939	157	21	j	j	PROPN
dpc-2939	157	22	clin	clin	PROPN
dpc-2939	157	23	dermatol	dermatol	NOUN
dpc-2939	157	24	.	.	PUNCT
dpc-2939	158	1	2022	2022	NUM
dpc-2939	158	2	apr	apr	VERB
dpc-2939	158	3	22	22	NUM
dpc-2939	158	4	]	]	PUNCT
dpc-2939	158	5	.	.	PUNCT
dpc-2939	159	1	am	be	AUX
dpc-2939	159	2	j	j	PROPN
dpc-2939	159	3	clin	clin	PROPN
dpc-2939	159	4	dermatol	dermatol	NOUN
dpc-2939	159	5	.	.	PUNCT
dpc-2939	160	1	2022;23(3):339	2022;23(3):339	NUM
dpc-2939	160	2	-	-	SYM
dpc-2939	160	3	352	352	NUM
dpc-2939	160	4	.	.	PUNCT
dpc-2939	160	5	doi:10.1007	doi:10.1007	VERB
dpc-2939	160	6	/	/	SYM
dpc-2939	160	7	s40257	s40257	NOUN
dpc-2939	160	8	-	-	PUNCT
dpc-2939	160	9	022	022	NUM
dpc-2939	160	10	-	-	PUNCT
dpc-2939	160	11	00674	00674	NUM
dpc-2939	160	12	-	-	SYM
dpc-2939	160	13	3	3	NUM
dpc-2939	160	14	.	.	PUNCT
dpc-2939	161	1	pmid	pmid	NOUN
dpc-2939	161	2	:	:	PUNCT
dpc-2939	161	3	35182332	35182332	NUM
dpc-2939	161	4	.	.	PUNCT
dpc-2939	162	1	pmcid	pmcid	NOUN
dpc-2939	162	2	:	:	PUNCT
dpc-2939	162	3	pmc9142445	pmc9142445	NOUN
dpc-2939	162	4	.	.	PUNCT
dpc-2939	163	1	13	13	NUM
dpc-2939	163	2	.	.	X
dpc-2939	163	3	dohil	dohil	PROPN
dpc-2939	163	4	ma	ma	PROPN
dpc-2939	163	5	.	.	PROPN
dpc-2939	163	6	efficacy	efficacy	PROPN
dpc-2939	163	7	,	,	PUNCT
dpc-2939	163	8	safety	safety	NOUN
dpc-2939	163	9	,	,	PUNCT
dpc-2939	163	10	and	and	CCONJ
dpc-2939	163	11	tolerability	tolerability	NOUN
dpc-2939	163	12	of	of	ADP
dpc-2939	163	13	4	4	NUM
dpc-2939	163	14	%	%	NOUN
dpc-2939	163	15	5	5	NUM
dpc-2939	163	16	-	-	PUNCT
dpc-2939	163	17	fluorouracil	fluorouracil	NOUN
dpc-2939	163	18	cream	cream	NOUN
dpc-2939	163	19	in	in	ADP
dpc-2939	163	20	a	a	DET
dpc-2939	163	21	novel	novel	ADJ
dpc-2939	163	22	patented	patent	VERB
dpc-2939	163	23	aqueous	aqueous	ADJ
dpc-2939	163	24	cream	cream	NOUN
dpc-2939	163	25	containing	contain	VERB
dpc-2939	163	26	peanut	peanut	NOUN
dpc-2939	163	27	oil	oil	NOUN
dpc-2939	163	28	once	once	ADV
dpc-2939	163	29	daily	daily	ADV
dpc-2939	163	30	compared	compare	VERB
dpc-2939	163	31	with	with	ADP
dpc-2939	163	32	5	5	NUM
dpc-2939	163	33	%	%	NOUN
dpc-2939	163	34	5	5	NUM
dpc-2939	163	35	-	-	PUNCT
dpc-2939	163	36	fluorouracil	fluorouracil	NOUN
dpc-2939	163	37	cream	cream	NOUN
dpc-2939	163	38	twice	twice	ADV
dpc-2939	163	39	daily	daily	ADV
dpc-2939	163	40	:	:	PUNCT
dpc-2939	163	41	meeting	meet	VERB
dpc-2939	163	42	the	the	DET
dpc-2939	163	43	challenge	challenge	NOUN
dpc-2939	163	44	in	in	ADP
dpc-2939	163	45	the	the	DET
dpc-2939	163	46	treatment	treatment	NOUN
dpc-2939	163	47	of	of	ADP
dpc-2939	163	48	actinic	actinic	ADJ
dpc-2939	163	49	keratosis	keratosis	NOUN
dpc-2939	163	50	.	.	PUNCT
dpc-2939	164	1	j	j	PROPN
dpc-2939	164	2	drugs	drug	NOUN
dpc-2939	164	3	dermatol	dermatol	NOUN
dpc-2939	164	4	.	.	PUNCT
dpc-2939	165	1	2016;15(10):1218	2016;15(10):1218	NUM
dpc-2939	165	2	-	-	SYM
dpc-2939	165	3	1224	1224	NUM
dpc-2939	165	4	.	.	PUNCT
dpc-2939	166	1	pmid	pmid	NOUN
dpc-2939	166	2	:	:	PUNCT
dpc-2939	166	3	27741339	27741339	NUM
dpc-2939	166	4	.	.	PUNCT
dpc-2939	167	1	14	14	NUM
dpc-2939	167	2	.	.	PUNCT
dpc-2939	167	3	ezzedine	ezzedine	PROPN
dpc-2939	168	1	k	k	NOUN
dpc-2939	168	2	,	,	PUNCT
dpc-2939	168	3	painchault	painchault	ADJ
dpc-2939	168	4	c	c	NOUN
dpc-2939	168	5	,	,	PUNCT
dpc-2939	168	6	brignone	brignone	NOUN
dpc-2939	168	7	m.	m.	NOUN
dpc-2939	168	8	systematic	systematic	PROPN
dpc-2939	168	9	literature	literature	PROPN
dpc-2939	168	10	review	review	NOUN
dpc-2939	168	11	and	and	CCONJ
dpc-2939	168	12	network	network	NOUN
dpc-2939	168	13	meta	meta	ADJ
dpc-2939	168	14	-	-	PUNCT
dpc-2939	168	15	analysis	analysis	NOUN
dpc-2939	168	16	of	of	ADP
dpc-2939	168	17	the	the	DET
dpc-2939	168	18	efficacy	efficacy	NOUN
dpc-2939	168	19	and	and	CCONJ
dpc-2939	168	20	acceptability	acceptability	NOUN
dpc-2939	168	21	of	of	ADP
dpc-2939	168	22	interventions	intervention	NOUN
dpc-2939	168	23	in	in	ADP
dpc-2939	168	24	actinic	actinic	ADJ
dpc-2939	168	25	keratoses	keratose	NOUN
dpc-2939	168	26	.	.	PUNCT
dpc-2939	169	1	acta	acta	PROPN
dpc-2939	169	2	derm	derm	PROPN
dpc-2939	169	3	venereol	venereol	NOUN
dpc-2939	169	4	.	.	PUNCT
dpc-2939	170	1	2021;101(1):adv00358	2021;101(1):adv00358	NOUN
dpc-2939	170	2	.	.	PUNCT
dpc-2939	171	1	doi:10.2340/00015555	doi:10.2340/00015555	NOUN
dpc-2939	171	2	-	-	PUNCT
dpc-2939	171	3	3690	3690	NUM
dpc-2939	171	4	.	.	PUNCT
dpc-2939	172	1	pmid	pmid	NOUN
dpc-2939	172	2	:	:	PUNCT
dpc-2939	172	3	33170301	33170301	NUM
dpc-2939	172	4	.	.	PUNCT
dpc-2939	173	1	pmcid	pmcid	NOUN
dpc-2939	173	2	:	:	PUNCT
dpc-2939	173	3	pmc9309865	pmc9309865	ADJ
dpc-2939	173	4	.	.	PUNCT
dpc-2939	174	1	15	15	X
dpc-2939	174	2	.	.	PUNCT
dpc-2939	174	3	sinclair	sinclair	PROPN
dpc-2939	174	4	r	r	PROPN
dpc-2939	174	5	,	,	PUNCT
dpc-2939	174	6	baker	baker	PROPN
dpc-2939	174	7	c	c	PROPN
dpc-2939	174	8	,	,	PUNCT
dpc-2939	174	9	spelman	spelman	PROPN
dpc-2939	174	10	l	l	PROPN
dpc-2939	174	11	,	,	PUNCT
dpc-2939	174	12	supranowicz	supranowicz	PROPN
dpc-2939	174	13	m	m	PROPN
dpc-2939	174	14	,	,	PUNCT
dpc-2939	174	15	macmahon	macmahon	PROPN
dpc-2939	174	16	b.	b.	PROPN
dpc-2939	175	1	a	a	DET
dpc-2939	175	2	review	review	NOUN
dpc-2939	175	3	of	of	ADP
dpc-2939	175	4	actinic	actinic	ADJ
dpc-2939	175	5	keratosis	keratosis	NOUN
dpc-2939	175	6	,	,	PUNCT
dpc-2939	175	7	skin	skin	NOUN
dpc-2939	175	8	field	field	NOUN
dpc-2939	175	9	cancerisation	cancerisation	NOUN
dpc-2939	175	10	and	and	CCONJ
dpc-2939	175	11	the	the	DET
dpc-2939	175	12	efficacy	efficacy	NOUN
dpc-2939	175	13	of	of	ADP
dpc-2939	175	14	topical	topical	ADJ
dpc-2939	175	15	therapies	therapy	NOUN
dpc-2939	175	16	.	.	PUNCT
dpc-2939	176	1	australas	australas	PROPN
dpc-2939	176	2	j	j	PROPN
dpc-2939	176	3	dermatol	dermatol	NOUN
dpc-2939	176	4	.	.	PUNCT
dpc-2939	177	1	2021;62(2	2021;62(2	NUM
dpc-2939	177	2	):	):	PUNCT
dpc-2939	177	3	119	119	NUM
dpc-2939	177	4	-	-	SYM
dpc-2939	177	5	123	123	NUM
dpc-2939	177	6	.	.	PUNCT
dpc-2939	178	1	doi:10.1111	doi:10.1111	ADJ
dpc-2939	178	2	/	/	SYM
dpc-2939	178	3	ajd.13447	ajd.13447	PROPN
dpc-2939	178	4	.	.	PUNCT
dpc-2939	179	1	pmid	pmid	NOUN
dpc-2939	179	2	:	:	PUNCT
dpc-2939	179	3	32840870	32840870	NUM
dpc-2939	179	4	.	.	PUNCT
dpc-2939	180	1	pmcid	pmcid	NOUN
dpc-2939	180	2	:	:	PUNCT
dpc-2939	180	3	pmc8247342	pmc8247342	NOUN
dpc-2939	180	4	.	.	PUNCT
dpc-2939	181	1	16	16	NUM
dpc-2939	181	2	.	.	PUNCT
dpc-2939	182	1	ingham	ingham	PROPN
dpc-2939	182	2	ai	ai	VERB
dpc-2939	182	3	,	,	PUNCT
dpc-2939	182	4	weightman	weightman	PROPN
dpc-2939	182	5	w.	w.	PROPN
dpc-2939	182	6	the	the	DET
dpc-2939	182	7	efficacy	efficacy	NOUN
dpc-2939	182	8	and	and	CCONJ
dpc-2939	182	9	safety	safety	NOUN
dpc-2939	182	10	of	of	ADP
dpc-2939	182	11	topical	topical	ADJ
dpc-2939	182	12	5	5	NUM
dpc-2939	182	13	%	%	NOUN
dpc-2939	182	14	5	5	NUM
dpc-2939	182	15	-	-	PUNCT
dpc-2939	182	16	fluorouracil	fluorouracil	NOUN
dpc-2939	182	17	in	in	ADP
dpc-2939	182	18	renal	renal	ADJ
dpc-2939	182	19	transplant	transplant	NOUN
dpc-2939	182	20	recipients	recipient	NOUN
dpc-2939	182	21	for	for	ADP
dpc-2939	182	22	the	the	DET
dpc-2939	182	23	treatment	treatment	NOUN
dpc-2939	182	24	of	of	ADP
dpc-2939	182	25	actinic	actinic	ADJ
dpc-2939	182	26	keratoses	keratose	NOUN
dpc-2939	182	27	.	.	PUNCT
dpc-2939	183	1	australas	australas	PROPN
dpc-2939	183	2	j	j	PROPN
dpc-2939	183	3	dermatol	dermatol	NOUN
dpc-2939	183	4	.	.	PUNCT
dpc-2939	184	1	2014;55(3):204	2014;55(3):204	NUM
dpc-2939	184	2	-	-	PUNCT
dpc-2939	184	3	208	208	NUM
dpc-2939	184	4	.	.	PUNCT
dpc-2939	185	1	doi:10.1111	doi:10.1111	NOUN
dpc-2939	185	2	/	/	SYM
dpc-2939	185	3	ajd.12158	ajd.12158	PROPN
dpc-2939	185	4	.	.	PUNCT
dpc-2939	186	1	pmid	pmid	NOUN
dpc-2939	186	2	:	:	PUNCT
dpc-2939	186	3	24627952	24627952	NUM
dpc-2939	186	4	.	.	PUNCT
dpc-2939	187	1	17	17	NUM
dpc-2939	187	2	.	.	PUNCT
dpc-2939	188	1	couch	couch	NOUN
dpc-2939	188	2	sm	sm	PROPN
dpc-2939	188	3	,	,	PUNCT
dpc-2939	188	4	custer	custer	PROPN
dpc-2939	188	5	pl	pl	PROPN
dpc-2939	188	6	.	.	PROPN
dpc-2939	188	7	topical	topical	ADJ
dpc-2939	188	8	5	5	NUM
dpc-2939	188	9	-	-	PUNCT
dpc-2939	188	10	fluorouracil	fluorouracil	NOUN
dpc-2939	188	11	for	for	ADP
dpc-2939	188	12	the	the	DET
dpc-2939	188	13	treatment	treatment	NOUN
dpc-2939	188	14	of	of	ADP
dpc-2939	188	15	periocular	periocular	ADJ
dpc-2939	188	16	actinic	actinic	ADJ
dpc-2939	188	17	keratosis	keratosis	NOUN
dpc-2939	188	18	and	and	CCONJ
dpc-2939	188	19	low	low	ADJ
dpc-2939	188	20	-	-	PUNCT
dpc-2939	188	21	grade	grade	NOUN
dpc-2939	188	22	squamous	squamous	ADJ
dpc-2939	188	23	malignancy	malignancy	NOUN
dpc-2939	188	24	.	.	PUNCT
dpc-2939	189	1	ophthalmic	ophthalmic	ADJ
dpc-2939	189	2	plast	plast	PROPN
dpc-2939	189	3	reconstr	reconstr	NOUN
dpc-2939	189	4	surg	surg	NOUN
dpc-2939	189	5	.	.	PUNCT
dpc-2939	190	1	2012;28(3):181	2012;28(3):181	NUM
dpc-2939	190	2	-	-	SYM
dpc-2939	190	3	183	183	NUM
dpc-2939	190	4	.	.	PUNCT
dpc-2939	191	1	doi:10.1097	doi:10.1097	PROPN
dpc-2939	191	2	/	/	SYM
dpc-2939	191	3	iop.0b013e3182467c68	iop.0b013e3182467c68	PROPN
dpc-2939	191	4	.	.	PUNCT
dpc-2939	192	1	pmid	pmid	NOUN
dpc-2939	192	2	:	:	PUNCT
dpc-2939	192	3	22460673	22460673	NUM
dpc-2939	192	4	.	.	PUNCT
dpc-2939	193	1	limited	limit	VERB
dpc-2939	193	2	to	to	ADP
dpc-2939	193	3	the	the	DET
dpc-2939	193	4	acute	acute	ADJ
dpc-2939	193	5	phase	phase	NOUN
dpc-2939	193	6	and	and	CCONJ
dpc-2939	193	7	they	they	PRON
dpc-2939	193	8	gradually	gradually	ADV
dpc-2939	193	9	disappeared	disappear	VERB
dpc-2939	193	10	during	during	ADP
dpc-2939	193	11	follow	follow	NOUN
dpc-2939	193	12	-	-	PUNCT
dpc-2939	193	13	up	up	NOUN
dpc-2939	193	14	,	,	PUNCT
dpc-2939	193	15	being	be	AUX
dpc-2939	193	16	managed	manage	VERB
dpc-2939	193	17	,	,	PUNCT
dpc-2939	193	18	when	when	SCONJ
dpc-2939	193	19	needed	need	VERB
dpc-2939	193	20	,	,	PUNCT
dpc-2939	193	21	according	accord	VERB
dpc-2939	193	22	to	to	ADP
dpc-2939	193	23	the	the	DET
dpc-2939	193	24	investigator	investigator	NOUN
dpc-2939	193	25	’s	’s	PART
dpc-2939	193	26	clinical	clinical	ADJ
dpc-2939	193	27	practice	practice	NOUN
dpc-2939	193	28	.	.	PUNCT
dpc-2939	194	1	these	these	DET
dpc-2939	194	2	results	result	NOUN
dpc-2939	194	3	are	be	AUX
dpc-2939	194	4	in	in	ADP
dpc-2939	194	5	line	line	NOUN
dpc-2939	194	6	with	with	ADP
dpc-2939	194	7	the	the	DET
dpc-2939	194	8	well	well	ADV
dpc-2939	194	9	-	-	PUNCT
dpc-2939	194	10	known	know	VERB
dpc-2939	194	11	5	5	NUM
dpc-2939	194	12	-	-	PUNCT
dpc-2939	194	13	fu	fu	NOUN
dpc-2939	194	14	safety	safety	NOUN
dpc-2939	194	15	profile	profile	NOUN
dpc-2939	194	16	,	,	PUNCT
dpc-2939	194	17	which	which	PRON
dpc-2939	194	18	resulted	result	VERB
dpc-2939	194	19	to	to	PART
dpc-2939	194	20	be	be	AUX
dpc-2939	194	21	favorable	favorable	ADJ
dpc-2939	194	22	both	both	CCONJ
dpc-2939	194	23	in	in	ADP
dpc-2939	194	24	challenging	challenging	ADJ
dpc-2939	194	25	patients	patient	NOUN
dpc-2939	194	26	(	(	PUNCT
dpc-2939	194	27	such	such	ADJ
dpc-2939	194	28	as	as	ADP
dpc-2939	194	29	those	those	PRON
dpc-2939	194	30	immunosuppressed	immunosuppressed	ADJ
dpc-2939	194	31	)	)	PUNCT
dpc-2939	194	32	and	and	CCONJ
dpc-2939	194	33	in	in	ADP
dpc-2939	194	34	sensitive	sensitive	ADJ
dpc-2939	194	35	skin	skin	NOUN
dpc-2939	194	36	areas	area	NOUN
dpc-2939	194	37	(	(	PUNCT
dpc-2939	194	38	such	such	ADJ
dpc-2939	194	39	as	as	ADP
dpc-2939	194	40	the	the	DET
dpc-2939	194	41	periocular	periocular	ADJ
dpc-2939	194	42	region	region	NOUN
dpc-2939	194	43	)	)	PUNCT
dpc-2939	195	1	[	[	X
dpc-2939	195	2	16,17	16,17	NUM
dpc-2939	195	3	]	]	PUNCT
dpc-2939	195	4	.	.	PUNCT
dpc-2939	196	1	this	this	DET
dpc-2939	196	2	study	study	NOUN
dpc-2939	196	3	has	have	VERB
dpc-2939	196	4	two	two	NUM
dpc-2939	196	5	limitations	limitation	NOUN
dpc-2939	196	6	.	.	PUNCT
dpc-2939	197	1	first	first	ADV
dpc-2939	197	2	,	,	PUNCT
dpc-2939	197	3	its	its	PRON
dpc-2939	197	4	retrospective	retrospective	ADJ
dpc-2939	197	5	design	design	NOUN
dpc-2939	197	6	,	,	PUNCT
dpc-2939	197	7	with	with	ADP
dpc-2939	197	8	the	the	DET
dpc-2939	197	9	lack	lack	NOUN
dpc-2939	197	10	of	of	ADP
dpc-2939	197	11	a	a	DET
dpc-2939	197	12	placebo	placebo	NOUN
dpc-2939	197	13	group	group	NOUN
dpc-2939	197	14	to	to	PART
dpc-2939	197	15	account	account	VERB
dpc-2939	197	16	for	for	ADP
dpc-2939	197	17	the	the	DET
dpc-2939	197	18	natural	natural	ADJ
dpc-2939	197	19	regression	regression	NOUN
dpc-2939	197	20	of	of	ADP
dpc-2939	197	21	ak	ak	PROPN
dpc-2939	197	22	lesions	lesion	NOUN
dpc-2939	197	23	.	.	PUNCT
dpc-2939	198	1	second	second	ADV
dpc-2939	198	2	,	,	PUNCT
dpc-2939	198	3	we	we	PRON
dpc-2939	198	4	did	do	AUX
dpc-2939	198	5	not	not	PART
dpc-2939	198	6	include	include	VERB
dpc-2939	198	7	patients	patient	NOUN
dpc-2939	198	8	who	who	PRON
dpc-2939	198	9	either	either	CCONJ
dpc-2939	198	10	suspended	suspend	VERB
dpc-2939	198	11	or	or	CCONJ
dpc-2939	198	12	discontinued	discontinue	VERB
dpc-2939	198	13	the	the	DET
dpc-2939	198	14	therapy	therapy	NOUN
dpc-2939	198	15	,	,	PUNCT
dpc-2939	198	16	since	since	SCONJ
dpc-2939	198	17	our	our	PRON
dpc-2939	198	18	first	first	ADJ
dpc-2939	198	19	aim	aim	NOUN
dpc-2939	198	20	was	be	AUX
dpc-2939	198	21	to	to	PART
dpc-2939	198	22	evaluate	evaluate	VERB
dpc-2939	198	23	the	the	DET
dpc-2939	198	24	treatment	treatment	NOUN
dpc-2939	198	25	response	response	NOUN
dpc-2939	198	26	.	.	PUNCT
dpc-2939	199	1	this	this	PRON
dpc-2939	199	2	did	do	AUX
dpc-2939	199	3	not	not	PART
dpc-2939	199	4	allow	allow	VERB
dpc-2939	199	5	us	we	PRON
dpc-2939	199	6	to	to	PART
dpc-2939	199	7	calculate	calculate	VERB
dpc-2939	199	8	the	the	DET
dpc-2939	199	9	rate	rate	NOUN
dpc-2939	199	10	of	of	ADP
dpc-2939	199	11	treatment	treatment	NOUN
dpc-2939	199	12	withdrawal	withdrawal	NOUN
dpc-2939	199	13	.	.	PUNCT
dpc-2939	200	1	however	however	ADV
dpc-2939	200	2	,	,	PUNCT
dpc-2939	200	3	we	we	PRON
dpc-2939	200	4	are	be	AUX
dpc-2939	200	5	convinced	convinced	ADJ
dpc-2939	200	6	that	that	SCONJ
dpc-2939	200	7	patient	patient	ADJ
dpc-2939	200	8	education	education	NOUN
dpc-2939	200	9	is	be	AUX
dpc-2939	200	10	crucial	crucial	ADJ
dpc-2939	200	11	for	for	ADP
dpc-2939	200	12	achieving	achieve	VERB
dpc-2939	200	13	a	a	DET
dpc-2939	200	14	satisfactory	satisfactory	ADJ
dpc-2939	200	15	compliance	compliance	NOUN
dpc-2939	200	16	to	to	ADP
dpc-2939	200	17	5	5	NUM
dpc-2939	200	18	-	-	PUNCT
dpc-2939	200	19	fu	fu	NOUN
dpc-2939	200	20	treatment	treatment	NOUN
dpc-2939	200	21	.	.	PUNCT
dpc-2939	201	1	patients	patient	NOUN
dpc-2939	201	2	should	should	AUX
dpc-2939	201	3	be	be	AUX
dpc-2939	201	4	taught	teach	VERB
dpc-2939	201	5	to	to	PART
dpc-2939	201	6	consider	consider	VERB
dpc-2939	201	7	erythema	erythema	ADJ
dpc-2939	201	8	and	and	CCONJ
dpc-2939	201	9	burning	burn	VERB
dpc-2939	201	10	sensation	sensation	NOUN
dpc-2939	201	11	as	as	ADP
dpc-2939	201	12	normal	normal	ADJ
dpc-2939	201	13	and	and	CCONJ
dpc-2939	201	14	transient	transient	ADJ
dpc-2939	201	15	signs	sign	NOUN
dpc-2939	201	16	of	of	ADP
dpc-2939	201	17	5	5	NUM
dpc-2939	201	18	-	-	PUNCT
dpc-2939	201	19	fu	fu	NOUN
dpc-2939	201	20	pharmacological	pharmacological	ADJ
dpc-2939	201	21	action	action	NOUN
dpc-2939	201	22	on	on	ADP
dpc-2939	201	23	dysplastic	dysplastic	ADJ
dpc-2939	201	24	ak	ak	NOUN
dpc-2939	201	25	cells	cell	NOUN
dpc-2939	201	26	,	,	PUNCT
dpc-2939	201	27	with	with	ADP
dpc-2939	201	28	a	a	DET
dpc-2939	201	29	peak	peak	NOUN
dpc-2939	201	30	after	after	ADP
dpc-2939	201	31	4	4	NUM
dpc-2939	201	32	weeks	week	NOUN
dpc-2939	201	33	of	of	ADP
dpc-2939	201	34	treatment	treatment	NOUN
dpc-2939	201	35	and	and	CCONJ
dpc-2939	201	36	then	then	ADV
dpc-2939	201	37	gradually	gradually	ADV
dpc-2939	201	38	resolving	resolve	VERB
dpc-2939	201	39	.	.	PUNCT
dpc-2939	202	1	in	in	ADP
dpc-2939	202	2	our	our	PRON
dpc-2939	202	3	study	study	NOUN
dpc-2939	202	4	this	this	DET
dpc-2939	202	5	simple	simple	ADJ
dpc-2939	202	6	strategy	strategy	NOUN
dpc-2939	202	7	resulted	result	VERB
dpc-2939	202	8	in	in	ADP
dpc-2939	202	9	a	a	DET
dpc-2939	202	10	low	low	ADJ
dpc-2939	202	11	rate	rate	NOUN
dpc-2939	202	12	(	(	PUNCT
dpc-2939	202	13	5.1	5.1	NUM
dpc-2939	202	14	%	%	NOUN
dpc-2939	202	15	)	)	PUNCT
dpc-2939	202	16	of	of	ADP
dpc-2939	202	17	additional	additional	ADJ
dpc-2939	202	18	consultations	consultation	NOUN
dpc-2939	202	19	for	for	ADP
dpc-2939	202	20	adverse	adverse	ADJ
dpc-2939	202	21	events	event	NOUN
dpc-2939	202	22	.	.	PUNCT
dpc-2939	203	1	references	reference	NOUN
dpc-2939	203	2	1	1	NUM
dpc-2939	203	3	.	.	PUNCT
dpc-2939	204	1	dianzani	dianzani	PROPN
dpc-2939	204	2	c	c	PROPN
dpc-2939	204	3	,	,	PUNCT
dpc-2939	204	4	conforti	conforti	PROPN
dpc-2939	204	5	c	c	PROPN
dpc-2939	204	6	,	,	PUNCT
dpc-2939	204	7	giuffrida	giuffrida	NOUN
dpc-2939	204	8	r	r	NOUN
dpc-2939	204	9	,	,	PUNCT
dpc-2939	204	10	et	et	PROPN
dpc-2939	204	11	al	al	PROPN
dpc-2939	204	12	.	.	PUNCT
dpc-2939	205	1	current	current	ADJ
dpc-2939	205	2	therapies	therapy	NOUN
dpc-2939	205	3	for	for	ADP
dpc-2939	205	4	actinic	actinic	ADJ
dpc-2939	205	5	keratosis	keratosis	NOUN
dpc-2939	205	6	.	.	PUNCT
dpc-2939	206	1	int	int	NOUN
dpc-2939	206	2	j	j	PROPN
dpc-2939	206	3	dermatol	dermatol	NOUN
dpc-2939	206	4	.	.	PUNCT
dpc-2939	207	1	2020;59(6):677	2020;59(6):677	NUM
dpc-2939	207	2	-	-	SYM
dpc-2939	207	3	684	684	NUM
dpc-2939	207	4	.	.	PUNCT
dpc-2939	208	1	doi:10.1111	doi:10.1111	ADJ
dpc-2939	208	2	/	/	SYM
dpc-2939	208	3	ijd.14767	ijd.14767	PROPN
dpc-2939	208	4	.	.	PUNCT
dpc-2939	209	1	pmid	pmid	NOUN
dpc-2939	209	2	:	:	PUNCT
dpc-2939	209	3	32012240	32012240	NUM
dpc-2939	209	4	.	.	PUNCT
dpc-2939	210	1	2	2	X
dpc-2939	210	2	.	.	X
dpc-2939	210	3	fargnoli	fargnoli	PROPN
dpc-2939	210	4	mc	mc	PROPN
dpc-2939	210	5	,	,	PUNCT
dpc-2939	210	6	altomare	altomare	VERB
dpc-2939	210	7	g	g	PROPN
dpc-2939	210	8	,	,	PUNCT
dpc-2939	210	9	benati	benati	NOUN
dpc-2939	210	10	e	e	PROPN
dpc-2939	210	11	,	,	PUNCT
dpc-2939	210	12	et	et	PROPN
dpc-2939	210	13	al	al	PROPN
dpc-2939	210	14	.	.	PUNCT
dpc-2939	211	1	prevalence	prevalence	NOUN
dpc-2939	211	2	and	and	CCONJ
dpc-2939	211	3	risk	risk	NOUN
dpc-2939	211	4	factors	factor	NOUN
dpc-2939	211	5	of	of	ADP
dpc-2939	211	6	actinic	actinic	ADJ
dpc-2939	211	7	keratosis	keratosis	NOUN
dpc-2939	211	8	in	in	ADP
dpc-2939	211	9	patients	patient	NOUN
dpc-2939	211	10	attending	attend	VERB
dpc-2939	211	11	italian	italian	ADJ
dpc-2939	211	12	dermatology	dermatology	NOUN
dpc-2939	211	13	clinics	clinic	NOUN
dpc-2939	211	14	.	.	PUNCT
dpc-2939	212	1	prevalence	prevalence	NOUN
dpc-2939	212	2	and	and	CCONJ
dpc-2939	212	3	risk	risk	NOUN
dpc-2939	212	4	factors	factor	NOUN
dpc-2939	212	5	of	of	ADP
dpc-2939	212	6	actinic	actinic	ADJ
dpc-2939	212	7	keratosis	keratosis	NOUN
dpc-2939	212	8	in	in	ADP
dpc-2939	212	9	patients	patient	NOUN
dpc-2939	212	10	attending	attend	VERB
dpc-2939	212	11	italian	italian	ADJ
dpc-2939	212	12	dermatology	dermatology	NOUN
dpc-2939	212	13	clinics	clinic	NOUN
dpc-2939	212	14	.	.	PUNCT
dpc-2939	213	1	eur	eur	PROPN
dpc-2939	213	2	j	j	PROPN
dpc-2939	213	3	dermatol	dermatol	NOUN
dpc-2939	213	4	.	.	PUNCT
dpc-2939	214	1	2017;27(6):599	2017;27(6):599	NUM
dpc-2939	214	2	-	-	SYM
dpc-2939	214	3	608	608	NUM
dpc-2939	214	4	.	.	PUNCT
dpc-2939	214	5	doi:10.1684	doi:10.1684	NOUN
dpc-2939	214	6	/	/	SYM
dpc-2939	214	7	ejd.2017.3126	ejd.2017.3126	NOUN
dpc-2939	214	8	.	.	PUNCT
dpc-2939	215	1	pmid	pmid	NOUN
dpc-2939	215	2	:	:	PUNCT
dpc-2939	215	3	29311040	29311040	NUM
dpc-2939	215	4	.	.	PUNCT
dpc-2939	216	1	3	3	X
dpc-2939	216	2	.	.	X
dpc-2939	216	3	calzavara	calzavara	NOUN
dpc-2939	216	4	-	-	PUNCT
dpc-2939	216	5	pinton	pinton	NOUN
dpc-2939	216	6	p	p	NOUN
dpc-2939	216	7	,	,	PUNCT
dpc-2939	216	8	calzavara	calzavara	NOUN
dpc-2939	216	9	-	-	PUNCT
dpc-2939	216	10	pinton	pinton	NOUN
dpc-2939	217	1	i	i	PROPN
dpc-2939	217	2	,	,	PUNCT
dpc-2939	217	3	rovati	rovati	PROPN
dpc-2939	217	4	c	c	PROPN
dpc-2939	217	5	,	,	PUNCT
dpc-2939	217	6	rossi	rossi	ADJ
dpc-2939	217	7	m.	m.	NOUN
dpc-2939	217	8	topical	topical	ADJ
dpc-2939	217	9	pharmacotherapy	pharmacotherapy	NOUN
dpc-2939	217	10	for	for	ADP
dpc-2939	217	11	actinic	actinic	ADJ
dpc-2939	217	12	keratoses	keratose	NOUN
dpc-2939	217	13	in	in	ADP
dpc-2939	217	14	older	old	ADJ
dpc-2939	217	15	adults	adult	NOUN
dpc-2939	217	16	.	.	PUNCT
dpc-2939	218	1	drugs	drug	NOUN
dpc-2939	218	2	aging	age	VERB
dpc-2939	218	3	.	.	PUNCT
dpc-2939	219	1	2022;39(2):143	2022;39(2):143	NUM
dpc-2939	219	2	-	-	PUNCT
dpc-2939	219	3	152	152	NUM
dpc-2939	219	4	.	.	PUNCT
dpc-2939	220	1	doi:10.1007	doi:10.1007	VERB
dpc-2939	220	2	/	/	SYM
dpc-2939	220	3	s40266	s40266	NOUN
dpc-2939	220	4	-	-	PUNCT
dpc-2939	220	5	022	022	NUM
dpc-2939	220	6	-00919	-00919	PROPN
dpc-2939	220	7	-	-	PUNCT
dpc-2939	220	8	0	0	PROPN
dpc-2939	220	9	.	.	PUNCT
dpc-2939	221	1	pmid	pmid	NOUN
dpc-2939	221	2	:	:	PUNCT
dpc-2939	221	3	35156172	35156172	NUM
dpc-2939	221	4	.	.	PUNCT
dpc-2939	222	1	pmcid	pmcid	NOUN
dpc-2939	222	2	:	:	PUNCT
dpc-2939	222	3	pmc8873057	pmc8873057	ADJ
dpc-2939	222	4	.	.	PUNCT
dpc-2939	223	1	4	4	X
dpc-2939	223	2	.	.	X
dpc-2939	223	3	stockfleth	stockfleth	PROPN
dpc-2939	223	4	e	e	PROPN
dpc-2939	223	5	,	,	PUNCT
dpc-2939	223	6	bégeault	bégeault	NOUN
dpc-2939	223	7	n	n	CCONJ
dpc-2939	223	8	,	,	PUNCT
dpc-2939	223	9	delarue	delarue	ADJ
dpc-2939	223	10	a.	a.	NOUN
dpc-2939	223	11	the	the	DET
dpc-2939	223	12	overall	overall	ADJ
dpc-2939	223	13	number	number	NOUN
dpc-2939	223	14	of	of	ADP
dpc-2939	223	15	actinic	actinic	ADJ
dpc-2939	223	16	keratosis	keratosis	NOUN
dpc-2939	223	17	lesions	lesion	NOUN
dpc-2939	223	18	is	be	AUX
dpc-2939	223	19	not	not	PART
dpc-2939	223	20	predictable	predictable	ADJ
dpc-2939	223	21	by	by	ADP
dpc-2939	223	22	the	the	DET
dpc-2939	223	23	number	number	NOUN
dpc-2939	223	24	of	of	ADP
dpc-2939	223	25	visible	visible	ADJ
dpc-2939	223	26	lesions	lesion	NOUN
dpc-2939	223	27	:	:	PUNCT
dpc-2939	223	28	consequences	consequence	NOUN
dpc-2939	223	29	for	for	ADP
dpc-2939	223	30	field	field	NOUN
dpc-2939	223	31	-	-	PUNCT
dpc-2939	223	32	directed	direct	VERB
dpc-2939	223	33	therapies	therapy	NOUN
dpc-2939	223	34	.	.	PUNCT
dpc-2939	224	1	curr	curr	PROPN
dpc-2939	224	2	ther	ther	PROPN
dpc-2939	224	3	res	re	VERB
dpc-2939	224	4	clin	clin	PROPN
dpc-2939	224	5	exp	exp	PROPN
dpc-2939	224	6	.	.	PUNCT
dpc-2939	225	1	2021;96:100661	2021;96:100661	NUM
dpc-2939	225	2	.	.	PUNCT
dpc-2939	225	3	doi:10.1016	doi:10.1016	PROPN
dpc-2939	225	4	/	/	SYM
dpc-2939	225	5	j.	j.	PROPN
dpc-2939	225	6	curtheres.2021.100661	curtheres.2021.100661	PROPN
dpc-2939	225	7	.	.	PUNCT
dpc-2939	226	1	pmid	pmid	NOUN
dpc-2939	226	2	:	:	PUNCT
dpc-2939	226	3	35035632	35035632	NUM
dpc-2939	226	4	.	.	PUNCT
dpc-2939	227	1	pmcid	pmcid	NOUN
dpc-2939	227	2	:	:	PUNCT
dpc-2939	227	3	pmc8752874	pmc8752874	NOUN
dpc-2939	227	4	.	.	PUNCT
dpc-2939	228	1	5	5	X
dpc-2939	228	2	.	.	X
dpc-2939	228	3	martin	martin	PROPN
dpc-2939	228	4	gm	gm	PROPN
dpc-2939	228	5	.	.	PUNCT
dpc-2939	228	6	impact	impact	NOUN
dpc-2939	228	7	of	of	ADP
dpc-2939	228	8	interval	interval	NOUN
dpc-2939	228	9	and	and	CCONJ
dpc-2939	228	10	combination	combination	NOUN
dpc-2939	228	11	therapies	therapy	NOUN
dpc-2939	228	12	on	on	ADP
dpc-2939	228	13	the	the	DET
dpc-2939	228	14	management	management	NOUN
dpc-2939	228	15	of	of	ADP
dpc-2939	228	16	actinic	actinic	ADJ
dpc-2939	228	17	keratosis	keratosis	NOUN
dpc-2939	228	18	:	:	PUNCT
dpc-2939	228	19	review	review	NOUN
dpc-2939	228	20	and	and	CCONJ
dpc-2939	228	21	clinical	clinical	ADJ
dpc-2939	228	22	considerations	consideration	NOUN
dpc-2939	228	23	.	.	PUNCT
dpc-2939	229	1	j	j	PROPN
dpc-2939	229	2	dermatolog	dermatolog	PROPN
dpc-2939	229	3	treat	treat	NOUN
dpc-2939	229	4	.	.	PUNCT
dpc-2939	230	1	2011;22(5):288	2011;22(5):288	NUM
dpc-2939	230	2	-	-	SYM
dpc-2939	230	3	297	297	NUM
dpc-2939	230	4	.	.	PUNCT
dpc-2939	231	1	doi:10.3109/09546631003797072	doi:10.3109/09546631003797072	NOUN
dpc-2939	231	2	.	.	PUNCT
dpc-2939	232	1	pmid	pmid	NOUN
dpc-2939	232	2	:	:	PUNCT
dpc-2939	232	3	20528483	20528483	NUM
dpc-2939	232	4	.	.	PUNCT
dpc-2939	233	1	6	6	NUM
dpc-2939	233	2	.	.	X
dpc-2939	233	3	willenbrink	willenbrink	PROPN
dpc-2939	233	4	tj	tj	PROPN
dpc-2939	233	5	,	,	PUNCT
dpc-2939	233	6	ruiz	ruiz	NOUN
dpc-2939	233	7	es	es	PROPN
dpc-2939	233	8	,	,	PUNCT
dpc-2939	233	9	cornejo	cornejo	PROPN
dpc-2939	233	10	cm	cm	PROPN
dpc-2939	233	11	,	,	PUNCT
dpc-2939	233	12	schmults	schmults	PROPN
dpc-2939	233	13	cd	cd	PROPN
dpc-2939	233	14	,	,	PUNCT
dpc-2939	233	15	arron	arron	PROPN
dpc-2939	233	16	st	st	PROPN
dpc-2939	233	17	,	,	PUNCT
dpc-2939	233	18	jambusaria	jambusaria	PROPN
dpc-2939	233	19	-	-	PUNCT
dpc-2939	233	20	pahlajani	pahlajani	ADJ
dpc-2939	233	21	a.	a.	NOUN
dpc-2939	233	22	field	field	NOUN
dpc-2939	233	23	cancerization	cancerization	NOUN
dpc-2939	233	24	:	:	PUNCT
dpc-2939	234	1	definition	definition	NOUN
dpc-2939	234	2	,	,	PUNCT
dpc-2939	234	3	epidemiology	epidemiology	NOUN
dpc-2939	234	4	,	,	PUNCT
dpc-2939	234	5	risk	risk	NOUN
dpc-2939	234	6	factors	factor	NOUN
dpc-2939	234	7	,	,	PUNCT
dpc-2939	234	8	and	and	CCONJ
dpc-2939	234	9	outcomes	outcome	NOUN
dpc-2939	234	10	.	.	PUNCT
dpc-2939	235	1	j	j	PROPN
dpc-2939	235	2	am	be	AUX
dpc-2939	235	3	acad	acad	ADJ
dpc-2939	235	4	dermatol	dermatol	NOUN
dpc-2939	235	5	.	.	PUNCT